Mutation_uniprot	uniprot_id	Mutation	uniprot_name	status	variant_or_mutagen	Orig_AA	Position	Mut_AA	info	match	Mut	type
Q13131/V307G	Q13131	AAPK1/V307G	AAPK1	Reviewed;	MUTAGEN	V	307	G	Q: Activates the kinase activity."";/evidence=""ECO:0000269|PubMed:17088252""	activating	V307G	A
P00519/A337T	P00519	ABL1/A337T	ABL1	Reviewed;	VARIANT	A	337	T	in CHDSKM; increases kinase activity; no;effect on protein levels; dbSNP:rs1060499548)"";/evidence=""ECO:0000269|PubMed:28288113"";/id=""VAR_079483""	activating	A337T	A
P00519/Y226C	P00519	ABL1/Y226C	ABL1	Reviewed;	VARIANT	Y	226	C	in CHDSKM; increases kinase activity; no;effect on protein levels; dbSNP:rs1060499547)"";/evidence=""ECO:0000269|PubMed:28288113"";/id=""VAR_079482""	activating	Y226C	A
Q07912/L487F	Q07912	ACK1/L487F	ACK1	Reviewed;	MUTAGEN	L	487	F	 Constantly active kinase."";/evidence=""ECO:0000269|PubMed:16288044""	activating	L487F	A
Q07912/V365R	Q07912	ACK1/V365R	ACK1	Reviewed;	MUTAGEN	V	365	R	 Increased autophosphorylation at Y-284."";/evidence=""ECO:0000269|PubMed:20110370""	activating	V365R	A
P36896/L40A	P36896	ACV1B/L40A	ACV1B	Reviewed;	MUTAGEN	L	40	A	 Increases binding to activin."";/evidence=""ECO:0000269|PubMed:12665502""	activating	L40A	A
P36896/T206V	P36896	ACV1B/T206V	ACV1B	Reviewed;	MUTAGEN	T	206	V	 Leads to constitutive activation."";/evidence=""ECO:0000269|PubMed:8622651""	activating	T206V	A
P36896/V73A	P36896	ACV1B/V73A	ACV1B	Reviewed;	MUTAGEN	V	73	A	 Increases binding to activin."";/evidence=""ECO:0000269|PubMed:12665502""	activating	V73A	A
P31749/E17K	P31749	AKT1/E17K	AKT1	Reviewed;	VARIANT	E	17	K	 (in PROTEUSS and breast cancer; also detected;in colorectal and ovarian cancer; somatic mutation; results;in increased phosphorylation at T-308 and higher basal;ubiquitination; the mutant protein is more efficiently;recruited to the plasma membrane; alters;phosphatidylinositiol phosphates lipid specificity of the;AKT1 PH domain; dbSNP:rs121434592)"";/evidence=""ECO:0000269|PubMed:17611497,;ECO:0000269|PubMed:18954143, ECO:0000269|PubMed:19713527,;ECO:0000269|PubMed:21793738"";/id=""VAR_055422""	activating	E17K	A
Q9Y243/E17K	Q9Y243	AKT3/E17K	AKT3	Reviewed;	VARIANT	E	17	K	 (in MPPH2 and melanoma; results in activation;of AKT; dbSNP:rs397514606)"";/evidence=""ECO:0000269|PubMed:18813315,;ECO:0000269|PubMed:22500628, ECO:0000269|PubMed:22729223"";/id=""VAR_065830""	activating	E17K	A
Q9UM73/F1174L	Q9UM73	ALK/F1174L	ALK	Reviewed;	VARIANT	F	1174	L	 (in NBLST3; somatic mutation; constitutively;activated; retained in the endoplasmic reticulum and Golgi;compartments; dbSNP:rs863225281)"";/evidence=""ECO:0000269|PubMed:18923523,;ECO:0000269|PubMed:18923525, ECO:0000269|PubMed:21242967"";/id=""VAR_063857""	activating	F1174L	A
Q9UM73/F1174V	Q9UM73	ALK/F1174V	ALK	Reviewed;	VARIANT	F	1174	V	 (in NBLST3; somatic mutation; constitutively;activated; retained in the endoplasmic reticulum and Golgi;compartments; dbSNP:rs281864719)"";/evidence=""ECO:0000269|PubMed:18923523,;ECO:0000269|PubMed:21242967"";/id=""VAR_063858""	activating	F1174V	A
Q9UM73/R1275Q	Q9UM73	ALK/R1275Q	ALK	Reviewed;	VARIANT	R	1275	Q	 (in NBLST3; constitutively activated;;retained in the endoplasmic reticulum and Golgi;compartments; dbSNP:rs113994087)"";/evidence=""ECO:0000269|PubMed:18724359,;ECO:0000269|PubMed:18923523, ECO:0000269|PubMed:18923525,;ECO:0000269|PubMed:21242967, ECO:0000269|PubMed:22932897"";/id=""VAR_063865""	activating	R1275Q	A
O14965/I57V	O14965	AURKA/I57V	AURKA	Reviewed;	VARIANT	I	57	V	 (increased kinase activity; dbSNP:rs1047972)"";/evidence=""ECO:0000269|PubMed:15489334,;ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022,;ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231,;ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714"";/id=""VAR_030842""	activating	I57V	A
O14965/T288D	O14965	AURKA/T288D	AURKA	Reviewed;	MUTAGEN	T	288	D	 Mimics phosphorylation state and increases;kinase activity."";/evidence=""ECO:0000269|PubMed:11039908""	activating	T288D	A
O14965/V174M	O14965	AURKA/V174M	AURKA	Reviewed;	VARIANT	V	174	M	 (in a metastatic melanoma sample; somatic;mutation; constitutively enhanced kinase activity)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:19801554"";/id=""VAR_041129""	activating	V174M	A
Q13873/R899P	Q13873	BMPR2/R899P	BMPR2	Reviewed;	VARIANT	R	899	P	 (in PPH1; leads to constitutive activation of;the MAPK14 pathway; dbSNP:rs137852752)"";/evidence=""ECO:0000269|PubMed:15965979"";/id=""VAR_033111""	activating	R899P	A
P15056/G464V	P15056	BRAF/G464V	BRAF	Reviewed;	VARIANT	G	464	V	 (in a colorectal cancer cell line; elevated;kinase activity; efficiently induces cell transformation;;dbSNP:rs121913348)"";/evidence=""ECO:0000269|PubMed:12068308"";/id=""VAR_018616""	activating	G464V	A
P15056/G469A	P15056	BRAF/G469A	BRAF	Reviewed;	VARIANT	G	469	A	 (in NHL; also in a lung adenocarcinoma;sample; somatic mutation; elevated kinase activity;;efficiently induces cell transformation;;dbSNP:rs121913355)"";/evidence=""ECO:0000269|PubMed:12068308,;ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846"";/id=""VAR_018620""	activating	G469A	A
P15056/L597V	P15056	BRAF/L597V	BRAF	Reviewed;	VARIANT	L	597	V	 (in NS7; also in a lung adenocarcinoma;sample; somatic mutation; elevated kinase activity;;efficiently induces cell transformation;;dbSNP:rs121913369)"";/evidence=""ECO:0000269|PubMed:12068308,;ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169"";/id=""VAR_018627""	activating	L597V	A
P15056/R671K	P15056	BRAF/R671K	BRAF	Reviewed;	MUTAGEN	R	671	K	 Increased kinase activity and stability in;response to EGF treatment."";/evidence=""ECO:0000269|PubMed:21917714""	activating	R671K	A
Q8IWQ3/T174E	Q8IWQ3	BRSK2/T174E	BRSK2	Reviewed;	MUTAGEN	T	174	E	 Constitutively activated."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:22798068""	activating	T174E	A
Q8IWQ3/T443A	Q8IWQ3	BRSK2/T443A	BRSK2	Reviewed;	MUTAGEN	T	443	A	 Constitutively activated. Promotes formation;of actin stress fibers."";/evidence=""ECO:0000269|PubMed:22669945""	activating	T443A	A
Q9BWU1/Y32H	Q9BWU1	CDK19/Y32H	CDK19	Reviewed;	VARIANT	Y	32	H	 (in DEE87; fails to rescue neurologic;phenotypes in a Drosophila model system; increased protein;kinase activity; dbSNP:rs1236246272)"";/evidence=""ECO:0000269|PubMed:32330417,;ECO:0000269|PubMed:33134521, ECO:0000269|PubMed:33495529"";/id=""VAR_084395""	activating	Y32H	A
P24941/T14A	P24941	CDK2/T14A	CDK2	Reviewed;	MUTAGEN	T	14	A	 2-fold increase in activity."";/evidence=""ECO:0000269|PubMed:1396589""	activating	T14A	A
P24941/Y15F	P24941	CDK2/Y15F	CDK2	Reviewed;	MUTAGEN	Y	15	F	 2-fold increase in activity."";/evidence=""ECO:0000269|PubMed:1396589""	activating	Y15F	A
P50750/S175A	P50750	CDK9/S175A	CDK9	Reviewed;	MUTAGEN	S	175	A	 Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:21533037""	activating	S175A	A
P50750/T186D	P50750	CDK9/T186D	CDK9	Reviewed;	MUTAGEN	T	186	D	 Mimics autophosphorylation; constitutive;kinase activity, independently of calcium signaling."";/evidence=""ECO:0000269|PubMed:11145967,;ECO:0000269|PubMed:18566585, ECO:0000269|PubMed:21448926""	activating	T186D	A
P07333/L301S	P07333	CSF1R/L301S	CSF1R	Reviewed;	MUTAGEN	L	301	S	 Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:15117969""	activating	L301S	A
Q08345/N211A	Q08345	DDR1/N211A	DDR1	Reviewed;	MUTAGEN	N	211	A	 Phosphorylates regardless of collagen;presence, collagen addition does not alter significantly;the levels of constitutive phosphorylation."";/evidence=""ECO:0000269|PubMed:24509848""	activating	N211A	A
Q08345/S213A	Q08345	DDR1/S213A	DDR1	Reviewed;	MUTAGEN	S	213	A	 Phosphorylates regardless of collagen;presence, collagen addition does not alter significantly;the levels of constitutive phosphorylation."";/evidence=""ECO:0000269|PubMed:24509848""	activating	S213A	A
Q16832/L610P	Q16832	DDR2/L610P	DDR2	Reviewed;	VARIANT	L	610	P	 (in WRCN; increased autophosphorylation in;patient fibroblasts)"";/evidence=""ECO:0000269|PubMed:30449416"";/id=""VAR_081931""	activating	L610P	A
Q16832/Y740C	Q16832	DDR2/Y740C	DDR2	Reviewed;	VARIANT	Y	740	C	 (in WRCN; increased autophosphorylation in;patient fibroblasts)"";/evidence=""ECO:0000269|PubMed:30449416"";/id=""VAR_081932""	activating	Y740C	A
Q9Y463/H90P	Q9Y463	DYR1B/H90P	DYR1B	Reviewed;	VARIANT	H	90	P	 (in AOMS3; expression of glucose-6-;phosphatase is significantly higher than wild-type;;dbSNP:rs587777380)"";/evidence=""ECO:0000269|PubMed:24827035"";/id=""VAR_071773""	activating	H90P	A
O43781/S350E	O43781	DYRK3/S350E	DYRK3	Reviewed;	MUTAGEN	S	350	E	D: Phosphomimetic mutant; increased stability;of the protein."";/evidence=""ECO:0000269|PubMed:29634919""	activating	S350E	A
P19525/G130R	P19525	E2AK2/G130R	E2AK2	Reviewed;	VARIANT	G	130	R	 (in DYT33; gain-of-function variant resulting;in increased levels of phosphorylated EIF2AK2 and EIF2A in;patient cells compared to controls)"";/evidence=""ECO:0000269|PubMed:33236446,;ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068"";/id=""VAR_086716""	activating	G130R	A
P19525/N32T	P19525	E2AK2/N32T	E2AK2	Reviewed;	VARIANT	N	32	T	 (in DYT33; unknown pathological significance;;gain-of-function variant resulting in increased levels of;phosphorylated EIF2AK2 and EIF2A in patient cells compared;to controls)"";/evidence=""ECO:0000269|PubMed:33236446"";/id=""VAR_086715""	activating	N32T	A
P00533/E709G	P00533	EGFR/E709G	EGFR	Reviewed;	VARIANT	E	709	G	 (found in a lung cancer sample;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs397517085)"";/evidence=""ECO:0000269|PubMed:15623594,;ECO:0000269|PubMed:16205628"";/id=""VAR_069498""	activating	E709G	A
P00533/G719S	P00533	EGFR/G719S	EGFR	Reviewed;	VARIANT	G	719	S	 (found in a lung cancer sample; somatic;mutation; strongly increased kinase activity;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs28929495)"";/evidence=""ECO:0000269|PubMed:15118125,;ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628,;ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"";/id=""VAR_019297""	activating	G719S	A
P00533/L858R	P00533	EGFR/L858R	EGFR	Reviewed;	VARIANT	L	858	R	 (found in a lung cancer sample; somatic;mutation; constitutively activated enzyme with strongly;increased kinase activity; more sensitive to gefitinib than;wild-type; dbSNP:rs121434568)"";/evidence=""ECO:0000269|PubMed:15118125,;ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628,;ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580"";/id=""VAR_019298""	activating	L858R	A
P00533/L861Q	P00533	EGFR/L861Q	EGFR	Reviewed;	VARIANT	L	861	Q	 (found in a lung cancer sample;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs121913444)"";/evidence=""ECO:0000269|PubMed:15623594,;ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793"";/id=""VAR_026102""	activating	L861Q	A
P00533/S768I	P00533	EGFR/S768I	EGFR	Reviewed;	VARIANT	S	768	I	 (found in a lung cancer sample;;constitutively activated kinase with higher levels of basal;autophosphorylation; more sensitive to gefitinib than wild-;type; dbSNP:rs121913465)"";/evidence=""ECO:0000269|PubMed:15623594,;ECO:0000269|PubMed:16205628"";/id=""VAR_069502""	activating	S768I	A
P00533/T693A	P00533	EGFR/T693A	EGFR	Reviewed;	MUTAGEN	T	693	A	 Increased phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	activating	T693A	A
P00533/T790M	P00533	EGFR/T790M	EGFR	Reviewed;	VARIANT	T	790	M	 (found in a lung cancer sample; increased;kinase activity; dbSNP:rs121434569)"";/evidence=""ECO:0000269|PubMed:16533793,;ECO:0000269|PubMed:18227510"";/id=""VAR_026098""	activating	T790M	A
P00533/V689M	P00533	EGFR/V689M	EGFR	Reviewed;	MUTAGEN	V	689	M	 Constitutively activated kinase."";/evidence=""ECO:0000269|PubMed:19560417""	activating	V689M	A
P29317/R721Q	P29317	EPHA2/R721Q	EPHA2	Reviewed;	VARIANT	R	721	Q	 (in CTRCT6; retained in the cytoplasm and;constitutively active it alters EPHA2 signaling;;dbSNP:rs116506614)"";/evidence=""ECO:0000269|PubMed:19649315"";/id=""VAR_062532""	activating	R721Q	A
P21860/A1337T	P21860	ERBB3/A1337T	ERBB3	Reviewed;	VARIANT	A	1337	T	 (in FERLK; risk factor for erythroleukemia;;results in increased ERBB-mediated signaling; results in a;block of erythroid differentiation and increased cell;proliferation; dbSNP:rs755855285)"";/evidence=""ECO:0000269|PubMed:27416908"";/id=""VAR_081641""	activating	A1337T	A
Q15303/I947R	Q15303	ERBB4/I947R	ERBB4	Reviewed;	MUTAGEN	I	947	R	 Constitutively autophosphorylated."";/evidence=""ECO:0000269|PubMed:18287036""	activating	I947R	A
Q15303/Q646C	Q15303	ERBB4/Q646C	ERBB4	Reviewed;	MUTAGEN	Q	646	C	 Constitutively activated kinase."";/evidence=""ECO:0000269|PubMed:17120616""	activating	Q646C	A
P07332/L145P	P07332	FES/L145P	FES	Reviewed;	MUTAGEN	L	145	P	 Constitutively activated kinase that can act;as oncogene. Promotes myeloid cell survival and;proliferation."";/evidence=""ECO:0000269|PubMed:11509660,;ECO:0000269|PubMed:15485904""	activating	L145P	A
P21802/C278F	P21802	FGFR2/C278F	FGFR2	Reviewed;	VARIANT	C	278	F	 (in CS, JWS and PS; forms disulfide-linked;dimers with constitutive kinase activity, is retained in an;intracellular compartment and not detected at the cell;surface; dbSNP:rs776587763)"";/evidence=""ECO:0000269|PubMed:11173845,;ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:16844695,;ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057"";/id=""VAR_004121""	activating	C278F	A
P21802/E565A	P21802	FGFR2/E565A	FGFR2	Reviewed;	MUTAGEN	E	565	A	 Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17803937""	activating	E565A	A
P21802/E565G	P21802	FGFR2/E565G	FGFR2	Reviewed;	VARIANT	E	565	G	 (in PS; constitutive kinase activity;;dbSNP:rs121918506)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017277""	activating	E565G	A
P21802/K526E	P21802	FGFR2/K526E	FGFR2	Reviewed;	VARIANT	K	526	E	 (in FSPC; constitutive kinase activity;;dbSNP:rs121918507)"";/evidence=""ECO:0000269|PubMed:16061565,;ECO:0000269|PubMed:17803937"";/id=""VAR_023788""	activating	K526E	A
P21802/K641R	P21802	FGFR2/K641R	FGFR2	Reviewed;	VARIANT	K	641	R	 (in PS; constitutive kinase activity;;dbSNP:rs1057519047)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017278""	activating	K641R	A
P21802/K659N	P21802	FGFR2/K659N	FGFR2	Reviewed;	VARIANT	K	659	N	 (in craniosynostosis; constitutive kinase;activity; dbSNP:rs1589722765)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017279""	activating	K659N	A
P21802/N549H	P21802	FGFR2/N549H	FGFR2	Reviewed;	VARIANT	N	549	H	 (in CS; constitutive kinase activity;;dbSNP:rs1057519045)"";/evidence=""ECO:0000269|PubMed:11781872,;ECO:0000269|PubMed:17803937"";/id=""VAR_017276""	activating	N549H	A
P21802/N549T	P21802	FGFR2/N549T	FGFR2	Reviewed;	MUTAGEN	N	549	T	 Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17803937""	activating	N549T	A
P22607/G380R	P22607	FGFR3/G380R	FGFR3	Reviewed;	VARIANT	G	380	R	in keratinocytic non-epidermolytic nevus and;ACH; very common mutation; constitutively activated kinase;with impaired internalization and degradation, resulting in;prolonged FGFR3 signaling; dbSNP:rs28931614)"";/evidence=""ECO:0000269|PubMed:10611230,;ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:16841094,;ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:7847369,;ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935"";/id=""VAR_004155""	activating	G380R	A
P22607/K650D	P22607	FGFR3/K650D	FGFR3	Reviewed;	MUTAGEN	K	650	D	 Constitutively activated kinase.""	activating	K650D	A
P22607/K650E	P22607	FGFR3/K650E	FGFR3	Reviewed;	VARIANT	K	650	E	in KERSEB, TD2, TGCT and BLC; bladder;transitional cell carcinoma; somatic mutation;;constitutively activated kinase with impaired;internalization and degradation, resulting in prolonged;FGFR3 signaling; dbSNP:rs78311289)"";/evidence=""ECO:0000269|PubMed:10471491,;ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:12297284,;ECO:0000269|PubMed:14534538, ECO:0000269|PubMed:15772091,;ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:19855393,;ECO:0000269|PubMed:7773297, ECO:0000269|PubMed:8754806,;ECO:0000269|PubMed:9207791"";/id=""VAR_004160""	activating	K650E	A
P22607/K650L	P22607	FGFR3/K650L	FGFR3	Reviewed;	MUTAGEN	K	650	L	 Constitutively activated kinase.""	activating	K650L	A
P22607/R248C	P22607	FGFR3/R248C	FGFR3	Reviewed;	VARIANT	R	248	C	 (in KERSEB, BLC, keratinocytic non-;epidermolytic nevus and TD1; severe and lethal; also found;as somatic mutation in one patient with multiple myeloma;;constitutive dimerization and kinase activation;;dbSNP:rs121913482)"";/evidence=""ECO:0000269|PubMed:10360402,;ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11529856,;ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:16841094,;ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:7773297,;ECO:0000269|PubMed:8845844"";/id=""VAR_004148""	activating	R248C	A
P22607/Y373C	P22607	FGFR3/Y373C	FGFR3	Reviewed;	VARIANT	Y	373	C	 (in KERSEB and TD1; disulfide-linked dimer;with constitutive kinase activation; dbSNP:rs121913485)"";/evidence=""ECO:0000269|PubMed:10360402,;ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:17509076,;ECO:0000269|PubMed:8845844, ECO:0000269|PubMed:9207791"";/id=""VAR_004153""	activating	Y373C	A
P09769/Y523F	P09769	FGR/Y523F	FGR	Reviewed;	MUTAGEN	Y	523	F	 Strongly increased catalytic activity.;Functions as oncogene."";/evidence=""ECO:0000269|PubMed:1737799""	activating	Y523F	A
P36888/D835E	P36888	FLT3/D835E	FLT3	Reviewed;	VARIANT	D	835	E	 (in acute lymphoblastic leukemia patients and;acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913487)"";/evidence=""ECO:0000269|PubMed:11290608,;ECO:0000269|PubMed:14504097"";/id=""VAR_065679""	activating	D835E	A
P36888/D835H	P36888	FLT3/D835H	FLT3	Reviewed;	VARIANT	D	835	H	 (in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913488)"";/evidence=""ECO:0000269|PubMed:11290608,;ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"";/id=""VAR_065680""	activating	D835H	A
P36888/D835N	P36888	FLT3/D835N	FLT3	Reviewed;	VARIANT	D	835	N	 (in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913488)"";/evidence=""ECO:0000269|PubMed:11290608"";/id=""VAR_065681""	activating	D835N	A
P36888/D835V	P36888	FLT3/D835V	FLT3	Reviewed;	VARIANT	D	835	V	 (in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121909646)"";/evidence=""ECO:0000269|PubMed:11290608"";/id=""VAR_065682""	activating	D835V	A
P36888/D835Y	P36888	FLT3/D835Y	FLT3	Reviewed;	VARIANT	D	835	Y	 (in acute lymphoblastic leukemia patients and;in acute myelogenous leukemia patients; somatic mutation;;constitutively activated; dbSNP:rs121913488)"";/evidence=""ECO:0000269|PubMed:11290608,;ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"";/id=""VAR_065683""	activating	D835Y	A
P49841/S9A	P49841	GSK3B/S9A	GSK3B	Reviewed;	MUTAGEN	S	9	A	oss of phosphorylation; abolished inhibition;of activity, leading to constitutively active."";/evidence=""ECO:0000269|PubMed:17050006,;ECO:0000269|PubMed:28992046, ECO:0000269|PubMed:7980435""	activating	S9A	A
P25092/S840I	P25092	GUC2C/S840I	GUC2C	Reviewed;	VARIANT	S	840	I	 (in DIAR6; activating mutation; exposure of;the mutant receptor to its ligands results in markedly;increased production of cyclic guanosine monophosphate;;dbSNP:rs587776871)"";/evidence=""ECO:0000269|PubMed:22436048"";/id=""VAR_067724""	activating	S840I	A
Q96GX5/K72M	Q96GX5	GWL/K72M	GWL	Reviewed;	MUTAGEN	K	72	M	 Hyperactive form."";/evidence=""ECO:0000269|PubMed:21164014""	activating	K72M	A
P08631/Y522F	P08631	HCK/Y522F	HCK	Reviewed;	MUTAGEN	Y	522	F	 Constitutively activated kinase, leading to;cellular transformation."";/evidence=""ECO:0000269|PubMed:10092522,;ECO:0000269|PubMed:11896602""	activating	Y522F	A
O15111/S176E	O15111	IKKA/S176E	IKKA	Reviewed;	MUTAGEN	S	176	E	 Full activation."";/evidence=""ECO:0000269|PubMed:9346484,;ECO:0000269|PubMed:9520446""	activating	S176E	A
O14920/K171E	O14920	IKKB/K171E	IKKB	Reviewed;	MUTAGEN	K	171	E	 Increased activation of NF-kappa-B signaling."";/evidence=""ECO:0000269|PubMed:30337470""	activating	K171E	A
O14920/V203I	O14920	IKKB/V203I	IKKB	Reviewed;	VARIANT	V	203	I	 (in IMD15A; gain-of-function mutation;resulting in increased activation of NF-kappa-B signaling;pathway; dbSNP:rs1563340753)"";/evidence=""ECO:0000269|PubMed:30337470"";/id=""VAR_081275""	activating	V203I	A
P06213/Y1011A	P06213	INSR/Y1011A	INSR	Reviewed;	MUTAGEN	Y	1011	A	 Increases kinase activity."";/evidence=""ECO:0000269|PubMed:12707268""	activating	Y1011A	A
P23458/A634D	P23458	JAK1/A634D	JAK1	Reviewed;	VARIANT	A	634	D	in AIIDE; constitutive gain of function;resulting in increased receptor signaling pathway via JAK-;STAT; no effect on protein abundance)"";/evidence=""ECO:0000269|PubMed:28111307"";/id=""VAR_084991""	activating	A634D	A
P23458/V658F	P23458	JAK1/V658F	JAK1	Reviewed;	MUTAGEN	V	658	F	 Constitutively active. Increased receptor;signaling pathway via JAK-STAT."";/evidence=""ECO:0000269|PubMed:16239216""	activating	V658F	A
P52333/C759R	P52333	JAK3/C759R	JAK3	Reviewed;	VARIANT	C	759	R	 (in T(-)B(+)NK(-) SCID; constitutive;phosphorylation)"";/evidence=""ECO:0000269|PubMed:9354668"";/id=""VAR_010497""	activating	C759R	A
P17612/L206R	P17612	KAPCA/L206R	KAPCA	Reviewed;	VARIANT	L	206	R	 (in PPNAD4; somatic mutation; the mutation;results in cAMP-independent basal protein kinase activity;and constitutive activation of protein kinase A;;dbSNP:rs386352352)"";/evidence=""ECO:0000269|PubMed:24571724,;ECO:0000269|PubMed:24700472, ECO:0000269|PubMed:24747643,;ECO:0000269|PubMed:24855271"";/id=""VAR_071707""	activating	L206R	A
Q9UQM7/P212Q	Q9UQM7	KCC2A/P212Q	KCC2A	Reviewed;	VARIANT	P	212	Q	 (in MRD53; increased basal;autophosphorylation)"";/evidence=""ECO:0000269|PubMed:29560374"";/id=""VAR_081160""	activating	P212Q	A
Q13555/R292P	Q13555	KCC2G/R292P	KCC2G	Reviewed;	VARIANT	R	292	P	 (in MRD59; gain-of-function variant affecting;regulation of neurite formation and arborization; results;in constitutive autophosphorylation; dbSNP:rs397514627)"";/evidence=""ECO:0000269|PubMed:23033978,;ECO:0000269|PubMed:30184290"";/id=""VAR_069390""	activating	R292P	A
Q13976/R177Q	Q13976	KGP1/R177Q	KGP1	Reviewed;	VARIANT	R	177	Q	in AAT8; impairs cGMP binding; the mutant;protein is constitutively active; dbSNP:rs397515330)"";/evidence=""ECO:0000269|PubMed:23910461"";/id=""VAR_070434""	activating	R177Q	A
P10721/D816F	P10721	KIT/D816F	KIT	Reviewed;	VARIANT	D	816	F	 (in MASTC; sporadic case; somatic mutation;;requires 2 nucleotide substitutions; constitutively;activated and is much more rapidly autophosphorylated than;wild type)"";/evidence=""ECO:0000269|PubMed:9990072"";/id=""VAR_033133""	activating	D816F	A
P10721/D816H	P10721	KIT/D816H	KIT	Reviewed;	VARIANT	D	816	H	 (in a testicular tumor; seminoma; somatic;mutation; constitutively activated; dbSNP:rs121913506)"";/evidence=""ECO:0000269|PubMed:10362788,;ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:20147452"";/id=""VAR_033134""	activating	D816H	A
P10721/D816I	P10721	KIT/D816I	KIT	Reviewed;	VARIANT	D	816	I	 (in MASTC; somatic mutation; constitutively;activated; requires 2 nucleotide substitutions;;dbSNP:rs1057519709)"";/evidence=""ECO:0000269|PubMed:19865100"";/id=""VAR_081064""	activating	D816I	A
P10721/D816Y	P10721	KIT/D816Y	KIT	Reviewed;	VARIANT	D	816	Y	 (in MASTSYS and MASTC; also found in acute;myeloid leukemia and a germ cell tumor of the testis;;somatic mutation; constitutively activated;;dbSNP:rs121913506)"";/evidence=""ECO:0000269|PubMed:16175573,;ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19865100,;ECO:0000269|PubMed:9657776, ECO:0000269|PubMed:9990072"";/id=""VAR_023828""	activating	D816Y	A
P10721/N822I	P10721	KIT/N822I	KIT	Reviewed;	VARIANT	N	822	I	 (in MASTC; constitutively activated;;dbSNP:rs993022333)"";/evidence=""ECO:0000269|PubMed:21689725"";/id=""VAR_081065""	activating	N822I	A
Q15139/Y463E	Q15139	KPCD1/Y463E	KPCD1	Reviewed;	MUTAGEN	Y	463	E	 Constitutive activation and constitutive;phosphorylation of S-738 and S-742."";/evidence=""ECO:0000269|PubMed:12637538""	activating	Y463E	A
Q04759/A148E	Q04759	KPCT/A148E	KPCT	Reviewed;	MUTAGEN	A	148	E	 Constitutively active form."";/evidence=""ECO:0000269|PubMed:10652356""	activating	A148E	A
O75676/F709A	O75676	KS6A4/F709A	KS6A4	Reviewed;	MUTAGEN	F	709	A	 Strongly elevates basal activity."";/evidence=""ECO:0000269|PubMed:11035004""	activating	F709A	A
P43405/A353T	P43405	KSYK/A353T	KSYK	Reviewed;	VARIANT	A	353	T	 (in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085996""	activating	A353T	A
P43405/M450I	P43405	KSYK/M450I	KSYK	Reviewed;	VARIANT	M	450	I	 (in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085997""	activating	M450I	A
P43405/P342T	P43405	KSYK/P342T	KSYK	Reviewed;	VARIANT	P	342	T	 (in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085995""	activating	P342T	A
P43405/S550F	P43405	KSYK/S550F	KSYK	Reviewed;	VARIANT	S	550	F	 (in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085998""	activating	S550F	A
P43405/S550Y	P43405	KSYK/S550Y	KSYK	Reviewed;	VARIANT	S	550	Y	 (in IMD82; constitutively active protein;tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:33782605"";/id=""VAR_085999""	activating	S550Y	A
P53667/T508E	P53667	LIMK1/T508E	LIMK1	Reviewed;	MUTAGEN	T	508	E	 Phosphomimetic mutant; enhances kinase;activity."";/evidence=""ECO:0000269|PubMed:22328514""	activating	T508E	A
P53667/T508EE	P53667	LIMK1/T508EE	LIMK1	Reviewed;	MUTAGEN	T	508	EE	: Enhances kinase activity."";/evidence=""ECO:0000269|PubMed:10196227,;ECO:0000269|PubMed:10652353""	activating	T508EE	A
P53671/T505E	P53671	LIMK2/T505E	LIMK2	Reviewed;	MUTAGEN	T	505	E	 Phosphomimetic mutant; enhances kinase;activity."";/evidence=""ECO:0000269|PubMed:11018042,;ECO:0000269|PubMed:22328514""	activating	T505E	A
Q5S007/H2391D	Q5S007	LRRK2/H2391D	LRRK2	Reviewed;	MUTAGEN	H	2391	D	 Increases kinase activity."";/evidence=""ECO:0000269|PubMed:30635421""	activating	H2391D	A
Q5S007/I2020T	Q5S007	LRRK2/I2020T	LRRK2	Reviewed;	VARIANT	I	2020	T	in PARK8; significant increase in;autophosphorylation of about 40% in comparison to wild-type;protein in vitro; shows a progressive reduction in neurite;length and branching; shows an increase in activity in;phosphorylation of RAB8A and RAB10; dbSNP:rs35870237)"";/evidence=""ECO:0000269|PubMed:15541309,;ECO:0000269|PubMed:15880653, ECO:0000269|PubMed:16172858,;ECO:0000269|PubMed:16251215, ECO:0000269|PubMed:16321986,;ECO:0000269|PubMed:17114044, ECO:0000269|PubMed:26824392,;ECO:0000269|PubMed:29212815"";/id=""VAR_024959""	activating	I2020T	A
Q5S007/R1441G	Q5S007	LRRK2/R1441G	LRRK2	Reviewed;	VARIANT	R	1441	G	in PARK8; shows a progressive reduction in;neurite length and branching; shows an increase in activity;in phosphorylation of RAB8A and RAB10; decreases;phosphorylation-dependent binding to YWHAG;;dbSNP:rs33939927)"";/evidence=""ECO:0000269|PubMed:15541308,;ECO:0000269|PubMed:15925109, ECO:0000269|PubMed:16172858,;ECO:0000269|PubMed:16533964, ECO:0000269|PubMed:17114044,;ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:28720718,;ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29212815,;ECO:0000269|PubMed:30398148, ECO:0000269|PubMed:30635421"";/id=""VAR_024946""	activating	R1441G	A
Q5S007/R1728H	Q5S007	LRRK2/R1728H	LRRK2	Reviewed;	VARIANT	R	1728	H	 (in PARK8; shows an increase in activity in;phosphorylation of RAB8A and RAB10; dbSNP:rs145364431)"";/evidence=""ECO:0000269|PubMed:18213618,;ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:29212815"";/id=""VAR_054744""	activating	R1728H	A
Q5S007/R2394E	Q5S007	LRRK2/R2394E	LRRK2	Reviewed;	MUTAGEN	R	2394	E	ecreases WD domain homodimerization.;Increases kinase activity and autophosphorylation at Ser-;1292."";/evidence=""ECO:0000269|PubMed:30635421""	activating	R2394E	A
Q5S007/T2031S	Q5S007	LRRK2/T2031S	LRRK2	Reviewed;	VARIANT	T	2031	S	 (in PARK8; shows an increase in activity in;phosphorylation of RAB8A and RAB10; dbSNP:rs78029637)"";/evidence=""ECO:0000269|PubMed:26824392,;ECO:0000269|PubMed:29212815"";/id=""VAR_082047""	activating	T2031S	A
P29376/E763K	P29376	LTK/E763K	LTK	Reviewed;	VARIANT	E	763	K	 (may possibly contribute to susceptibility to;systemic lupus erythematosus; increases autophosphorylation;and interaction with PI3-kinase subunit p85;;dbSNP:rs76282169)"";/evidence=""ECO:0000269|PubMed:14695357"";/id=""VAR_065465""	activating	E763K	A
P29376/G750E	P29376	LTK/G750E	LTK	Reviewed;	MUTAGEN	G	750	E	 Increases autophosphorylation and interaction;with PI3-kinase subunit p85 (demonstrated with chimeric;EGFR-LTK)."";/evidence=""ECO:0000269|PubMed:14695357""	activating	G750E	A
P07948/Y508F	P07948	LYN/Y508F	LYN	Reviewed;	MUTAGEN	Y	508	F	bolishes autoinhibition and thereby increases;kinase activity."";/evidence=""ECO:0000269|PubMed:16920712""	activating	Y508F	A
Q13233/L189P	Q13233	M3K1/L189P	M3K1	Reviewed;	VARIANT	L	189	P	 (in SRXY6; increases phosphorylation of the;downstream target MAPK3/MAPK1 compared to wild-type and;enhances binding of RHOA to the mutant MAP3K1 complex;;dbSNP:rs387906788)"";/evidence=""ECO:0000269|PubMed:21129722"";/id=""VAR_065504""	activating	L189P	A
Q13233/L189R	Q13233	M3K1/L189R	M3K1	Reviewed;	VARIANT	L	189	R	 (in SRXY6; increases phosphorylation of the;downstream targets MAPK14 and MAPK3/MAPK1 compared to wild-;type and enhances binding of RHOA to the mutant MAP3K1;complex; dbSNP:rs387906788)"";/evidence=""ECO:0000269|PubMed:21129722"";/id=""VAR_065505""	activating	L189R	A
Q56UN5/T161E	Q56UN5	M3K19/T161E	M3K19	Reviewed;	MUTAGEN	T	161	E	 Constitutively active kinase with normal;accumulation in the nucleus."";/evidence=""ECO:0000269|PubMed:26443375""	activating	T161E	A
Q99683/S1033A	Q99683	M3K5/S1033A	M3K5	Reviewed;	MUTAGEN	S	1033	A	 Enhanced induction of apoptosis and increased;kinase activity."";/evidence=""ECO:0000269|PubMed:15094778""	activating	S1033A	A
O43318/P512L	O43318	M3K7/P512L	M3K7	Reviewed;	VARIANT	P	512	L	 (in FMD2; does not affect interaction with;TAB2; does not affect homodimerization; increases;autophosphorylation; increases MAPK signaling; increases;NF-kappa-B signaling; dbSNP:rs886039230)"";/evidence=""ECO:0000269|PubMed:27426733"";/id=""VAR_077347""	activating	P512L	A
Q92918/T355A	Q92918	M4K1/T355A	M4K1	Reviewed;	MUTAGEN	T	355	A	 Retains kinase activity. Not degraded by the;Cul7-RING ubiquitin-protein ligase complex containing;FBXW8."";/evidence=""ECO:0000269|PubMed:24362026""	activating	T355A	A
P49137/K353R	P49137	MAPK2/K353R	MAPK2	Reviewed;	MUTAGEN	K	353	R	nduces decreased sumoylation and increase in;protein kinase activity."";/evidence=""ECO:0000269|PubMed:21131586""	activating	K353R	A
P49137/S272D	P49137	MAPK2/S272D	MAPK2	Reviewed;	MUTAGEN	S	272	D	 Mimicks phosphorylation state, leading to;slight increase of basal kinase activity."";/evidence=""ECO:0000269|PubMed:8846784""	activating	S272D	A
P49137/T222D	P49137	MAPK2/T222D	MAPK2	Reviewed;	MUTAGEN	T	222	D	 Mimicks phosphorylation state, leading to;slight increase of basal kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	activating	T222D	A
P49137/T334D	P49137	MAPK2/T334D	MAPK2	Reviewed;	MUTAGEN	T	334	D	E: Mimicks phosphorylation state, leading to;elevated basal kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	activating	T334D	A
Q16644/K73M	Q16644	MAPK3/K73M	MAPK3	Reviewed;	MUTAGEN	K	73	M	 Higher affinity toward PCH2."";/evidence=""ECO:0000269|PubMed:15563468""	activating	K73M	A
Q8IW41/L337G	Q8IW41	MAPK5/L337G	MAPK5	Reviewed;	MUTAGEN	L	337	G	 Induces constitutive protein kinase activity."";/evidence=""ECO:0000269|PubMed:21329882""	activating	L337G	A
Q8IW41/S212D	Q8IW41	MAPK5/S212D	MAPK5	Reviewed;	MUTAGEN	S	212	D	 Mimicks phosphorylation state and displays a;slightly higher protein kinase activity."";/evidence=""ECO:0000269|PubMed:12808055""	activating	S212D	A
Q8IW41/T182D	Q8IW41	MAPK5/T182D	MAPK5	Reviewed;	MUTAGEN	T	182	D	 Mimicks phosphorylation state and induces;constitutive protein kinase activity."";/evidence=""ECO:0000269|PubMed:12808055,;ECO:0000269|PubMed:21329882, ECO:0000269|PubMed:9628874""	activating	T182D	A
Q9P0L2/T215E	Q9P0L2	MARK1/T215E	MARK1	Reviewed;	MUTAGEN	T	215	E	 Constitutively active."";/evidence=""ECO:0000269|PubMed:14976552""	activating	T215E	A
Q96L34/T214E	Q96L34	MARK4/T214E	MARK4	Reviewed;	MUTAGEN	T	214	E	imicks phosphorylation state, leading to;increased activity. Decreases mTORC1 activity."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:23184942""	activating	T214E	A
Q14680/T167D	Q14680	MELK/T167D	MELK	Reviewed;	MUTAGEN	T	167	D	E: Phosphomimetic mutant that has similar;kinase activity as wild-type."";/evidence=""ECO:0000269|PubMed:14976552""	activating	T167D	A
P08581/H1094L	P08581	MET/H1094L	MET	Reviewed;	VARIANT	H	1094	L	 (in RCCP; constitutive autophosphorylation;;causes malignant transformation in cell lines)"";/evidence=""ECO:0000269|PubMed:10327054"";/id=""VAR_032486""	activating	H1094L	A
P08581/H1094Y	P08581	MET/H1094Y	MET	Reviewed;	VARIANT	H	1094	Y	 (in RCCP; constitutive autophosphorylation;;causes malignant transformation in cell lines;;dbSNP:rs121913244)"";/evidence=""ECO:0000269|PubMed:10327054"";/id=""VAR_032488""	activating	H1094Y	A
P08581/H1106D	P08581	MET/H1106D	MET	Reviewed;	VARIANT	H	1106	D	 (in RCCP; constitutive autophosphorylation;;causes malignant transformation in cell lines)"";/evidence=""ECO:0000269|PubMed:10327054,;ECO:0000269|PubMed:10433944"";/id=""VAR_032489""	activating	H1106D	A
P08581/V1092I	P08581	MET/V1092I	MET	Reviewed;	VARIANT	V	1092	I	 (in RCCP; constitutive autophosphorylation;;dbSNP:rs786202724)"";/evidence=""ECO:0000269|PubMed:10327054,;ECO:0000269|PubMed:10417759, ECO:0000269|PubMed:10433944"";/id=""VAR_032485""	activating	V1092I	A
P08581/Y1230D	P08581	MET/Y1230D	MET	Reviewed;	VARIANT	Y	1230	D	 (in RCCP; constitutive autophosphorylation;;causes malignant transformation in cell lines)"";/evidence=""ECO:0000269|PubMed:10327054,;ECO:0000269|PubMed:10433944"";/id=""VAR_032491""	activating	Y1230D	A
P53778/D179A	P53778	MK12/D179A	MK12	Reviewed;	MUTAGEN	D	179	A	 Emulation of the active state."";/evidence=""ECO:0000269|PubMed:15284239""	activating	D179A	A
Q9BUB5/T385D	Q9BUB5	MKNK1/T385D	MKNK1	Reviewed;	MUTAGEN	T	385	D	 Constitutively active."";/evidence=""ECO:0000269|PubMed:11463832""	activating	T385D	A
Q9HBH9/T379D	Q9HBH9	MKNK2/T379D	MKNK2	Reviewed;	MUTAGEN	T	379	D	 Constitutively active."";/evidence=""ECO:0000269|PubMed:11463832""	activating	T379D	A
Q02750/K57N	Q02750	MP2K1/K57N	MP2K1	Reviewed;	VARIANT	K	57	N	 (in MEL; somatic mutation; results in;increased MAPK signal transduction; dbSNP:rs869025608)"";/evidence=""ECO:0000269|PubMed:29643386"";/id=""VAR_084454""	activating	K57N	A
Q02750/M219V	Q02750	MP2K1/M219V	MP2K1	Reviewed;	MUTAGEN	M	219	V	 Increases interaction with KSR1 and BRAF."";/evidence=""ECO:0000269|PubMed:29433126""	activating	M219V	A
Q02750/N221Y	Q02750	MP2K1/N221Y	MP2K1	Reviewed;	MUTAGEN	N	221	Y	 Increases interaction with KSR1 and BRAF."";/evidence=""ECO:0000269|PubMed:29433126""	activating	N221Y	A
P36507/P128Q	P36507	MP2K2/P128Q	MP2K2	Reviewed;	VARIANT	P	128	Q	 (in CFC4; results in increased kinase;activity; dbSNP:rs267607230)"";/evidence=""ECO:0000269|PubMed:20358587"";/id=""VAR_069782""	activating	P128Q	A
P46734/S218E	P46734	MP2K3/S218E	MP2K3	Reviewed;	MUTAGEN	S	218	E	 Constitutive activation."";/evidence=""ECO:0000269|PubMed:8622669""	activating	S218E	A
P46734/T222E	P46734	MP2K3/T222E	MP2K3	Reviewed;	MUTAGEN	T	222	E	 Constitutive activation."";/evidence=""ECO:0000269|PubMed:8622669""	activating	T222E	A
P52564/S207E	P52564	MP2K6/S207E	MP2K6	Reviewed;	MUTAGEN	S	207	E	 Constitutive activation according to;PubMed:8622669, but not to PubMed:8621675.""	activating	S207E	A
P52564/T211E	P52564	MP2K6/T211E	MP2K6	Reviewed;	MUTAGEN	T	211	E	 Constitutive activation according to;PubMed:8622669, but not to PubMed:8621675.""	activating	T211E	A
Q5VT25/D478A	Q5VT25	MRCKA/D478A	MRCKA	Reviewed;	MUTAGEN	D	478	A	revents cleavage by CASP3, impairs the;increase of its kinase activity and impairs extrusion;apical actin ring assembly."";/evidence=""ECO:0000269|PubMed:29162624""	activating	D478A	A
Q5VT25/S222L	Q5VT25	MRCKA/S222L	MRCKA	Reviewed;	MUTAGEN	S	222	L	 Increase in autophosphorylation but not kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	activating	S222L	A
P42345/A1459D	P42345	MTOR/A1459D	MTOR	Reviewed;	VARIANT	A	1459	D	 (in FCORD2; somatic mutation; increased TOR;signaling)"";/evidence=""ECO:0000269|PubMed:26018084"";/id=""VAR_078828""	activating	A1459D	A
P42345/A431T	P42345	MTOR/A431T	MTOR	Reviewed;	MUTAGEN	A	431	T	 Does not completely restore mitochondrial DNA-;dependent respiratory chain activities in respiration-;defective mutant cells."";/evidence=""ECO:0000269|PubMed:22608499""	activating	A431T	A
P42345/C1483R	P42345	MTOR/C1483R	MTOR	Reviewed;	VARIANT	C	1483	R	 (in FCORD2; somatic mutation; increased TOR;signaling; increased kinase activity; dbSNP:rs1057519914)"";/evidence=""ECO:0000269|PubMed:25799227"";/id=""VAR_078831""	activating	C1483R	A
P42345/E1799K	P42345	MTOR/E1799K	MTOR	Reviewed;	VARIANT	E	1799	K	 (in SKS; results in increased mTOR signaling;;dbSNP:rs863225264)"";/evidence=""ECO:0000269|PubMed:25851998,;ECO:0000269|PubMed:26542245"";/id=""VAR_075072""	activating	E1799K	A
P42345/L1460P	P42345	MTOR/L1460P	MTOR	Reviewed;	VARIANT	L	1460	P	 (in FCORD2; somatic mutation; increased TOR;signaling; dbSNP:rs1057519779)"";/evidence=""ECO:0000269|PubMed:26018084,;ECO:0000269|PubMed:27830187"";/id=""VAR_078830""	activating	L1460P	A
P42345/L2427P	P42345	MTOR/L2427P	MTOR	Reviewed;	VARIANT	L	2427	P	 (in FCORD2; somatic mutation; increased TOR;signaling; increased kinase activity; dbSNP:rs1085307113)"";/evidence=""ECO:0000269|PubMed:25799227"";/id=""VAR_078841""	activating	L2427P	A
P42345/L2427Q	P42345	MTOR/L2427Q	MTOR	Reviewed;	VARIANT	L	2427	Q	 (in FCORD2; somatic mutation; increased TOR;signaling; increased kinase activity; dbSNP:rs1085307113)"";/evidence=""ECO:0000269|PubMed:25799227"";/id=""VAR_078842""	activating	L2427Q	A
P42345/S2215F	P42345	MTOR/S2215F	MTOR	Reviewed;	VARIANT	S	2215	F	 (in FCORD2; somatic mutation; increased TOR;signaling; dbSNP:rs587777894)"";/evidence=""ECO:0000269|PubMed:25799227,;ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187"";/id=""VAR_078839""	activating	S2215F	A
P42345/S2215Y	P42345	MTOR/S2215Y	MTOR	Reviewed;	VARIANT	S	2215	Y	 (in FCORD2; also found in a colorectal;adenocarcinoma sample; somatic mutation; increased TOR;signaling; dbSNP:rs587777894)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187"";/id=""VAR_041543""	activating	S2215Y	A
P42345/T2173A	P42345	MTOR/T2173A	MTOR	Reviewed;	MUTAGEN	T	2173	A	 Increased mTOR kinase activity."";/evidence=""ECO:0000269|PubMed:24247430""	activating	T2173A	A
P51955/S171D	P51955	NEK2/S171D	NEK2	Reviewed;	MUTAGEN	S	171	D	 Kinase activity increased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	activating	S171D	A
P51955/T170E	P51955	NEK2/T170E	NEK2	Reviewed;	MUTAGEN	T	170	E	 Kinase activity increased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	activating	T170E	A
P51955/T175E	P51955	NEK2/T175E	NEK2	Reviewed;	MUTAGEN	T	175	E	 Kinase activity increased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	activating	T175E	A
Q9HC98/Y108A	Q9HC98	NEK6/Y108A	NEK6	Reviewed;	MUTAGEN	Y	108	A	 Increase in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	activating	Y108A	A
Q8TDX7/Y97A	Q8TDX7	NEK7/Y97A	NEK7	Reviewed;	MUTAGEN	Y	97	A	 5-fold increase in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	activating	Y97A	A
Q8TDX7/Y97F	Q8TDX7	NEK7/Y97F	NEK7	Reviewed;	MUTAGEN	Y	97	F	L: Moderate increase in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	activating	Y97F	A
Q8TD19/I167T	Q8TD19	NEK9/I167T	NEK9	Reviewed;	VARIANT	I	167	T	 (in NC; increased autophosphorylation at T-;210; dbSNP:rs879253775)"";/evidence=""ECO:0000269|PubMed:27153399"";/id=""VAR_077801""	activating	I167T	A
Q8TD19/I573T	Q8TD19	NEK9/I573T	NEK9	Reviewed;	VARIANT	I	573	T	 (in NC; increased autophosphorylation at T-;210; dbSNP:rs1555352529)"";/evidence=""ECO:0000269|PubMed:27153399"";/id=""VAR_077802""	activating	I573T	A
Q13153/L107F	Q13153	PAK1/L107F	PAK1	Reviewed;	MUTAGEN	L	107	F	bolishes autoinhibition, leading to;constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:10551809""	activating	L107F	A
Q13153/T423E	Q13153	PAK1/T423E	PAK1	Reviewed;	MUTAGEN	T	423	E	 Constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:10551809""	activating	T423E	A
O96013/S445N	O96013	PAK4/S445N	PAK4	Reviewed;	MUTAGEN	S	445	N	 Approximately 30-fold increased;autophosphorylation (constitutively active mutant)."";/evidence=""ECO:0000269|PubMed:11313478""	activating	S445N	A
O96013/S474E	O96013	PAK4/S474E	PAK4	Reviewed;	MUTAGEN	S	474	E	 Approximately 3-fold increased;autophosphorylation."";/evidence=""ECO:0000269|PubMed:11313478""	activating	S474E	A
Q96RG2/A1151K	Q96RG2	PASK/A1151K	PASK	Reviewed;	MUTAGEN	A	1151	K	 Induces lower protein kinase activity and;ability to autophosphorylate."";/evidence=""ECO:0000269|PubMed:20943661""	activating	A1151K	A
Q96RG2/R1058A	Q96RG2	PASK/R1058A	PASK	Reviewed;	MUTAGEN	R	1058	A	 Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	activating	R1058A	A
Q96RG2/Y1152F	Q96RG2	PASK/Y1152F	PASK	Reviewed;	MUTAGEN	Y	1152	F	 Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	activating	Y1152F	A
O15530/A277V	O15530	PDPK1/A277V	PDPK1	Reviewed;	MUTAGEN	A	277	V	 3-fold increase in kinase activity."";/evidence=""ECO:0000269|PubMed:10364160""	activating	A277V	A
O15530/T513E	O15530	PDPK1/T513E	PDPK1	Reviewed;	MUTAGEN	T	513	E	 Enhanced kinase activity towards PKB."";/evidence=""ECO:0000269|PubMed:20978239""	activating	T513E	A
P16234/D842V	P16234	PGFRA/D842V	PGFRA	Reviewed;	VARIANT	D	842	V	 (in a GIST sample; imatinib resistant,;constitutively activated kinase; dbSNP:rs121908585)"";/evidence=""ECO:0000269|PubMed:12522257,;ECO:0000269|PubMed:15928335, ECO:0000269|PubMed:20972453"";/id=""VAR_066471""	activating	D842V	A
P16234/D842Y	P16234	PGFRA/D842Y	PGFRA	Reviewed;	VARIANT	D	842	Y	 (in a GIST sample; imatinib sensitive,;constitutively activated kinase; dbSNP:rs121913265)"";/evidence=""ECO:0000269|PubMed:15928335"";/id=""VAR_066472""	activating	D842Y	A
P16234/H650Q	P16234	PGFRA/H650Q	PGFRA	Reviewed;	VARIANT	H	650	Q	 (in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066465""	activating	H650Q	A
P16234/N659K	P16234	PGFRA/N659K	PGFRA	Reviewed;	VARIANT	N	659	K	 (in GIST sample; constitutively activated;kinase; dbSNP:rs1057519700)"";/evidence=""ECO:0000269|PubMed:15928335"";/id=""VAR_066466""	activating	N659K	A
P16234/N659S	P16234	PGFRA/N659S	PGFRA	Reviewed;	VARIANT	N	659	S	 (in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066467""	activating	N659S	A
P16234/R748G	P16234	PGFRA/R748G	PGFRA	Reviewed;	VARIANT	R	748	G	 (in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066469""	activating	R748G	A
P16234/V561D	P16234	PGFRA/V561D	PGFRA	Reviewed;	VARIANT	V	561	D	 (in a GIST sample; constitutively activated;kinase; dbSNP:rs121908586)"";/evidence=""ECO:0000269|PubMed:12522257,;ECO:0000269|PubMed:15928335"";/id=""VAR_066462""	activating	V561D	A
P16234/Y555C	P16234	PGFRA/Y555C	PGFRA	Reviewed;	VARIANT	Y	555	C	 (in GISTPS; increased platelet-derived growth;factor alpha-receptor activity; constitutively activated;kinase; dbSNP:rs121908589)"";/evidence=""ECO:0000269|PubMed:17087943"";/id=""VAR_083158""	activating	Y555C	A
P16234/Y849S	P16234	PGFRA/Y849S	PGFRA	Reviewed;	VARIANT	Y	849	S	 (in a hypereosinophilic syndrome sample;;constitutively activated kinase)"";/evidence=""ECO:0000269|PubMed:21224473"";/id=""VAR_066475""	activating	Y849S	A
P09619/V665A	P09619	PGFRB/V665A	PGFRB	Reviewed;	VARIANT	V	665	A	 (in PENTT; gain of function in protein;tyrosine kinase activity; shows ligand-independent;constitutive signaling; dbSNP:rs1554108211)"";/evidence=""ECO:0000269|PubMed:26279204"";/id=""VAR_075866""	activating	V665A	A
P11309/H68Y	P11309	PIM1/H68Y	PIM1	Reviewed;	MUTAGEN	H	68	Y	 Increased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	activating	H68Y	A
P53350/K492R	P53350	PLK1/K492R	PLK1	Reviewed;	MUTAGEN	K	492	R	 Severe mitotic defects leading to prometaphase;delay. Increased localization at kinetochores leading to;increased levels of phosphorylated BUBR1."";/evidence=""ECO:0000269|PubMed:23455478""	activating	K492R	A
P53350/S137D	P53350	PLK1/S137D	PLK1	Reviewed;	MUTAGEN	S	137	D	 Increases activity. Results in a block in;G1/S."";/evidence=""ECO:0000269|PubMed:12207013,;ECO:0000269|PubMed:18615013""	activating	S137D	A
P53350/T210D	P53350	PLK1/T210D	PLK1	Reviewed;	MUTAGEN	T	210	D	 Increases activity and restores recovery after;DNA damage checkpoint."";/evidence=""ECO:0000269|PubMed:12207013,;ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553,;ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488""	activating	T210D	A
O00444/T170D	O00444	PLK4/T170D	PLK4	Reviewed;	MUTAGEN	T	170	D	 Activating mutant."";/evidence=""ECO:0000269|PubMed:18239451,;ECO:0000269|PubMed:19164942""	activating	T170D	A
Q13882/W184A	Q13882	PTK6/W184A	PTK6	Reviewed;	MUTAGEN	W	184	A	 Abrogates interaction between PTK6-domain;kinase and PTK6-linker. Abrogates autophosphorylation and;phosphorylation of KHDRBS1."";/evidence=""ECO:0000269|PubMed:15961400""	activating	W184A	A
P04049/A237T	P04049	RAF1/A237T	RAF1	Reviewed;	VARIANT	A	237	T	 (in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs587777588)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071844""	activating	A237T	A
P04049/H626R	P04049	RAF1/H626R	RAF1	Reviewed;	VARIANT	H	626	R	 (in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs1553609795)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071848""	activating	H626R	A
P04049/L613V	P04049	RAF1/L613V	RAF1	Reviewed;	VARIANT	L	613	V	 (in NS5 and LPRD2; shows in vitro greater;kinase activity and enhanced MAPK1 activation than wild-;type; dbSNP:rs80338797)"";/evidence=""ECO:0000269|PubMed:17603482,;ECO:0000269|PubMed:17603483"";/id=""VAR_037821""	activating	L613V	A
P04049/P261A	P04049	RAF1/P261A	RAF1	Reviewed;	VARIANT	P	261	A	 (in NS5; shows in vitro greater kinase;activity and enhanced MAPK1 activation than wild-type;;dbSNP:rs121434594)"";/evidence=""ECO:0000269|PubMed:17603482"";/id=""VAR_037812""	activating	P261A	A
P04049/P261L	P04049	RAF1/P261L	RAF1	Reviewed;	VARIANT	P	261	L	 (in NS5; shows greater kinase activity and;enhanced MAPK1 activation than wild-type;;dbSNP:rs397516828)"";/evidence=""ECO:0000269|PubMed:17603483"";/id=""VAR_037813""	activating	P261L	A
P04049/P261S	P04049	RAF1/P261S	RAF1	Reviewed;	VARIANT	P	261	S	 (in NS5; shows in vitro greater kinase;activity and enhanced MAPK1 activation than wild-type;;dbSNP:rs121434594)"";/evidence=""ECO:0000269|PubMed:17603482,;ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980"";/id=""VAR_037814""	activating	P261S	A
P04049/P332A	P04049	RAF1/P332A	RAF1	Reviewed;	VARIANT	P	332	A	 (in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs1057403865)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071846""	activating	P332A	A
P04049/R563K	P04049	RAF1/R563K	RAF1	Reviewed;	MUTAGEN	R	563	K	oss of methylation. Increased stability and;catalytic activity in response to EGF treatment."";/evidence=""ECO:0000269|PubMed:21917714""	activating	R563K	A
P04049/S257L	P04049	RAF1/S257L	RAF1	Reviewed;	VARIANT	S	257	L	 (in NS5 and LPRD2; shows in vitro greater;kinase activity and enhanced ERK activation than wild-type;;dbSNP:rs80338796)"";/evidence=""ECO:0000269|PubMed:17603482,;ECO:0000269|PubMed:17603483"";/id=""VAR_037808""	activating	S257L	A
P04049/S259A	P04049	RAF1/S259A	RAF1	Reviewed;	VARIANT	S	259	A	 (in an ovarian serous carcinoma sample;;somatic mutation; increased ERK activation;;dbSNP:rs3730271)"";/evidence=""ECO:0000269|PubMed:16630891,;ECO:0000269|PubMed:17344846"";/id=""VAR_041037""	activating	S259A	A
P04049/T310A	P04049	RAF1/T310A	RAF1	Reviewed;	VARIANT	T	310	A	 (in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs778155315)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071845""	activating	T310A	A
P04049/T641M	P04049	RAF1/T641M	RAF1	Reviewed;	VARIANT	T	641	M	 (in CMD1NN; shows a mild increase in kinase;activity; dbSNP:rs587777587)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071849""	activating	T641M	A
P04049/V263A	P04049	RAF1/V263A	RAF1	Reviewed;	VARIANT	V	263	A	 (in NS5; shows in vitro greater kinase;activity and enhanced MAPK1 activation than wild-type;;dbSNP:rs397516830)"";/evidence=""ECO:0000269|PubMed:17603482"";/id=""VAR_037815""	activating	V263A	A
P07949/G894S	P07949	RET/G894S	RET	Reviewed;	VARIANT	G	894	S	 (in a patient with renal agenesis; unknown;pathological significance; constitutively phosphorylated;;expressed only the immature intracellular form)"";/evidence=""ECO:0000269|PubMed:18252215"";/id=""VAR_044396""	activating	G894S	A
P07949/V376A	P07949	RET/V376A	RET	Reviewed;	VARIANT	V	376	A	 (in a patient with renal agenesis; unknown;pathological significance; constitutively phosphorylated;;expressed only the immature intracellular form)"";/evidence=""ECO:0000269|PubMed:18252215"";/id=""VAR_044393""	activating	V376A	A
P07949/V778I	P07949	RET/V778I	RET	Reviewed;	VARIANT	V	778	I	 (in a patient with renal agenesis; unknown;pathological significance; constitutively phosphorylated;;dbSNP:rs75686697)"";/evidence=""ECO:0000269|PubMed:18252215"";/id=""VAR_044395""	activating	V778I	A
Q13546/D324H	Q13546	RIPK1/D324H	RIPK1	Reviewed;	VARIANT	D	324	H	 (in AIEFL; prevents cleavage by CASP8;;increased kinase activity; increased inflammatory;response)"";/evidence=""ECO:0000269|PubMed:31827280,;ECO:0000269|PubMed:31827281"";/id=""VAR_083518""	activating	D324H	A
Q13546/D324V	Q13546	RIPK1/D324V	RIPK1	Reviewed;	VARIANT	D	324	V	 (in AIEFL; prevents cleavage by CASP8;;increased kinase activity; increased inflammatory;response)"";/evidence=""ECO:0000269|PubMed:31827280"";/id=""VAR_084135""	activating	D324V	A
Q05823/H583A	Q05823	RN5A/H583A	RN5A	Reviewed;	MUTAGEN	H	583	A	 No change in enzymatic activity."";/evidence=""ECO:0000269|PubMed:11333017""	activating	H583A	A
Q05823/P584A	Q05823	RN5A/P584A	RN5A	Reviewed;	MUTAGEN	P	584	A	 No change in enzymatic activity."";/evidence=""ECO:0000269|PubMed:11333017""	activating	P584A	A
Q05823/W632A	Q05823	RN5A/W632A	RN5A	Reviewed;	MUTAGEN	W	632	A	 No change in enzymatic activity."";/evidence=""ECO:0000269|PubMed:11333017""	activating	W632A	A
Q01974/D482G	Q01974	ROR2/D482G	ROR2	Reviewed;	MUTAGEN	D	482	G	 Slight increase in kinase activity."";/evidence=""ECO:0000269|PubMed:25029443""	activating	D482G	A
O00141/S422D	O00141	SGK1/S422D	SGK1	Reviewed;	MUTAGEN	S	422	D	 10-fold activation."";/evidence=""ECO:0000269|PubMed:10191262,;ECO:0000269|PubMed:11696533, ECO:0000269|PubMed:12911626,;ECO:0000269|PubMed:15040001""	activating	S422D	A
Q9HBY8/S356D	Q9HBY8	SGK2/S356D	SGK2	Reviewed;	MUTAGEN	S	356	D	 Increased activation."";/evidence=""ECO:0000269|PubMed:10548550""	activating	S356D	A
Q96BR1/S486D	Q96BR1	SGK3/S486D	SGK3	Reviewed;	MUTAGEN	S	486	D	 Increased activation."";/evidence=""ECO:0000269|PubMed:10548550""	activating	S486D	A
Q9H0K1/T175E	Q9H0K1	SIK2/T175E	SIK2	Reviewed;	MUTAGEN	T	175	E	 Constitutively active."";/evidence=""ECO:0000269|PubMed:14976552""	activating	T175E	A
P12931/E527K	P12931	SRC/E527K	SRC	Reviewed;	VARIANT	E	527	K	in THC6; increased protein tyrosine kinase;activity; increased autophosphorylation at Y-419; causes;defective megakaryopoiesis associated with increased;overall tyrosine phosphorylation in megakaryocytes;;dbSNP:rs879255268)"";/evidence=""ECO:0000269|PubMed:26936507"";/id=""VAR_076919""	activating	E527K	A
Q15831/K48R	Q15831	STK11/K48R	STK11	Reviewed;	MUTAGEN	K	48	R	 Enhanced phosphorylation at Thr-336 and Ser-;428, enhanced cytoplasmic localization and increased kinase;activity."";/evidence=""ECO:0000269|PubMed:18687677""	activating	K48R	A
P49842/D89N	P49842	STK19/D89N	STK19	Reviewed;	VARIANT	D	89	N	 (recurrent gain-of-function variant found in;metastatic melanoma; promotes NRAS signaling; somatic;mutation; dbSNP:rs267600971)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:30712867"";/id=""VAR_042361""	activating	D89N	A
P36897/T204D	P36897	TGFR1/T204D	TGFR1	Reviewed;	MUTAGEN	T	204	D	 Constitutive activation."";/evidence=""ECO:0000269|PubMed:7774578""	activating	T204D	A
Q02763/A925S	Q02763	TIE2/A925S	TIE2	Reviewed;	VARIANT	A	925	S	 (in VMCM; increased ligand-independent;autophosphorylation and kinase activation)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066610""	activating	A925S	A
Q02763/K1100N	Q02763	TIE2/K1100N	TIE2	Reviewed;	VARIANT	K	1100	N	 (in VMCM; strongly increased ligand-;independent autophosphorylation and kinase activation)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066611""	activating	K1100N	A
Q02763/L914F	Q02763	TIE2/L914F	TIE2	Reviewed;	VARIANT	L	914	F	 (found in patients with solitary and multiple;sporadic venous malformations; increased ligand-independent;autophosphorylation; novel location at endoplasmic;reticulum and Golgi apparatus; partially retained at;endoplasmic reticulum and Golgi apparatus;;dbSNP:rs1825682849)"";/evidence=""ECO:0000269|PubMed:19079259"";/id=""VAR_078051""	activating	L914F	A
Q02763/R849W	Q02763	TIE2/R849W	TIE2	Reviewed;	VARIANT	R	849	W	in VMCM; increased ligand-independent;autophosphorylation and kinase activation; no effect on;location at membrane; dbSNP:rs80338908)"";/evidence=""ECO:0000269|PubMed:10369874,;ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299,;ECO:0000269|PubMed:8980225"";/id=""VAR_006352""	activating	R849W	A
Q02763/R915C	Q02763	TIE2/R915C	TIE2	Reviewed;	VARIANT	R	915	C	 (found in a patient with solitary sporadic;venous malformations; increased ligand-independent;autophosphorylation; dbSNP:rs1825682922)"";/evidence=""ECO:0000269|PubMed:19079259"";/id=""VAR_078052""	activating	R915C	A
Q02763/R915H	Q02763	TIE2/R915H	TIE2	Reviewed;	VARIANT	R	915	H	 (in VMCM; strongly increased ligand-;independent autophosphorylation and kinase activation;;dbSNP:rs387906745)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066607""	activating	R915H	A
Q02763/R918C	Q02763	TIE2/R918C	TIE2	Reviewed;	VARIANT	R	918	C	 (in VMCM; strongly increased ligand-;independent autophosphorylation and kinase activation;;dbSNP:rs1825683100)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066608""	activating	R918C	A
Q02763/S917I	Q02763	TIE2/S917I	TIE2	Reviewed;	VARIANT	S	917	I	 (found in a patient with solitary sporadic;venous malformations; increased ligand-independent;autophosphorylation)"";/evidence=""ECO:0000269|PubMed:19079259"";/id=""VAR_078054""	activating	S917I	A
Q02763/V919L	Q02763	TIE2/V919L	TIE2	Reviewed;	VARIANT	V	919	L	 (in VMCM; increased ligand-independent;autophosphorylation and kinase activation)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066609""	activating	V919L	A
Q02763/Y897C	Q02763	TIE2/Y897C	TIE2	Reviewed;	VARIANT	Y	897	C	 (in VMCM; increased ligand-independent;autophosphorylation and kinase activation;;dbSNP:rs80338909)"";/evidence=""ECO:0000269|PubMed:19888299"";/id=""VAR_066606""	activating	Y897C	A
Q02763/Y897H	Q02763	TIE2/Y897H	TIE2	Reviewed;	VARIANT	Y	897	H	 (found in a patient with solitary sporadic;venous malformations; increased ligand-independent;autophosphorylation)"";/evidence=""ECO:0000269|PubMed:19079259"";/id=""VAR_078050""	activating	Y897H	A
Q02763/Y897S	Q02763	TIE2/Y897S	TIE2	Reviewed;	VARIANT	Y	897	S	 (in VMCM; also found in a patient with;solitary sporadic venous malformations; increased ligand-;independent autophosphorylation and kinase activation;;dbSNP:rs80338909)"";/evidence=""ECO:0000269|PubMed:10369874,;ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299"";/id=""VAR_008716""	activating	Y897S	A
Q86UE8/S617A	Q86UE8	TLK2/S617A	TLK2	Reviewed;	MUTAGEN	S	617	A	 Increase in autophosphorylation."";/evidence=""ECO:0000269|PubMed:29955062""	activating	S617A	A
O75962/P1461L	O75962	TRIO/P1461L	TRIO	Reviewed;	VARIANT	P	1461	L	 (in MRD63; slightly increased occipitofrontal;circumference; slightly increased RAC1-mediated signaling;;slightly increased neurite outgrowth)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083921""	activating	P1461L	A
O75962/R1078G	O75962	TRIO/R1078G	TRIO	Reviewed;	VARIANT	R	1078	G	 (in MRD63; increased activation of RAC1-;mediated signaling; increased neurite outgrowth)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083917""	activating	R1078G	A
O75962/R1078Q	O75962	TRIO/R1078Q	TRIO	Reviewed;	VARIANT	R	1078	Q	 (in MRD63; increased activation of RAC1-;mediated signaling; increased neurite outgrowth)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083918""	activating	R1078Q	A
O75962/R1078W	O75962	TRIO/R1078W	TRIO	Reviewed;	VARIANT	R	1078	W	 (in MRD63; increased activation of RAC1-;mediated signaling; increased neurite outgrowth;;dbSNP:rs1554065887)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083919""	activating	R1078W	A
Q9BXA7/T174E	Q9BXA7	TSSK1/T174E	TSSK1	Reviewed;	MUTAGEN	T	174	E	 Constitutively active."";/evidence=""ECO:0000269|PubMed:15733851""	activating	T174E	A
P17948/N1050D	P17948	VGFR1/N1050D	VGFR1	Reviewed;	MUTAGEN	N	1050	D	 Strongly increases kinase activity. Increases;activity in promoting proliferation of endothelial cells."";/evidence=""ECO:0000269|PubMed:16286478""	activating	N1050D	A
P35968/C1045A	P35968	VGFR2/C1045A	VGFR2	Reviewed;	MUTAGEN	C	1045	A	 Significantly higher kinase activity."";/evidence=""ECO:0000269|PubMed:23199280""	activating	C1045A	A
P43403/A141E	P43403	ZAP70/A141E	ZAP70	Reviewed;	MUTAGEN	A	141	E	 Increased constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17512407""	activating	A141E	A
P43403/D327P	P43403	ZAP70/D327P	ZAP70	Reviewed;	MUTAGEN	D	327	P	ncreases constitutive kinase activity on LAT;phosphorylation, strongly increases subcellular;localization of CD69 at the cell surface and decreases;autoinhibition conformation."";/evidence=""ECO:0000269|PubMed:26783323""	activating	D327P	A
P43403/K362E	P43403	ZAP70/K362E	ZAP70	Reviewed;	MUTAGEN	K	362	E	ncreases constitutive kinase activity on LAT;phosphorylation, strongly increases subcellular;localization of CD69 at the cell surface and decreases;autoinhibition conformation."";/evidence=""ECO:0000269|PubMed:26783323""	activating	K362E	A
P43403/L133A	P43403	ZAP70/L133A	ZAP70	Reviewed;	MUTAGEN	L	133	A	 Increased constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17512407""	activating	L133A	A
P43403/P147A	P43403	ZAP70/P147A	ZAP70	Reviewed;	MUTAGEN	P	147	A	 Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	P147A	A
P43403/Q145A	P43403	ZAP70/Q145A	ZAP70	Reviewed;	MUTAGEN	Q	145	A	 Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	Q145A	A
P43403/S144A	P43403	ZAP70/S144A	ZAP70	Reviewed;	MUTAGEN	S	144	A	 Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	S144A	A
P43403/V314A	P43403	ZAP70/V314A	ZAP70	Reviewed;	MUTAGEN	V	314	A	 Increased constitutive kinase activity.""	activating	V314A	A
P43403/W131A	P43403	ZAP70/W131A	ZAP70	Reviewed;	MUTAGEN	W	131	A	 Increased constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:17512407""	activating	W131A	A
P43403/Y292F	P43403	ZAP70/Y292F	ZAP70	Reviewed;	MUTAGEN	Y	292	F	 Induces constitutive TCR stimulation-;independent NFAT induction."";/evidence=""ECO:0000269|PubMed:8943331""	activating	Y292F	A
P43403/Y492F	P43403	ZAP70/Y492F	ZAP70	Reviewed;	MUTAGEN	Y	492	F	 Increases kinase activity."";/evidence=""ECO:0000269|PubMed:7781602""	activating	Y492F	A
P43403/Y597A	P43403	ZAP70/Y597A	ZAP70	Reviewed;	MUTAGEN	Y	597	A	 Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	Y597A	A
P43403/Y598A	P43403	ZAP70/Y598A	ZAP70	Reviewed;	MUTAGEN	Y	598	A	 Increased kinase activity after activation by;LCK."";/evidence=""ECO:0000269|PubMed:17512407""	activating	Y598A	A
Q07912/K158R	Q07912	ACK1/K158R	ACK1_HUMAN	Reviewed;	MUTAGEN	K	158	R	 Loss of autophosphorylation at Y-284."";/evidence=""ECO:0000269|PubMed:16288044,;ECO:0000269|PubMed:20110370""	loss	K158R	D
Q8NER5/K222R	Q8NER5	ACV1C/K222R	ACV1C_HUMAN	Reviewed;	MUTAGEN	K	222	R	 Loss of response to NODAL and SMAD2;phosphorylation."";/evidence=""ECO:0000269|PubMed:12063393,;ECO:0000269|PubMed:15531507""	loss	K222R	D
P37023/C41G	P37023	ACVL1/C41G	ACVL1_HUMAN	Reviewed;	VARIANT	C	41	G	 (in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075231""	loss	C41G	D
P37023/C41Y	P37023	ACVL1/C41Y	ACVL1_HUMAN	Reviewed;	VARIANT	C	41	Y	 (in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum; dbSNP:rs1184716348)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075232""	loss	C41Y	D
P37023/C46G	P37023	ACVL1/C46G	ACVL1_HUMAN	Reviewed;	VARIANT	C	46	G	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075233""	loss	C46G	D
P37023/R47P	P37023	ACVL1/R47P	ACVL1_HUMAN	Reviewed;	VARIANT	R	47	P	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs774389618)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075234""	loss	R47P	D
P37023/H66Y	P37023	ACVL1/H66Y	ACVL1_HUMAN	Reviewed;	VARIANT	H	66	Y	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs1480110873)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075235""	loss	H66Y	D
P37023/C77F	P37023	ACVL1/C77F	ACVL1_HUMAN	Reviewed;	VARIANT	C	77	F	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs1330837892)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075236""	loss	C77F	D
P37023/G211D	P37023	ACVL1/G211D	ACVL1_HUMAN	Reviewed;	VARIANT	G	211	D	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs28936687)"";/evidence=""ECO:0000269|PubMed:14684682,;ECO:0000269|PubMed:26176610"";/id=""VAR_026788""	loss	G211D	D
P37023/G211S	P37023	ACVL1/G211S	ACVL1_HUMAN	Reviewed;	VARIANT	G	211	S	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075238""	loss	G211S	D
P37023/A306P	P37023	ACVL1/A306P	ACVL1_HUMAN	Reviewed;	VARIANT	A	306	P	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum)"";/evidence=""ECO:0000269|PubMed:15024723,;ECO:0000269|PubMed:26176610"";/id=""VAR_026795""	loss	A306P	D
P37023/L313V	P37023	ACVL1/L313V	ACVL1_HUMAN	Reviewed;	VARIANT	L	313	V	 (in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075240""	loss	L313V	D
P37023/H314Y	P37023	ACVL1/H314Y	ACVL1_HUMAN	Reviewed;	VARIANT	H	314	Y	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs1565594311)"";/evidence=""ECO:0000269|PubMed:15024723,;ECO:0000269|PubMed:26176610"";/id=""VAR_026796""	loss	H314Y	D
P37023/P378S	P37023	ACVL1/P378S	ACVL1_HUMAN	Reviewed;	VARIANT	P	378	S	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs959973779)"";/evidence=""ECO:0000269|PubMed:20414677,;ECO:0000269|PubMed:26176610"";/id=""VAR_070335""	loss	P378S	D
P37023/E379D	P37023	ACVL1/E379D	ACVL1_HUMAN	Reviewed;	VARIANT	E	379	D	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075241""	loss	E379D	D
P37023/E379K	P37023	ACVL1/E379K	ACVL1_HUMAN	Reviewed;	VARIANT	E	379	K	 (in HHT2; loss of receptor activity in;response to BMP9; retained in the endoplasmic reticulum;;dbSNP:rs1131691686)"";/evidence=""ECO:0000269|PubMed:15024723,;ECO:0000269|PubMed:15712270, ECO:0000269|PubMed:26176610"";/id=""VAR_026803""	loss	E379K	D
P37023/V404G	P37023	ACVL1/V404G	ACVL1_HUMAN	Reviewed;	VARIANT	V	404	G	 (in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum)"";/evidence=""ECO:0000269|PubMed:26176610"";/id=""VAR_075242""	loss	V404G	D
P37023/R411W	P37023	ACVL1/R411W	ACVL1_HUMAN	Reviewed;	VARIANT	R	411	W	 (in HHT2; loss of receptor activity in;response to BMP9; predominantly retained in the endoplasmic;reticulum; dbSNP:rs121909287)"";/evidence=""ECO:0000269|PubMed:11484689,;ECO:0000269|PubMed:15024723, ECO:0000269|PubMed:15712270,;ECO:0000269|PubMed:26176610"";/id=""VAR_026809""	loss	R411W	D
P31749/K14Q	P31749	AKT1/K14Q	AKT1_HUMAN	Reviewed;	MUTAGEN	K	14	Q	 Substantial reduction of phosphorylation at T-;308 and S-473, loss of AKT activation, and loss of binding;to PIP3 as well as IGF1-induced membrane recruitment."";/evidence=""ECO:0000269|PubMed:12176338,;ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:21775285""	decrease	K14Q	D
P31749/K179M	P31749	AKT1/K179M	AKT1_HUMAN	Reviewed;	MUTAGEN	K	179	M	 Abolished serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:33594058""	loss	K179M	D
P31749/T305Y	P31749	AKT1/T305Y	AKT1_HUMAN	Reviewed;	MUTAGEN	T	305	Y	 Abolishes phosphorylation at Thr-308."";/evidence=""ECO:0000269|PubMed:22629392""	loss	T305Y	D
P31749/T312Y	P31749	AKT1/T312Y	AKT1_HUMAN	Reviewed;	MUTAGEN	T	312	Y	 Abolishes phosphorylation at Thr-308."";/evidence=""ECO:0000269|PubMed:22629392""	loss	T312Y	D
Q9Y243/S472A	Q9Y243	AKT3/S472A	AKT3_HUMAN	Reviewed;	MUTAGEN	S	472	A	 67% decrease of activity after pervanadate;treatment."";/evidence=""ECO:0000269|PubMed:10092583""	decrease	S472A	D
Q96QP1/K1067M	Q96QP1	ALPK1/K1067M	ALPK1_HUMAN	Reviewed;	MUTAGEN	K	1067	M	 Abolishes the serine/threonine-protein kinase;and ability to initiate the innate immune response."";/evidence=""ECO:0000269|PubMed:30111836""	loss	K1067M	D
P20594/W115G	P20594	ANPRB/W115G	ANPRB_HUMAN	Reviewed;	VARIANT	W	115	G	 (in AMD1; markedly deficient activity;;dbSNP:rs28931582)"";/evidence=""ECO:0000269|PubMed:15146390"";/id=""VAR_022584""	decrease	W115G	D
P20594/T297M	P20594	ANPRB/T297M	ANPRB_HUMAN	Reviewed;	VARIANT	T	297	M	 (in AMD1; markedly deficient activity;;dbSNP:rs1313765432)"";/evidence=""ECO:0000269|PubMed:15146390"";/id=""VAR_022586""	decrease	T297M	D
P20594/G413E	P20594	ANPRB/G413E	ANPRB_HUMAN	Reviewed;	VARIANT	G	413	E	 (in AMD1; markedly deficient activity)"";/evidence=""ECO:0000269|PubMed:15146390"";/id=""VAR_022589""	decrease	G413E	D
P25098/K220R	P25098	ARBK1/K220R	ARBK1_HUMAN	Reviewed;	MUTAGEN	K	220	R	 Loss of activity."";/evidence=""ECO:0000269|PubMed:9892019""	loss	K220R	D
P25098/D3A	P25098	ARBK1/D3A	ARBK1_HUMAN	Reviewed;	MUTAGEN	D	3	A	 85% reduction in phosphorylation of G-protein;coupled receptor rhodopsin."";/evidence=""ECO:0000269|PubMed:19715378""	decrease	D3A	D
P25098/D3N	P25098	ARBK1/D3N	ARBK1_HUMAN	Reviewed;	MUTAGEN	D	3	N	 60% reduction in phosphorylation of G-protein;coupled receptor rhodopsin."";/evidence=""ECO:0000269|PubMed:19715378""	decrease	D3N	D
P25098/L4K	P25098	ARBK1/L4K	ARBK1_HUMAN	Reviewed;	MUTAGEN	L	4	K	 95% reduction in phosphorylation of G-protein;coupled receptor rhodopsin."";/evidence=""ECO:0000269|PubMed:19715378""	decrease	L4K	D
P25098/E5A	P25098	ARBK1/E5A	ARBK1_HUMAN	Reviewed;	MUTAGEN	E	5	A	 50% reduction in phosphorylation of G-protein;coupled receptor rhodopsin."";/evidence=""ECO:0000269|PubMed:19715378""	decrease	E5A	D
Q13315/I323V	Q13315	ATM/I323V	ATM_HUMAN	Reviewed;	VARIANT	I	323	V	 (in AT; loss of protein expression;;dbSNP:rs587781511)"";/evidence=""ECO:0000269|PubMed:10817650,;ECO:0000269|PubMed:27664052"";/id=""VAR_010803""	loss	I323V	D
Q13315/L1046P	Q13315	ATM/L1046P	ATM_HUMAN	Reviewed;	VARIANT	L	1046	P	 (in AT; loss of protein expression;;dbSNP:rs568461905)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077237""	loss	L1046P	D
Q13315/L1465P	Q13315	ATM/L1465P	ATM_HUMAN	Reviewed;	VARIANT	L	1465	P	 (in AT; decreased phosphorylation of target;proteins; dbSNP:rs730881391)"";/evidence=""ECO:0000269|PubMed:10234507,;ECO:0000269|PubMed:19431188"";/id=""VAR_010826""	decrease	L1465P	D
Q13315/G2023R	Q13315	ATM/G2023R	ATM_HUMAN	Reviewed;	VARIANT	G	2023	R	 (in AT; loss of protein expression;;dbSNP:rs11212587)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077238""	loss	G2023R	D
Q13315/L2068S	Q13315	ATM/L2068S	ATM_HUMAN	Reviewed;	VARIANT	L	2068	S	 (in AT; decreased protein abundance; loss of;DNA damage induced protein autophosphorylation;;dbSNP:rs1555114558)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077239""	decrease	L2068S	D
Q13315/Y2080D	Q13315	ATM/Y2080D	ATM_HUMAN	Reviewed;	VARIANT	Y	2080	D	 (in AT; loss of DNA damage induced protein;autophosphorylation; dbSNP:rs1064795467)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077240""	loss	Y2080D	D
Q13315/Y2627H	Q13315	ATM/Y2627H	ATM_HUMAN	Reviewed;	VARIANT	Y	2627	H	 (in AT; loss of protein expression)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077241""	loss	Y2627H	D
Q13315/F2827C	Q13315	ATM/F2827C	ATM_HUMAN	Reviewed;	VARIANT	F	2827	C	 (in AT; mild; decreased phosphorylation of;target proteins; dbSNP:rs121434216)"";/evidence=""ECO:0000269|PubMed:19431188,;ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9463314"";/id=""VAR_010879""	decrease	F2827C	D
Q13315/F2834L	Q13315	ATM/F2834L	ATM_HUMAN	Reviewed;	VARIANT	F	2834	L	 (in AT; decreased protein abundance)"";/evidence=""ECO:0000269|PubMed:27664052"";/id=""VAR_077242""	decrease	F2834L	D
Q13315/N3003D	Q13315	ATM/N3003D	ATM_HUMAN	Reviewed;	VARIANT	N	3003	D	 (in AT; decreased protein abundance;;dbSNP:rs1137889)"";/evidence=""ECO:0000269|PubMed:27664052,;ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678,;ECO:0000269|PubMed:8665503"";/id=""VAR_077243""	decrease	N3003D	D
Q13315/K1807E	Q13315	ATM/K1807E	ATM_HUMAN	Reviewed;	MUTAGEN	K	1807	E	 Decreased phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	decrease	K1807E	D
Q13315/V1941L	Q13315	ATM/V1941L	ATM_HUMAN	Reviewed;	MUTAGEN	V	1941	L	 Decreased phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	decrease	V1941L	D
Q13315/Y2019C	Q13315	ATM/Y2019C	ATM_HUMAN	Reviewed;	MUTAGEN	Y	2019	C	 Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	Y2019C	D
Q13315/E2039K	Q13315	ATM/E2039K	ATM_HUMAN	Reviewed;	MUTAGEN	E	2039	K	 Decreased phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	decrease	E2039K	D
Q13315/L2338P	Q13315	ATM/L2338P	ATM_HUMAN	Reviewed;	MUTAGEN	L	2338	P	 Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	L2338P	D
Q13315/S2394L	Q13315	ATM/S2394L	ATM_HUMAN	Reviewed;	MUTAGEN	S	2394	L	 Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	S2394L	D
Q13315/L2452P	Q13315	ATM/L2452P	ATM_HUMAN	Reviewed;	MUTAGEN	L	2452	P	 Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	L2452P	D
Q13315/P2699L	Q13315	ATM/P2699L	ATM_HUMAN	Reviewed;	MUTAGEN	P	2699	L	 Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	P2699L	D
Q13315/D2708N	Q13315	ATM/D2708N	ATM_HUMAN	Reviewed;	MUTAGEN	D	2708	N	 Decreased phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	decrease	D2708N	D
Q13315/Q2730P	Q13315	ATM/Q2730P	ATM_HUMAN	Reviewed;	MUTAGEN	Q	2730	P	 Loss of phosphorylation of target proteins."";/evidence=""ECO:0000269|PubMed:19431188""	loss	Q2730P	D
Q13315/D2870A	Q13315	ATM/D2870A	ATM_HUMAN	Reviewed;	MUTAGEN	D	2870	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9733515""	loss	D2870A	D
Q13315/N2875K	Q13315	ATM/N2875K	ATM_HUMAN	Reviewed;	MUTAGEN	N	2875	K	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9733515""	loss	N2875K	D
Q13315/K3016R	Q13315	ATM/K3016R	ATM_HUMAN	Reviewed;	MUTAGEN	K	3016	R	 Loss of DNA damage-inducible acetylation.;Retains constitutive kinase activity, but blocks DNA;damage-induced kinase activation. Disrupts dimer and;abolishes S-1981 autophosphorylation."";/evidence=""ECO:0000269|PubMed:17923702""	loss	K3016R	D
Q13315/R3047Q	Q13315	ATM/R3047Q	ATM_HUMAN	Reviewed;	MUTAGEN	R	3047	Q	 Abolished interaction with PEX5 and;translocation to peroxisomes in response to reactive oxygen;species (ROS)."";/evidence=""ECO:0000269|PubMed:26344566""	loss	R3047Q	D
Q13535/K2327R	Q13535	ATR/K2327R	ATR_HUMAN	Reviewed;	MUTAGEN	K	2327	R	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:11114888,;ECO:0000269|PubMed:12011431, ECO:0000269|PubMed:9925639""	loss	K2327R	D
Q13535/D2475A	Q13535	ATR/D2475A	ATR_HUMAN	Reviewed;	MUTAGEN	D	2475	A	 Abolishes kinase activity; increases;sensitivity to IR and impairs translocation to nuclear foci;upon DNA damage."";/evidence=""ECO:0000269|PubMed:12814551,;ECO:0000269|PubMed:9427750, ECO:0000269|PubMed:9925639""	loss	D2475A	D
Q13535/D2494E	Q13535	ATR/D2494E	ATR_HUMAN	Reviewed;	MUTAGEN	D	2494	E	 Abolishes kinase activity; reduces cell;viability, augments sensitivity to IR and UV."";/evidence=""ECO:0000269|PubMed:10597277,;ECO:0000269|PubMed:9636169""	decrease	D2494E	D
O14965/K162R	O14965	AURKA/K162R	AURKA_HUMAN	Reviewed;	MUTAGEN	K	162	R	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:14702041""	loss	K162R	D
O14965/D274N	O14965	AURKA/D274N	AURKA_HUMAN	Reviewed;	MUTAGEN	D	274	N	 Abolishes cilia disassembly and kinase;activity."";/evidence=""ECO:0000269|PubMed:14580337,;ECO:0000269|PubMed:17604723""	loss	D274N	D
O14965/T288A	O14965	AURKA/T288A	AURKA_HUMAN	Reviewed;	MUTAGEN	T	288	A	 Reduces cilia disassembly and kinase;activity."";/evidence=""ECO:0000269|PubMed:17604723""	decrease	T288A	D
Q96GD4/K106R	Q96GD4	AURKB/K106R	AURKB_HUMAN	Reviewed;	MUTAGEN	K	106	R	 Leads to loss of kinase activity and severely;impairs mitotic progression."";/evidence=""ECO:0000269|PubMed:12686604,;ECO:0000269|PubMed:12925766, ECO:0000269|PubMed:14722118,;ECO:0000269|PubMed:16179162""	loss	K106R	D
Q9UQB9/K72R	Q9UQB9	AURKC/K72R	AURKC_HUMAN	Reviewed;	MUTAGEN	K	72	R	 Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:15316025,;ECO:0000269|PubMed:15499654""	decrease	K72R	D
Q9UQB9/D166Y	Q9UQB9	AURKC/D166Y	AURKC_HUMAN	Reviewed;	MUTAGEN	D	166	Y	 Impairs kinase activity, and keeps AURKC with;the chromosomes until the end of mitosis."";/evidence=""ECO:0000269|PubMed:15938719""	decrease	D166Y	D
Q9UQB9/T198A	Q9UQB9	AURKC/T198A	AURKC_HUMAN	Reviewed;	MUTAGEN	T	198	A	 Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:15316025,;ECO:0000269|PubMed:15670791""	decrease	T198A	D
Q9UIG0/C338A	Q9UIG0	BAZ1B/C338A	BAZ1B_HUMAN	Reviewed;	MUTAGEN	C	338	A	 Loss of tyrosine-protein kinase activity."";/evidence=""ECO:0000269|PubMed:19092802""	loss	C338A	D
O14874/R174G	O14874	BCKD/R174G	BCKD_HUMAN	Reviewed;	VARIANT	R	174	G	 (in BCKDKD; partial loss of kinase activity)"";/evidence=""ECO:0000269|PubMed:24449431"";/id=""VAR_072184""	decrease	R174G	D
O14874/L389P	O14874	BCKD/L389P	BCKD_HUMAN	Reviewed;	VARIANT	L	389	P	 (in BCKDKD; complete loss of kinase;activity)"";/evidence=""ECO:0000269|PubMed:24449431"";/id=""VAR_072185""	loss	L389P	D
Q13873/D485G	Q13873	BMPR2/D485G	BMPR2_HUMAN	Reviewed;	VARIANT	D	485	G	 (in PPH1; complete loss of function;;dbSNP:rs137852745)"";/evidence=""ECO:0000269|PubMed:10973254,;ECO:0000269|PubMed:11115378"";/id=""VAR_013679""	loss	D485G	D
P51813/Y566F	P51813	BMX/Y566F	BMX_HUMAN	Reviewed;	MUTAGEN	Y	566	F	 Abolishes almost completely the SRC-induced;phosphorylation of BMX."";/evidence=""ECO:0000269|PubMed:10688651""	loss	Y566F	D
P15056/K483S	P15056	BRAF/K483S	BRAF_HUMAN	Reviewed;	MUTAGEN	K	483	S	 Reduces kinase activity with MAP2K1."";/evidence=""ECO:0000269|PubMed:21441910""	decrease	K483S	D
O60885/S503A	O60885	BRD4/S503A	BRD4_HUMAN	Reviewed;	MUTAGEN	S	503	A	 Impaired phosphorylation by CK2 and binding to;acetylated histones."";/evidence=""ECO:0000269|PubMed:23317504""	decrease	S503A	D
Q8TDC3/K59A	Q8TDC3	BRSK1/K59A	BRSK1_HUMAN	Reviewed;	MUTAGEN	K	59	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15150265""	loss	K59A	D
Q8TDC3/G327A	Q8TDC3	BRSK1/G327A	BRSK1_HUMAN	Reviewed;	MUTAGEN	G	327	A	 Abolishes activation of kinase activity."";/evidence=""ECO:0000269|PubMed:18339622""	loss	G327A	D
Q8IWQ3/K48M	Q8IWQ3	BRSK2/K48M	BRSK2_HUMAN	Reviewed;	MUTAGEN	K	48	M	 Loss of catalytic activity. Causes;disintegration of actin stress fibers."";/evidence=""ECO:0000269|PubMed:22669945,;ECO:0000269|PubMed:22798068""	loss	K48M	D
Q8IWQ3/T260A	Q8IWQ3	BRSK2/T260A	BRSK2_HUMAN	Reviewed;	MUTAGEN	T	260	A	 Decreased phosphorylation. Nearly abolishes;stimulation of insulin secretion."";/evidence=""ECO:0000269|PubMed:16870137,;ECO:0000269|PubMed:22669945""	decrease	T260A	D
Q8IWQ3/G310A	Q8IWQ3	BRSK2/G310A	BRSK2_HUMAN	Reviewed;	MUTAGEN	G	310	A	 Decreased activation of kinase activity."";/evidence=""ECO:0000269|PubMed:18339622""	decrease	G310A	D
Q06187/R307G	Q06187	BTK/R307G	BTK_HUMAN	Reviewed;	VARIANT	R	307	G	 (in XLA; loss of activity;;dbSNP:rs128621195)"";/evidence=""ECO:0000269|PubMed:8162056"";/id=""VAR_006231""	loss	R307G	D
Q06187/K430E	Q06187	BTK/K430E	BTK_HUMAN	Reviewed;	VARIANT	K	430	E	 (in XLA; loss of phosphorylation of GTF2I;;dbSNP:rs128620184)"";/evidence=""ECO:0000269|PubMed:7809124"";/id=""VAR_006242""	loss	K430E	D
Q06187/Y223F	Q06187	BTK/Y223F	BTK_HUMAN	Reviewed;	MUTAGEN	Y	223	F	 Loss of phosphorylation of GTF2I."";/evidence=""ECO:0000269|PubMed:8630736,;ECO:0000269|PubMed:9012831""	loss	Y223F	D
Q06187/R307K	Q06187	BTK/R307K	BTK_HUMAN	Reviewed;	MUTAGEN	R	307	K	 Loss of phosphorylation of GTF2I."";/evidence=""ECO:0000269|PubMed:9012831""	loss	R307K	D
Q06187/Y551F	Q06187	BTK/Y551F	BTK_HUMAN	Reviewed;	MUTAGEN	Y	551	F	 Loss of phosphorylation of GTF2I."";/evidence=""ECO:0000269|PubMed:9012831""	loss	Y551F	D
O43683/K821A	O43683	BUB1/K821A	BUB1_HUMAN	Reviewed;	MUTAGEN	K	821	A	 Loss of activity."";/evidence=""ECO:0000269|PubMed:10198256""	loss	K821A	D
Q9NYV4/D877N	Q9NYV4	CDK12/D877N	CDK12_HUMAN	Reviewed;	MUTAGEN	D	877	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:24662513""	loss	D877N	D
O94921/K164R	O94921	CDK14/K164R	CDK14_HUMAN	Reviewed;	MUTAGEN	K	164	R	 Abolishes protein kinase activity."";/evidence=""ECO:0000269|PubMed:17517622,;ECO:0000269|PubMed:19524571""	loss	K164R	D
Q00536/S12A	Q00536	CDK16/S12A	CDK16_HUMAN	Reviewed;	MUTAGEN	S	12	A	 Abolishes phosphorylation by BRSK2. Abolishes;effect on insulin secretion."";/evidence=""ECO:0000269|PubMed:22798068""	loss	S12A	D
Q00536/K194A	Q00536	CDK16/K194A	CDK16_HUMAN	Reviewed;	MUTAGEN	K	194	A	 Loss of kinase activity. Abolishes effect on;insulin secretion."";/evidence=""ECO:0000269|PubMed:22184064,;ECO:0000269|PubMed:22798068""	loss	K194A	D
Q00536/K194R	Q00536	CDK16/K194R	CDK16_HUMAN	Reviewed;	MUTAGEN	K	194	R	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:22184064,;ECO:0000269|PubMed:22798068""	loss	K194R	D
Q9BWU1/G28R	Q9BWU1	CDK19/G28R	CDK19_HUMAN	Reviewed;	VARIANT	G	28	R	 (in DEE87; decreased protein kinase;activity)"";/evidence=""ECO:0000269|PubMed:33495529"";/id=""VAR_084393""	decrease	G28R	D
Q8IZL9/T161A	Q8IZL9	CDK20/T161A	CDK20_HUMAN	Reviewed;	MUTAGEN	T	161	A	 Impairs CDK2 T-160 phosphorylation and;activity."";/evidence=""ECO:0000269|PubMed:14597612""	decrease	T161A	D
P24941/K9F	P24941	CDK2/K9F	CDK2_HUMAN	Reviewed;	MUTAGEN	K	9	F	 Reduced phosphorylation by CAK."";/evidence=""ECO:0000269|PubMed:17373709""	decrease	K9F	D
P24941/T160A	P24941	CDK2/T160A	CDK2_HUMAN	Reviewed;	MUTAGEN	T	160	A	 Abolishes activity."";/evidence=""ECO:0000269|PubMed:1396589""	loss	T160A	D
P24941/L166R	P24941	CDK2/L166R	CDK2_HUMAN	Reviewed;	MUTAGEN	L	166	R	 Reduced phosphorylation by CAK and reduced;kinase activity."";/evidence=""ECO:0000269|PubMed:17373709""	decrease	L166R	D
P50613/K41A	P50613	CDK7/K41A	CDK7_HUMAN	Reviewed;	MUTAGEN	K	41	A	 Total loss of activity.""	loss	K41A	D
P50613/T170A	P50613	CDK7/T170A	CDK7_HUMAN	Reviewed;	MUTAGEN	T	170	A	 Total loss of activity. Total loss of;transcriptional activity of the reconstituted TFIIH;complex."";/evidence=""ECO:0000269|PubMed:8069918,;ECO:0000269|PubMed:9832506""	loss	T170A	D
P49336/V27L	P49336	CDK8/V27L	CDK8_HUMAN	Reviewed;	VARIANT	V	27	L	 (in IDDHBA; decreased protein kinase;activity)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083786""	decrease	V27L	D
P49336/R29G	P49336	CDK8/R29G	CDK8_HUMAN	Reviewed;	VARIANT	R	29	G	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1593218885)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083787""	decrease	R29G	D
P49336/G30S	P49336	CDK8/G30S	CDK8_HUMAN	Reviewed;	VARIANT	G	30	S	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1593218890)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083788""	decrease	G30S	D
P49336/S62L	P49336	CDK8/S62L	CDK8_HUMAN	Reviewed;	VARIANT	S	62	L	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1565977796)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083789""	decrease	S62L	D
P49336/R178Q	P49336	CDK8/R178Q	CDK8_HUMAN	Reviewed;	VARIANT	R	178	Q	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1418353379)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083791""	decrease	R178Q	D
P49336/V193G	P49336	CDK8/V193G	CDK8_HUMAN	Reviewed;	VARIANT	V	193	G	 (in IDDHBA; decreased protein kinase;activity)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083792""	decrease	V193G	D
P49336/I223M	P49336	CDK8/I223M	CDK8_HUMAN	Reviewed;	VARIANT	I	223	M	 (in IDDHBA; decreased protein kinase;activity; dbSNP:rs1593310364)"";/evidence=""ECO:0000269|PubMed:30905399"";/id=""VAR_083793""	decrease	I223M	D
P50750/K44R	P50750	CDK9/K44R	CDK9_HUMAN	Reviewed;	MUTAGEN	K	44	R	 Impaired kinase and transcriptional elongation;activities, but normal cyclin T1 and HEXIM1 binding."";/evidence=""ECO:0000269|PubMed:17452463""	decrease	K44R	D
P50750/K48Q	P50750	CDK9/K48Q	CDK9_HUMAN	Reviewed;	MUTAGEN	K	48	Q	 Mimics acetylation; leading to impaired;protein kinase activity."";/evidence=""ECO:0000269|PubMed:28426094""	decrease	K48Q	D
P50750/K48R	P50750	CDK9/K48R	CDK9_HUMAN	Reviewed;	MUTAGEN	K	48	R	 Decreased acetylation; leading to enhanced;protein kinase activity."";/evidence=""ECO:0000269|PubMed:28426094""	decrease	K48R	D
P50750/S175D	P50750	CDK9/S175D	CDK9_HUMAN	Reviewed;	MUTAGEN	S	175	D	 Mimics phosphorylation, constitutive loss of;kinase activity."";/evidence=""ECO:0000269|PubMed:21533037""	loss	S175D	D
Q9Y5P4/S132A	Q9Y5P4	CERT/S132A	CERT_HUMAN	Reviewed;	MUTAGEN	S	132	A	 Abolishes the phosphorylation. Strongly;reduces the interaction with phosphatidylinositol 4-;phosphate. Increases the ceramide transfer activity."";/evidence=""ECO:0000269|PubMed:17591919""	decrease	S132A	D
O14757/K38R	O14757	CHK1/K38R	CHK1_HUMAN	Reviewed;	MUTAGEN	K	38	R	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:12446774,;ECO:0000269|PubMed:14681223""	loss	K38R	D
O14757/D130A	O14757	CHK1/D130A	CHK1_HUMAN	Reviewed;	MUTAGEN	D	130	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:10673501,;ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:11535615,;ECO:0000269|PubMed:11821419, ECO:0000269|PubMed:12588868,;ECO:0000269|PubMed:14681206, ECO:0000269|PubMed:15311285,;ECO:0000269|PubMed:9278511""	loss	D130A	D
O96017/H371Y	O96017	CHK2/H371Y	CHK2_HUMAN	Reviewed;	VARIANT	H	371	Y	 (confers a moderate risk of breast cancer;;partially reduces kinase activity; dbSNP:rs531398630)"";/evidence=""ECO:0000269|PubMed:21618645"";/id=""VAR_066012""	decrease	H371Y	D
O96017/T68A	O96017	CHK2/T68A	CHK2_HUMAN	Reviewed;	MUTAGEN	T	68	A	 Loss of activation and phosphorylation."";/evidence=""ECO:0000269|PubMed:11901158,;ECO:0000269|PubMed:15342622""	loss	T68A	D
O96017/S73A	O96017	CHK2/S73A	CHK2_HUMAN	Reviewed;	MUTAGEN	S	73	A	 Impaired activation, phosphorylation by ATM;and G2/M transition checkpoint."";/evidence=""ECO:0000269|PubMed:16481012""	decrease	S73A	D
O96017/D347A	O96017	CHK2/D347A	CHK2_HUMAN	Reviewed;	MUTAGEN	D	347	A	 Loss of kinase activity and of the ability to;phosphorylate CDC25A."";/evidence=""ECO:0000269|PubMed:11298456,;ECO:0000269|PubMed:9836640""	loss	D347A	D
O96017/D368N	O96017	CHK2/D368N	CHK2_HUMAN	Reviewed;	MUTAGEN	D	368	N	 Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	loss	D368N	D
O96017/T383A	O96017	CHK2/T383A	CHK2_HUMAN	Reviewed;	MUTAGEN	T	383	A	 Loss of phosphorylation in response to;ionizing radiation."";/evidence=""ECO:0000269|PubMed:11390408""	loss	T383A	D
O96017/T387A	O96017	CHK2/T387A	CHK2_HUMAN	Reviewed;	MUTAGEN	T	387	A	 Loss of phosphorylation in response to;ionizing radiation."";/evidence=""ECO:0000269|PubMed:11390408""	loss	T387A	D
Q9UPZ9/R272Q	Q9UPZ9	CILK1/R272Q	CILK1_HUMAN	Reviewed;	VARIANT	R	272	Q	 (in ECO; significantly impairs kinase;activity; decreased localization at the ciliary tips;;impaired ciliogenesis; results in abnormally elongated;cilia; impairs mitosis, cell-cycle exit and radial;neuroblast migration, while promoting apoptosis, when;tested in a heterologous system; loss of nuclear;localization; dbSNP:rs118203918)"";/evidence=""ECO:0000269|PubMed:19185282,;ECO:0000269|PubMed:24797473, ECO:0000269|PubMed:24853502,;ECO:0000269|PubMed:29539279"";/id=""VAR_057994""	decrease	R272Q	D
Q9HAZ1/K189R	Q9HAZ1	CLK4/K189R	CLK4_HUMAN	Reviewed;	MUTAGEN	K	189	R	 Loss of function."";/evidence=""ECO:0000269|PubMed:11170754""	loss	K189R	D
P07333/P132L	P07333	CSF1R/P132L	CSF1R_HUMAN	Reviewed;	VARIANT	P	132	L	 (in BANDDOS; impairs phosphorylation of JNK;kinases upon stimulation with CSF1; dbSNP:rs1351319114)"";/evidence=""ECO:0000269|PubMed:30982609"";/id=""VAR_083140""	decrease	P132L	D
P07333/E633K	P07333	CSF1R/E633K	CSF1R_HUMAN	Reviewed;	VARIANT	E	633	K	 (in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860269)"";/evidence=""ECO:0000269|PubMed:22197934"";/id=""VAR_067398""	decrease	E633K	D
P07333/G765D	P07333	CSF1R/G765D	CSF1R_HUMAN	Reviewed;	VARIANT	G	765	D	 (in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs690016566)"";/evidence=""ECO:0000269|PubMed:24336230"";/id=""VAR_083144""	decrease	G765D	D
P07333/M766T	P07333	CSF1R/M766T	CSF1R_HUMAN	Reviewed;	VARIANT	M	766	T	 (in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860270)"";/evidence=""ECO:0000269|PubMed:22197934,;ECO:0000269|PubMed:23408870"";/id=""VAR_067401""	decrease	M766T	D
P07333/I775N	P07333	CSF1R/I775N	CSF1R_HUMAN	Reviewed;	VARIANT	I	775	N	 (in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860273)"";/evidence=""ECO:0000269|PubMed:22197934"";/id=""VAR_067404""	decrease	I775N	D
P07333/A781E	P07333	CSF1R/A781E	CSF1R_HUMAN	Reviewed;	VARIANT	A	781	E	 (in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs587777247)"";/evidence=""ECO:0000269|PubMed:24336230"";/id=""VAR_083145""	decrease	A781E	D
P07333/R782H	P07333	CSF1R/R782H	CSF1R_HUMAN	Reviewed;	VARIANT	R	782	H	 (in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860281)"";/evidence=""ECO:0000269|PubMed:23408870"";/id=""VAR_083146""	decrease	R782H	D
P07333/I794T	P07333	CSF1R/I794T	CSF1R_HUMAN	Reviewed;	VARIANT	I	794	T	 (in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860274)"";/evidence=""ECO:0000269|PubMed:22197934,;ECO:0000269|PubMed:24336230"";/id=""VAR_067405""	decrease	I794T	D
P07333/P824S	P07333	CSF1R/P824S	CSF1R_HUMAN	Reviewed;	VARIANT	P	824	S	 (in HDLS1; impairs autophosphorylation upon;stimulation with CSF1)"";/evidence=""ECO:0000269|PubMed:24336230"";/id=""VAR_083147""	decrease	P824S	D
P07333/M875T	P07333	CSF1R/M875T	CSF1R_HUMAN	Reviewed;	VARIANT	M	875	T	 (in HDLS1; impairs autophosphorylation upon;stimulation with CSF1; dbSNP:rs281860279)"";/evidence=""ECO:0000269|PubMed:22197934,;ECO:0000269|PubMed:23408870"";/id=""VAR_067410""	decrease	M875T	D
P07333/Y809F	P07333	CSF1R/Y809F	CSF1R_HUMAN	Reviewed;	MUTAGEN	Y	809	F	 Reduced kinase activity. Reduced interaction;with SRC, FYN and YES1."";/evidence=""ECO:0000269|PubMed:7681396""	decrease	Y809F	D
P07333/Y969F	P07333	CSF1R/Y969F	CSF1R_HUMAN	Reviewed;	MUTAGEN	Y	969	F	 Abolishes down-regulation of activated CSF1R."";/evidence=""ECO:0000269|PubMed:15117969""	loss	Y969F	D
P41240/Y184F	P41240	CSK/Y184F	CSK_HUMAN	Reviewed;	MUTAGEN	Y	184	F	 Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:9148770""	loss	Y184F	D
P41240/Y304F	P41240	CSK/Y304F	CSK_HUMAN	Reviewed;	MUTAGEN	Y	304	F	 Decreases activity by two-thirds and alters;conformation."";/evidence=""ECO:0000269|PubMed:9148770""	decrease	Y304F	D
P41240/S364A	P41240	CSK/S364A	CSK_HUMAN	Reviewed;	MUTAGEN	S	364	A	 Strong decrease of phosphorylation by PRKACA;(catalytic subunit of PKA)."";/evidence=""ECO:0000269|PubMed:11181701""	decrease	S364A	D
O14578/G106V	O14578	CTRO/G106V	CTRO_HUMAN	Reviewed;	VARIANT	G	106	V	 (in MCPH17; impairs kinase activity; exhibits;abnormal mitotic cytokinesis; exhibits multipolar spindles;;increases the neurons apoptotic process;;dbSNP:rs886037892)"";/evidence=""ECO:0000269|PubMed:27453578"";/id=""VAR_077442""	decrease	G106V	D
O14578/K126Q	O14578	CTRO/K126Q	CTRO_HUMAN	Reviewed;	VARIANT	K	126	Q	 (in MCPH17; impairs kinase activity; exhibits;abnormal mitotic cytokinesis; exhibits multipolar spindles;;increases the neurons apoptotic process;;dbSNP:rs886037893)"";/evidence=""ECO:0000269|PubMed:27453578"";/id=""VAR_077443""	decrease	K126Q	D
O14578/D230V	O14578	CTRO/D230V	CTRO_HUMAN	Reviewed;	VARIANT	D	230	V	 (in MCPH17; impairs kinase activity; exhibits;abnormal mitotic cytokinesis; exhibits multipolar spindles;;increases the neurons apoptotic process;;dbSNP:rs886037894)"";/evidence=""ECO:0000269|PubMed:27453578"";/id=""VAR_077444""	decrease	D230V	D
P53355/K42A	P53355	DAPK1/K42A	DAPK1_HUMAN	Reviewed;	MUTAGEN	K	42	A	 Loss of activity, apoptotic function and of;autophosphorylation."";/evidence=""ECO:0000269|PubMed:11579085,;ECO:0000269|PubMed:7828849""	loss	K42A	D
P53355/S289A	P53355	DAPK1/S289A	DAPK1_HUMAN	Reviewed;	MUTAGEN	S	289	A	 Loss of phosphorylation and significant;increase in proapoptotic activity.""	loss	S289A	D
P53355/S308D	P53355	DAPK1/S308D	DAPK1_HUMAN	Reviewed;	MUTAGEN	S	308	D	 Reduced Ca(2+)-calmodulin binding and Ca(2+)-;calmodulin-independent kinase activity. Decreases apoptotic;activity."";/evidence=""ECO:0000269|PubMed:11579085""	decrease	S308D	D
Q9UIK4/K52A	Q9UIK4	DAPK2/K52A	DAPK2_HUMAN	Reviewed;	MUTAGEN	K	52	A	 Loss of activity, apoptotic function and of;autophosphorylation."";/evidence=""ECO:0000269|PubMed:10376525,;ECO:0000269|PubMed:10629061, ECO:0000269|PubMed:11230133""	loss	K52A	D
Q9UIK4/S318A	Q9UIK4	DAPK2/S318A	DAPK2_HUMAN	Reviewed;	MUTAGEN	S	318	A	 Loss of Ca(2+)-calmodulin independent;phosphorylation, increase in apoptotic activity."";/evidence=""ECO:0000269|PubMed:11230133""	loss	S318A	D
O43293/T112M	O43293	DAPK3/T112M	DAPK3_HUMAN	Reviewed;	VARIANT	T	112	M	 (in a colorectal adenocarcinoma sample;;somatic mutation; greatly reduces kinase activity,;increases cell proliferation and cell survival)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:21487036"";/id=""VAR_040438""	decrease	T112M	D
O43293/D161N	O43293	DAPK3/D161N	DAPK3_HUMAN	Reviewed;	VARIANT	D	161	N	 (in an ovarian mucinous carcinoma sample;;somatic mutation; greatly reduces kinase activity,;increases cell proliferation and cell survival)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:21487036"";/id=""VAR_040439""	decrease	D161N	D
O43293/P216S	O43293	DAPK3/P216S	DAPK3_HUMAN	Reviewed;	VARIANT	P	216	S	 (in a lung neuroendocrine carcinoma sample;;somatic mutation; greatly reduces kinase activity,;increases cell proliferation, cell adhesion and cell;survival)"";/evidence=""ECO:0000269|PubMed:17344846,;ECO:0000269|PubMed:21487036"";/id=""VAR_040440""	decrease	P216S	D
O43293/K42A	O43293	DAPK3/K42A	DAPK3_HUMAN	Reviewed;	MUTAGEN	K	42	A	 Loss of kinase activity at low concentrations;of ATP."";/evidence=""ECO:0000269|PubMed:17158456""	loss	K42A	D
O43293/D161A	O43293	DAPK3/D161A	DAPK3_HUMAN	Reviewed;	MUTAGEN	D	161	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17158456""	loss	D161A	D
O43293/T180A	O43293	DAPK3/T180A	DAPK3_HUMAN	Reviewed;	MUTAGEN	T	180	A	 Greatly reduced kinase activity."";/evidence=""ECO:0000269|PubMed:21487036""	decrease	T180A	D
O43293/T225A	O43293	DAPK3/T225A	DAPK3_HUMAN	Reviewed;	MUTAGEN	T	225	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17158456""	loss	T225A	D
O43293/T265A	O43293	DAPK3/T265A	DAPK3_HUMAN	Reviewed;	MUTAGEN	T	265	A	 Loss of phosphorylation by ROCK1,;catalytically inactive."";/evidence=""ECO:0000269|PubMed:17158456""	loss	T265A	D
O43293/T299A	O43293	DAPK3/T299A	DAPK3_HUMAN	Reviewed;	MUTAGEN	T	299	A	 Loss of phosphorylation by ROCK1."";/evidence=""ECO:0000269|PubMed:17158456""	loss	T299A	D
Q16832/K608A	Q16832	DDR2/K608A	DDR2_HUMAN	Reviewed;	MUTAGEN	K	608	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:16186108""	loss	K608A	D
Q09013/K100A	Q09013	DMPK/K100A	DMPK_HUMAN	Reviewed;	MUTAGEN	K	100	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15598648""	loss	K100A	D
Q13627/K188R	Q13627	DYR1A/K188R	DYR1A_HUMAN	Reviewed;	MUTAGEN	K	188	R	 Abolished protein kinase activity."";/evidence=""ECO:0000269|PubMed:23665168,;ECO:0000269|PubMed:25620562""	loss	K188R	D
Q13627/Y321F	Q13627	DYR1A/Y321F	DYR1A_HUMAN	Reviewed;	MUTAGEN	Y	321	F	 Mildly reduces kinase activity. Does not;abolish autophosphorylation on tyrosine residues."";/evidence=""ECO:0000269|PubMed:23665168""	decrease	Y321F	D
Q9Y463/K140R	Q9Y463	DYR1B/K140R	DYR1B_HUMAN	Reviewed;	MUTAGEN	K	140	R	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:10910078""	loss	K140R	D
Q9Y463/D239A	Q9Y463	DYR1B/D239A	DYR1B_HUMAN	Reviewed;	MUTAGEN	D	239	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:32611815""	loss	D239A	D
Q92630/T106A	Q92630	DYRK2/T106A	DYRK2_HUMAN	Reviewed;	MUTAGEN	T	106	A	 Impaired ATM-mediated phosphorylation, reduced;affinity with MDM2 and altered MDM2-triggered;ubiquitination."";/evidence=""ECO:0000269|PubMed:19965871""	decrease	T106A	D
Q92630/K251R	Q92630	DYRK2/K251R	DYRK2_HUMAN	Reviewed;	MUTAGEN	K	251	R	 Abolishes protein serine/threonine kinase;activity."";/evidence=""ECO:0000269|PubMed:23362280""	loss	K251R	D
Q92630/S442A	Q92630	DYRK2/S442A	DYRK2_HUMAN	Reviewed;	MUTAGEN	S	442	A	 Impaired ATM-mediated phosphorylation, reduced;affinity with MDM2 and altered MDM2-triggered;ubiquitination."";/evidence=""ECO:0000269|PubMed:19965871""	decrease	S442A	D
Q9NR20/K133R	Q9NR20	DYRK4/K133R	DYRK4_HUMAN	Reviewed;	MUTAGEN	K	133	R	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17292540""	loss	K133R	D
Q9NR20/Y264F	Q9NR20	DYRK4/Y264F	DYRK4_HUMAN	Reviewed;	MUTAGEN	Y	264	F	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:21127067""	loss	Y264F	D
P19525/A67E	P19525	E2AK2/A67E	E2AK2_HUMAN	Reviewed;	MUTAGEN	A	67	E	 Significant loss of activity; loss of dsRNA;binding and dimerization."";/evidence=""ECO:0000269|PubMed:11337501""	loss	A67E	D
P19525/T258A	P19525	E2AK2/T258A	E2AK2_HUMAN	Reviewed;	MUTAGEN	T	258	A	 Moderate loss of activity."";/evidence=""ECO:0000269|PubMed:11152499""	loss	T258A	D
P19525/K296R	P19525	E2AK2/K296R	E2AK2_HUMAN	Reviewed;	MUTAGEN	K	296	R	 Loss of activity."";/evidence=""ECO:0000269|PubMed:11152499""	loss	K296R	D
P19525/T446A	P19525	E2AK2/T446A	E2AK2_HUMAN	Reviewed;	MUTAGEN	T	446	A	 Significant loss of activity and impairs;autophosphorylation of T-451."";/evidence=""ECO:0000269|PubMed:11337501""	loss	T446A	D
P19525/T451A	P19525	E2AK2/T451A	E2AK2_HUMAN	Reviewed;	MUTAGEN	T	451	A	 Loss of activity."";/evidence=""ECO:0000269|PubMed:11337501""	loss	T451A	D
Q9P2K8/K614A	Q9P2K8	E2AK4/K614A	E2AK4_HUMAN	Reviewed;	MUTAGEN	K	614	A	 Loss of activity."";/evidence=""ECO:0000269|PubMed:10026192""	loss	K614A	D
O00418/S78A	O00418	EF2K/S78A	EF2K_HUMAN	Reviewed;	MUTAGEN	S	78	A	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:22216903""	decrease	S78A	D
O00418/T348A	O00418	EF2K/T348A	EF2K_HUMAN	Reviewed;	MUTAGEN	T	348	A	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:22216903""	decrease	T348A	D
O00418/S366A	O00418	EF2K/S366A	EF2K_HUMAN	Reviewed;	MUTAGEN	S	366	A	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:11500364,;ECO:0000269|PubMed:22216903""	decrease	S366A	D
P00533/G428D	P00533	EGFR/G428D	EGFR_HUMAN	Reviewed;	VARIANT	G	428	D	 (in NISBD2; loss of function; the mutant does;not localize to the cell membrane; has diffuse cytoplasmic;localization; dbSNP:rs606231253)"";/evidence=""ECO:0000269|PubMed:24691054"";/id=""VAR_072435""	loss	G428D	D
P00533/R429E	P00533	EGFR/R429E	EGFR_HUMAN	Reviewed;	MUTAGEN	R	429	E	 Abolishes autophosphorylation and activation;of downstream kinases."";/evidence=""ECO:0000269|PubMed:12297050""	loss	R429E	D
P00533/L688A	P00533	EGFR/L688A	EGFR_HUMAN	Reviewed;	MUTAGEN	L	688	A	 Strongly reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417,;ECO:0000269|PubMed:19563760""	decrease	L688A	D
P00533/V689A	P00533	EGFR/V689A	EGFR_HUMAN	Reviewed;	MUTAGEN	V	689	A	 Reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	decrease	V689A	D
P00533/E690A	P00533	EGFR/E690A	EGFR_HUMAN	Reviewed;	MUTAGEN	E	690	A	 Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417,;ECO:0000269|PubMed:19563760""	decrease	E690A	D
P00533/L692A	P00533	EGFR/L692A	EGFR_HUMAN	Reviewed;	MUTAGEN	L	692	A	P: Strongly reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417,;ECO:0000269|PubMed:19563760""	decrease	L692A	D
P00533/T693D	P00533	EGFR/T693D	EGFR_HUMAN	Reviewed;	MUTAGEN	T	693	D	 Strongly reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	decrease	T693D	D
P00533/P694A	P00533	EGFR/P694A	EGFR_HUMAN	Reviewed;	MUTAGEN	P	694	A	 Strongly reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	decrease	P694A	D
P00533/P699A	P00533	EGFR/P699A	EGFR_HUMAN	Reviewed;	MUTAGEN	P	699	A	 Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	decrease	P699A	D
P00533/N700A	P00533	EGFR/N700A	EGFR_HUMAN	Reviewed;	MUTAGEN	N	700	A	 Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	loss	N700A	D
P00533/L704A	P00533	EGFR/L704A	EGFR_HUMAN	Reviewed;	MUTAGEN	L	704	A	 Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	loss	L704A	D
P00533/R705A	P00533	EGFR/R705A	EGFR_HUMAN	Reviewed;	MUTAGEN	R	705	A	 Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	loss	R705A	D
P00533/I706A	P00533	EGFR/I706A	EGFR_HUMAN	Reviewed;	MUTAGEN	I	706	A	 Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:19560417""	loss	I706A	D
P00533/K745A	P00533	EGFR/K745A	EGFR_HUMAN	Reviewed;	MUTAGEN	K	745	A	M: Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:19560417""	loss	K745A	D
P00533/D974A	P00533	EGFR/D974A	EGFR_HUMAN	Reviewed;	MUTAGEN	D	974	A	 Strongly reduced phosphorylation.""	decrease	D974A	D
P00533/R977A	P00533	EGFR/R977A	EGFR_HUMAN	Reviewed;	MUTAGEN	R	977	A	 Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:19563760""	decrease	R977A	D
P29317/K646M	P29317	EPHA2/K646M	EPHA2_HUMAN	Reviewed;	MUTAGEN	K	646	M	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:16236711""	loss	K646M	D
P29317/S897A	P29317	EPHA2/S897A	EPHA2_HUMAN	Reviewed;	MUTAGEN	S	897	A	D: Loss of serum-induced phosphorylation by;PKB. Loss of serum-induced chemotaxis."";/evidence=""ECO:0000269|PubMed:19573808""	loss	S897A	D
P29320/V133E	P29320	EPHA3/V133E	EPHA3_HUMAN	Reviewed;	MUTAGEN	V	133	E	 Loss of EFNA5-binding ability and function."";/evidence=""ECO:0000269|PubMed:14660665""	loss	V133E	D
P29320/F152L	P29320	EPHA3/F152L	EPHA3_HUMAN	Reviewed;	MUTAGEN	F	152	L	 Loss of EFNA5-binding ability and function."";/evidence=""ECO:0000269|PubMed:14660665""	loss	F152L	D
P54762/K651R	P54762	EPHB1/K651R	EPHB1_HUMAN	Reviewed;	MUTAGEN	K	651	R	 Kinase-dead mutant. Unable to;autophosphorylate, to interact with SH2 domain-containing;interactors, to activate the MAPK/ERK and JUN signaling;cascades. Not ubiquitinated by CBL."";/evidence=""ECO:0000269|PubMed:18034775,;ECO:0000269|PubMed:9430661""	loss	K651R	D
P54753/K665R	P54753	EPHB3/K665R	EPHB3_HUMAN	Reviewed;	MUTAGEN	K	665	R	 Kinase-dead. Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:9674711""	loss	K665R	D
P54760/K650N	P54760	EPHB4/K650N	EPHB4_HUMAN	Reviewed;	VARIANT	K	650	N	 (in CMAVM2; highly decreased tyrosine;phosphorylation; highly decreased interaction with RASA1;;dbSNP:rs1584658113)"";/evidence=""ECO:0000269|PubMed:30578106"";/id=""VAR_081706""	decrease	K650N	D
P54760/E664K	P54760	EPHB4/E664K	EPHB4_HUMAN	Reviewed;	VARIANT	E	664	K	 (in CMAVM2; the mutant protein is not;detected by Western blot; loss of localization to cell;membrane; dbSNP:rs1562969219)"";/evidence=""ECO:0000269|PubMed:28687708"";/id=""VAR_081708""	loss	E664K	D
P54760/R739Q	P54760	EPHB4/R739Q	EPHB4_HUMAN	Reviewed;	VARIANT	R	739	Q	 (in LMPHM7; loss of kinase activity;;dbSNP:rs1057519263)"";/evidence=""ECO:0000269|PubMed:27400125"";/id=""VAR_078063""	loss	R739Q	D
P54760/I782S	P54760	EPHB4/I782S	EPHB4_HUMAN	Reviewed;	VARIANT	I	782	S	 (in LMPHM7; loss of kinase activity;;dbSNP:rs1057519264)"";/evidence=""ECO:0000269|PubMed:27400125"";/id=""VAR_078064""	loss	I782S	D
P54760/R838W	P54760	EPHB4/R838W	EPHB4_HUMAN	Reviewed;	VARIANT	R	838	W	 (in CMAVM2; the mutant protein is not;detected by Western blot; loss of localization to cell;membrane; dbSNP:rs764827256)"";/evidence=""ECO:0000269|PubMed:28687708"";/id=""VAR_081719""	loss	R838W	D
P54760/C845R	P54760	EPHB4/C845R	EPHB4_HUMAN	Reviewed;	VARIANT	C	845	R	 (in CMAVM2; the mutant protein is not;detected by Western blot; loss of localization to cell;membrane; dbSNP:rs1584653054)"";/evidence=""ECO:0000269|PubMed:28687708"";/id=""VAR_081720""	loss	C845R	D
P54760/R864W	P54760	EPHB4/R864W	EPHB4_HUMAN	Reviewed;	VARIANT	R	864	W	 (in CMAVM2; the mutant protein is not;detected by Western blot; loss of localization to cell;membrane; dbSNP:rs769965440)"";/evidence=""ECO:0000269|PubMed:28687708"";/id=""VAR_081722""	loss	R864W	D
P04626/A710V	P04626	ERBB2/A710V	ERBB2_HUMAN	Reviewed;	VARIANT	A	710	V	 (in VSCN2; almost complete loss of ERBB2 and;ERBB3 phosphorylation in the presence or in the absence of;NRG1 stimulation, suggesting alteration of downstream;signaling; does not affect the subcellular localization at;the cell membrane)"";/evidence=""ECO:0000269|PubMed:33497358"";/id=""VAR_086107""	loss	A710V	D
P21860/T787P	P21860	ERBB3/T787P	ERBB3_HUMAN	Reviewed;	VARIANT	T	787	P	 (in VSCN1; almost complete loss of ERBB2 and;ERBB3 phosphorylation in the presence or in the absence of;NRG1 stimulation, suggesting alteration of downstream;signaling; does not affect the subcellular localization at;the cell membrane)"";/evidence=""ECO:0000269|PubMed:33497358"";/id=""VAR_086108""	loss	T787P	D
P21860/V899M	P21860	ERBB3/V899M	ERBB3_HUMAN	Reviewed;	VARIANT	V	899	M	 (in VSCN1; almost complete loss of ERBB2 and;ERBB3 phosphorylation in the presence or in the absence of;NRG1 stimulation, suggesting alteration of downstream;signaling; does not affect the subcellular localization at;the cell membrane)"";/evidence=""ECO:0000269|PubMed:33497358"";/id=""VAR_086110""	loss	V899M	D
P21860/K742M	P21860	ERBB3/K742M	ERBB3_HUMAN	Reviewed;	MUTAGEN	K	742	M	 Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:20351256""	decrease	K742M	D
P21860/Y868E	P21860	ERBB3/Y868E	ERBB3_HUMAN	Reviewed;	MUTAGEN	Y	868	E	 Strongly reduced tyrosine phosphorylation."";/evidence=""ECO:0000269|PubMed:20351256""	decrease	Y868E	D
Q15303/R927Q	Q15303	ERBB4/R927Q	ERBB4_HUMAN	Reviewed;	VARIANT	R	927	Q	 (in ALS19; reduces autophosphorylation upon;NRG1 stimulation; dbSNP:rs397514262)"";/evidence=""ECO:0000269|PubMed:24119685"";/id=""VAR_070810""	decrease	R927Q	D
Q15303/R1275W	Q15303	ERBB4/R1275W	ERBB4_HUMAN	Reviewed;	VARIANT	R	1275	W	 (in ALS19; reduces autophosphorylation upon;NRG1 stimulation; dbSNP:rs397514263)"";/evidence=""ECO:0000269|PubMed:24119685"";/id=""VAR_070811""	decrease	R1275W	D
Q15303/L710N	Q15303	ERBB4/L710N	ERBB4_HUMAN	Reviewed;	MUTAGEN	L	710	N	 Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:18287036""	decrease	L710N	D
Q15303/K751R	Q15303	ERBB4/K751R	ERBB4_HUMAN	Reviewed;	MUTAGEN	K	751	R	 Abolishes kinase activity. Abolishes;phosphorylation, proteolytic processing and nuclear;localization."";/evidence=""ECO:0000269|PubMed:11390655,;ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867""	loss	K751R	D
Q15303/M766R	Q15303	ERBB4/M766R	ERBB4_HUMAN	Reviewed;	MUTAGEN	M	766	R	 Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:18287036""	decrease	M766R	D
Q15303/D843N	Q15303	ERBB4/D843N	ERBB4_HUMAN	Reviewed;	MUTAGEN	D	843	N	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:16978839""	loss	D843N	D
Q15303/D861Y	Q15303	ERBB4/D861Y	ERBB4_HUMAN	Reviewed;	MUTAGEN	D	861	Y	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:19098003""	loss	D861Y	D
Q15303/L864R	Q15303	ERBB4/L864R	ERBB4_HUMAN	Reviewed;	MUTAGEN	L	864	R	 Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:18287036""	decrease	L864R	D
O75460/K599A	O75460	ERN1/K599A	ERN1_HUMAN	Reviewed;	MUTAGEN	K	599	A	 Loss of autophosphorylation and of;endoribonuclease activity. Inhibition of growth arrest."";/evidence=""ECO:0000269|PubMed:11175748,;ECO:0000269|PubMed:9637683""	loss	K599A	D
Q76MJ5/K548A	Q76MJ5	ERN2/K548A	ERN2_HUMAN	Reviewed;	MUTAGEN	K	548	A	 Loss of autophosphorylation, of induction of;apoptosis and of 28S rRNA cleavage, attenuation of;repression of protein synthesis."";/evidence=""ECO:0000269|PubMed:11175748""	loss	K548A	D
Q14289/K457A	Q14289	FAK2/K457A	FAK2_HUMAN	Reviewed;	MUTAGEN	K	457	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:15166227""	loss	K457A	D
Q14289/Y881F	Q14289	FAK2/Y881F	FAK2_HUMAN	Reviewed;	MUTAGEN	Y	881	F	 Loss of phosphorylation site. Strongly reduced;interaction with GRB2."";/evidence=""ECO:0000269|PubMed:20521079""	decrease	Y881F	D
P16591/R483Q	P16591	FER/R483Q	FER_HUMAN	Reviewed;	MUTAGEN	R	483	Q	 Abolishes kinase activity. Abolishes location;at microtubules."";/evidence=""ECO:0000269|PubMed:12972546""	loss	R483Q	D
P16591/K591R	P16591	FER/K591R	FER_HUMAN	Reviewed;	MUTAGEN	K	591	R	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:9722593""	loss	K591R	D
P07332/L334P	P07332	FES/L334P	FES_HUMAN	Reviewed;	MUTAGEN	L	334	P	 Abolishes autophosphorylation."";/evidence=""ECO:0000269|PubMed:11509660""	loss	L334P	D
P07332/G463V	P07332	FES/G463V	FES_HUMAN	Reviewed;	MUTAGEN	G	463	V	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:18775312""	loss	G463V	D
P07332/K590E	P07332	FES/K590E	FES_HUMAN	Reviewed;	MUTAGEN	K	590	E	 Abolishes kinase activity. Fails to inhibit;proliferation of melanoma cells."";/evidence=""ECO:0000269|PubMed:15485904,;ECO:0000269|PubMed:28463229""	loss	K590E	D
P07332/M704V	P07332	FES/M704V	FES_HUMAN	Reviewed;	MUTAGEN	M	704	V	 Reduced autophosphorylation and strongly;reduced kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	decrease	M704V	D
P07332/Y713F	P07332	FES/Y713F	FES_HUMAN	Reviewed;	MUTAGEN	Y	713	F	 Reduces kinase activity by over 90%."";/evidence=""ECO:0000269|PubMed:7687763""	decrease	Y713F	D
P07332/V743M	P07332	FES/V743M	FES_HUMAN	Reviewed;	MUTAGEN	V	743	M	 Strongly reduced autophosphorylation and;kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	decrease	V743M	D
P07332/S759F	P07332	FES/S759F	FES_HUMAN	Reviewed;	MUTAGEN	S	759	F	 Reduced autophosphorylation and strongly;reduced kinase activity."";/evidence=""ECO:0000269|PubMed:15867340,;ECO:0000269|PubMed:16455651""	decrease	S759F	D
P11362/K618N	P11362	FGFR1/K618N	FGFR1_HUMAN	Reviewed;	VARIANT	K	618	N	 (in HH2; some patients also carry GNRHR;mutations; impairs tyrosine kinase activity)"";/evidence=""ECO:0000269|PubMed:19820032,;ECO:0000269|PubMed:23643382"";/id=""VAR_069293""	decrease	K618N	D
P11362/K514A	P11362	FGFR1/K514A	FGFR1_HUMAN	Reviewed;	MUTAGEN	K	514	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15117958""	loss	K514A	D
P11362/D623A	P11362	FGFR1/D623A	FGFR1_HUMAN	Reviewed;	MUTAGEN	D	623	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:19224897""	loss	D623A	D
P21802/M391R	P21802	FGFR2/M391R	FGFR2_HUMAN	Reviewed;	VARIANT	M	391	R	 (in BBDS; the mutation selectively reduces;plasma-membrane levels of the protein and markedly;diminishes the receptor's responsiveness to extracellular;FGF; dbSNP:rs387906677)"";/evidence=""ECO:0000269|PubMed:22387015"";/id=""VAR_067978""	decrease	M391R	D
P21802/A628T	P21802	FGFR2/A628T	FGFR2_HUMAN	Reviewed;	VARIANT	A	628	T	 (in LADDS; strongly reduced kinase activity;;dbSNP:rs121918509)"";/evidence=""ECO:0000269|PubMed:16501574"";/id=""VAR_029884""	decrease	A628T	D
P21802/Y769F	P21802	FGFR2/Y769F	FGFR2_HUMAN	Reviewed;	MUTAGEN	Y	769	F	 Increases fibroblast proliferation. Decreases;phosphorylation of PLCG1 and FRS2. Decreases activation of;MAP kinases."";/evidence=""ECO:0000269|PubMed:15629145,;ECO:0000269|PubMed:19103595""	decrease	Y769F	D
P22607/K508A	P22607	FGFR3/K508A	FGFR3_HUMAN	Reviewed;	MUTAGEN	K	508	A	 Loss of kinase activity. Abolishes;ubiquitination."";/evidence=""ECO:0000269|PubMed:12297284,;ECO:0000269|PubMed:16410555""	loss	K508A	D
P22607/Y724F	P22607	FGFR3/Y724F	FGFR3_HUMAN	Reviewed;	MUTAGEN	Y	724	F	 Strongly reduced kinase activity. Strongly;reduced mitogen activity."";/evidence=""ECO:0000269|PubMed:11294897""	decrease	Y724F	D
P22455/K503R	P22455	FGFR4/K503R	FGFR4_HUMAN	Reviewed;	MUTAGEN	K	503	R	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11433297,;ECO:0000269|PubMed:17311277""	loss	K503R	D
P36888/K644A	P36888	FLT3/K644A	FLT3_HUMAN	Reviewed;	MUTAGEN	K	644	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:15831474""	loss	K644A	D
P42685/K262R	P42685	FRK/K262R	FRK_HUMAN	Reviewed;	MUTAGEN	K	262	R	 Loss of ability to phosphorylate PTEN."";/evidence=""ECO:0000269|PubMed:19345329""	loss	K262R	D
Q15835/K219A	Q15835	GRK1/K219A	GRK1_HUMAN	Reviewed;	MUTAGEN	K	219	A	 Loss of autophosphorylation and RHO;phosphorylation."";/evidence=""ECO:0000269|PubMed:15946941""	loss	K219A	D
P49841/L128A	P49841	GSK3B/L128A	GSK3B_HUMAN	Reviewed;	MUTAGEN	L	128	A	 Abolishes activity toward AXIN1."";/evidence=""ECO:0000269|PubMed:11430833""	loss	L128A	D
Q02846/F565S	Q02846	GUC2D/F565S	GUC2D_HUMAN	Reviewed;	VARIANT	F	565	S	 (in LCA1; loss of activity;;dbSNP:rs61749755)"";/evidence=""ECO:0000269|PubMed:9888789"";/id=""VAR_009131""	loss	F565S	D
Q8TF76/K282M	Q8TF76	HASP/K282M	HASP_HUMAN	Reviewed;	MUTAGEN	K	282	M	 Loss of catalytic activity. Reduced nuclear;size in larval salivary glands."";/evidence=""ECO:0000269|PubMed:32750047""	decrease	K282M	D
Q8TF76/E492A	Q8TF76	HASP/E492A	HASP_HUMAN	Reviewed;	MUTAGEN	E	492	A	 Markedly reduced affinity for histone H3 and;reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	E492A	D
Q8TF76/K511A	Q8TF76	HASP/K511A	HASP_HUMAN	Reviewed;	MUTAGEN	K	511	A	 Strongly reduced enzyme activity."";/evidence=""ECO:0000269|PubMed:19918057""	decrease	K511A	D
Q8TF76/H651A	Q8TF76	HASP/H651A	HASP_HUMAN	Reviewed;	MUTAGEN	H	651	A	 Strongly reduced enzyme activity, markedly;reduced affinity for histone H3."";/evidence=""ECO:0000269|PubMed:19918049,;ECO:0000269|PubMed:19918057""	decrease	H651A	D
Q8TF76/D707L	Q8TF76	HASP/D707L	HASP_HUMAN	Reviewed;	MUTAGEN	D	707	L	 Markedly reduced affinity for histone H3 and;reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	D707L	D
Q8TF76/D709N	Q8TF76	HASP/D709N	HASP_HUMAN	Reviewed;	MUTAGEN	D	709	N	 Markedly reduced affinity for histone H3 and;reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	D709N	D
Q8TF76/G713F	Q8TF76	HASP/G713F	HASP_HUMAN	Reviewed;	MUTAGEN	G	713	F	 Markedly reduced affinity for histone H3 and;reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	G713F	D
Q8TF76/D716L	Q8TF76	HASP/D716L	HASP_HUMAN	Reviewed;	MUTAGEN	D	716	L	 Markedly reduced histone H3 phosphorylation."";/evidence=""ECO:0000269|PubMed:19918049""	decrease	D716L	D
P08631/K290E	P08631	HCK/K290E	HCK_HUMAN	Reviewed;	MUTAGEN	K	290	E	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11896602""	loss	K290E	D
P08631/E305A	P08631	HCK/E305A	HCK_HUMAN	Reviewed;	MUTAGEN	E	305	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10644735""	loss	E305A	D
P08631/D381E	P08631	HCK/D381E	HCK_HUMAN	Reviewed;	MUTAGEN	D	381	E	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15998323""	loss	D381E	D
P08631/Y411A	P08631	HCK/Y411A	HCK_HUMAN	Reviewed;	MUTAGEN	Y	411	A	 Reduced catalytic activity and higher affinity;for target peptides."";/evidence=""ECO:0000269|PubMed:10644735""	decrease	Y411A	D
Q86Z02/K219A	Q86Z02	HIPK1/K219A	HIPK1_HUMAN	Reviewed;	MUTAGEN	K	219	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:19646965""	loss	K219A	D
Q86Z02/D315N	Q86Z02	HIPK1/D315N	HIPK1_HUMAN	Reviewed;	MUTAGEN	D	315	N	 Loss of kinase activity and impaired MAP3K5-;JNK inactivation."";/evidence=""ECO:0000269|PubMed:15701637""	loss	D315N	D
Q9H422/K226R	Q9H422	HIPK3/K226R	HIPK3_HUMAN	Reviewed;	MUTAGEN	K	226	R	 Loss of kinase activity and impaired;activation of SF1."";/evidence=""ECO:0000269|PubMed:17210646""	loss	K226R	D
P08069/R138Q	P08069	IGF1R/R138Q	IGF1R_HUMAN	Reviewed;	VARIANT	R	138	Q	 (in IGF1RES; has decreased IGF1R function;;dbSNP:rs121912426)"";/evidence=""ECO:0000269|PubMed:14657428"";/id=""VAR_034891""	decrease	R138Q	D
P08069/K145N	P08069	IGF1R/K145N	IGF1R_HUMAN	Reviewed;	VARIANT	K	145	N	 (in IGF1RES; has decreased IGF1R function;;dbSNP:rs121912427)"";/evidence=""ECO:0000269|PubMed:14657428"";/id=""VAR_034892""	decrease	K145N	D
P08069/N359Y	P08069	IGF1R/N359Y	IGF1R_HUMAN	Reviewed;	VARIANT	N	359	Y	 (in IGF1RES; significant decrease in IGF1-;induced DNA synthesis and AKT1 phosphorylation in patient;fibroblasts)"";/evidence=""ECO:0000269|PubMed:25040157"";/id=""VAR_076247""	decrease	N359Y	D
P08069/Y865C	P08069	IGF1R/Y865C	IGF1R_HUMAN	Reviewed;	VARIANT	Y	865	C	 (in IGF1RES; significant decrease in IGF1-;induced DNA synthesis and AKT1 phosphorylation in patient;fibroblasts)"";/evidence=""ECO:0000269|PubMed:25040157"";/id=""VAR_076248""	decrease	Y865C	D
P08069/R1256S	P08069	IGF1R/R1256S	IGF1R_HUMAN	Reviewed;	VARIANT	R	1256	S	 (in IGF1RES; significant decrease in IGF1-;induced DNA synthesis and AKT1 phosphorylation in patient;fibroblasts)"";/evidence=""ECO:0000269|PubMed:25040157"";/id=""VAR_076249""	decrease	R1256S	D
O15111/T23A	O15111	IKKA/T23A	IKKA_HUMAN	Reviewed;	MUTAGEN	T	23	A	 Loss of phosphorylation and decrease of kinase;activity."";/evidence=""ECO:0000269|PubMed:10485710""	decrease	T23A	D
O15111/K44A	O15111	IKKA/K44A	IKKA_HUMAN	Reviewed;	MUTAGEN	K	44	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9244310,;ECO:0000269|PubMed:9346484""	loss	K44A	D
O15111/K44M	O15111	IKKA/K44M	IKKA_HUMAN	Reviewed;	MUTAGEN	K	44	M	 Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:9244310,;ECO:0000269|PubMed:9346484""	loss	K44M	D
O15111/S176A	O15111	IKKA/S176A	IKKA_HUMAN	Reviewed;	MUTAGEN	S	176	A	 Loss of phosphorylation and of activity."";/evidence=""ECO:0000269|PubMed:9346484,;ECO:0000269|PubMed:9520446""	loss	S176A	D
O14920/D166A	O14920	IKKB/D166A	IKKB_HUMAN	Reviewed;	MUTAGEN	D	166	A	 Loss of protein kinase activity."";/evidence=""ECO:0000269|PubMed:25326418""	loss	D166A	D
O14920/S177A	O14920	IKKB/S177A	IKKB_HUMAN	Reviewed;	MUTAGEN	S	177	A	 Decrease of activity."";/evidence=""ECO:0000269|PubMed:19675099,;ECO:0000269|PubMed:9346484""	decrease	S177A	D
O14920/S181A	O14920	IKKB/S181A	IKKB_HUMAN	Reviewed;	MUTAGEN	S	181	A	 Decrease of activity."";/evidence=""ECO:0000269|PubMed:19675099,;ECO:0000269|PubMed:9346484""	decrease	S181A	D
Q14164/K38A	Q14164	IKKE/K38A	IKKE_HUMAN	Reviewed;	MUTAGEN	K	38	A	 Loss of kinase activity and loss of nuclear;import."";/evidence=""ECO:0000269|PubMed:10421793""	loss	K38A	D
Q14164/E168A	Q14164	IKKE/E168A	IKKE_HUMAN	Reviewed;	MUTAGEN	E	168	A	 Slight decrease of kinase activity."";/evidence=""ECO:0000269|PubMed:10421793""	decrease	E168A	D
Q14164/S172A	Q14164	IKKE/S172A	IKKE_HUMAN	Reviewed;	MUTAGEN	S	172	A	 Loss of autophosphorylation and of kinase;activity."";/evidence=""ECO:0000269|PubMed:10421793""	loss	S172A	D
Q14164/S172E	Q14164	IKKE/S172E	IKKE_HUMAN	Reviewed;	MUTAGEN	S	172	E	 Decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:10421793""	decrease	S172E	D
P06213/E1206D	P06213	INSR/E1206D	INSR_HUMAN	Reviewed;	VARIANT	E	1206	D	 (in IRAN type A; accelerates degradation of;the protein and impairs kinase activity)"";/evidence=""ECO:0000269|PubMed:7983039"";/id=""VAR_015931""	decrease	E1206D	D
P06213/W1220L	P06213	INSR/W1220L	INSR_HUMAN	Reviewed;	VARIANT	W	1220	L	 (in IRAN type A; accelerates degradation of;the protein and impairs kinase activity; dbSNP:rs52800171)"";/evidence=""ECO:0000269|PubMed:7983039,;ECO:0000269|PubMed:8390949"";/id=""VAR_004100""	decrease	W1220L	D
P06213/K1057M	P06213	INSR/K1057M	INSR_HUMAN	Reviewed;	MUTAGEN	K	1057	M	R: Abolishes the kinase activity."";/evidence=""ECO:0000269|PubMed:10803466,;ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849""	loss	K1057M	D
P06213/D1159N	P06213	INSR/D1159N	INSR_HUMAN	Reviewed;	MUTAGEN	D	1159	N	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11598120""	loss	D1159N	D
P06213/R1163Q	P06213	INSR/R1163Q	INSR_HUMAN	Reviewed;	MUTAGEN	R	1163	Q	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11598120""	loss	R1163Q	D
P51617/T209A	P51617	IRAK1/T209A	IRAK1_HUMAN	Reviewed;	MUTAGEN	T	209	A	 Completely abolishes auto-phosphorylation in;the kinase domain."";/evidence=""ECO:0000269|PubMed:14625308""	loss	T209A	D
P51617/K239S	P51617	IRAK1/K239S	IRAK1_HUMAN	Reviewed;	MUTAGEN	K	239	S	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15084582""	loss	K239S	D
P51617/D340N	P51617	IRAK1/D340N	IRAK1_HUMAN	Reviewed;	MUTAGEN	D	340	N	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:18691762""	loss	D340N	D
P51617/T387A	P51617	IRAK1/T387A	IRAK1_HUMAN	Reviewed;	MUTAGEN	T	387	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:14625308""	loss	T387A	D
Q9NWZ3/K213A	Q9NWZ3	IRAK4/K213A	IRAK4_HUMAN	Reviewed;	MUTAGEN	K	213	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15084582""	loss	K213A	D
P23458/K908A	P23458	JAK1/K908A	JAK1_HUMAN	Reviewed;	MUTAGEN	K	908	A	 Loss of protein tyrosine kinase activity."";/evidence=""ECO:0000269|PubMed:32750333""	loss	K908A	D
P52333/Y785F	P52333	JAK3/Y785F	JAK3_HUMAN	Reviewed;	MUTAGEN	Y	785	F	 Strong decrease of JAK3 phosphorylation."";/evidence=""ECO:0000269|PubMed:15121872""	decrease	Y785F	D
P52333/K855A	P52333	JAK3/K855A	JAK3_HUMAN	Reviewed;	MUTAGEN	K	855	A	 More than 90% loss of STAT5a activation."";/evidence=""ECO:0000269|PubMed:18250158""	loss	K855A	D
P52333/Y904F	P52333	JAK3/Y904F	JAK3_HUMAN	Reviewed;	MUTAGEN	Y	904	F	 About 40% loss of STAT5a activation."";/evidence=""ECO:0000269|PubMed:18250158""	decrease	Y904F	D
P52333/Y939F	P52333	JAK3/Y939F	JAK3_HUMAN	Reviewed;	MUTAGEN	Y	939	F	 About 80% loss of STAT5a activation."";/evidence=""ECO:0000269|PubMed:18250158""	loss	Y939F	D
O60229/K2713A	O60229	KALRN/K2713A	KALRN_HUMAN	Reviewed;	MUTAGEN	K	2713	A	 Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:10023074""	loss	K2713A	D
P22612/I74M	P22612	KAPCG/I74M	KAPCG_HUMAN	Reviewed;	VARIANT	I	74	M	 (in BDPLT19; patient platelets show impaired;activation; dbSNP:rs724159972)"";/evidence=""ECO:0000269|PubMed:25061177"";/id=""VAR_072672""	decrease	I74M	D
P48730/T44A	P48730	KC1D/T44A	KC1D_HUMAN	Reviewed;	VARIANT	T	44	A	 (in FASPS2; strongly reduces kinase activity;;dbSNP:rs104894561)"";/evidence=""ECO:0000269|PubMed:15800623,;ECO:0000269|PubMed:23636092"";/id=""VAR_029075""	decrease	T44A	D
P48730/H46R	P48730	KC1D/H46R	KC1D_HUMAN	Reviewed;	VARIANT	H	46	R	 (in FASPS2; strongly reduces kinase activity;;dbSNP:rs397514693)"";/evidence=""ECO:0000269|PubMed:23636092"";/id=""VAR_069801""	decrease	H46R	D
P48730/K38M	P48730	KC1D/K38M	KC1D_HUMAN	Reviewed;	MUTAGEN	K	38	M	 Impaired kinase activity and abnormal;subcellular localization with exclusive accumulation to the;nucleus."";/evidence=""ECO:0000269|PubMed:11161704""	decrease	K38M	D
P48730/T176I	P48730	KC1D/T176I	KC1D_HUMAN	Reviewed;	MUTAGEN	T	176	I	 Impaired kinase activity and abnormal;subcellular localization with exclusive accumulation to the;nucleus."";/evidence=""ECO:0000269|PubMed:11161704""	decrease	T176I	D
P49674/K38R	P49674	KC1E/K38R	KC1E_HUMAN	Reviewed;	MUTAGEN	K	38	R	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:29222110""	loss	K38R	D
Q9HCP0/N169A	Q9HCP0	KC1G1/N169A	KC1G1_HUMAN	Reviewed;	MUTAGEN	N	169	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:21680713""	loss	N169A	D
Q14012/T177A	Q14012	KCC1A/T177A	KCC1A_HUMAN	Reviewed;	MUTAGEN	T	177	A	 Loss of activation by CaMKK1."";/evidence=""ECO:0000269|PubMed:7641687""	loss	T177A	D
Q6P2M8/T179A	Q6P2M8	KCC1B/T179A	KCC1B_HUMAN	Reviewed;	MUTAGEN	T	179	A	 Loss of activation by cmkC."";/evidence=""ECO:0000269|PubMed:10988293""	loss	T179A	D
Q8IU85/T180A	Q8IU85	KCC1D/T180A	KCC1D_HUMAN	Reviewed;	MUTAGEN	T	180	A	 Loss of ionomycin-induced activation."";/evidence=""ECO:0000269|PubMed:12935886,;ECO:0000269|PubMed:16324104""	loss	T180A	D
Q16566/S12A	Q16566	KCC4/S12A	KCC4_HUMAN	Reviewed;	MUTAGEN	S	12	A	 Loss of activity."";/evidence=""ECO:0000269|PubMed:8702940""	loss	S12A	D
Q16566/S13A	Q16566	KCC4/S13A	KCC4_HUMAN	Reviewed;	MUTAGEN	S	13	A	 Loss of activity."";/evidence=""ECO:0000269|PubMed:8702940""	loss	S13A	D
Q16566/K75E	Q16566	KCC4/K75E	KCC4_HUMAN	Reviewed;	MUTAGEN	K	75	E	 Loss of activity; dominant negative form."";/evidence=""ECO:0000269|PubMed:10617605""	loss	K75E	D
Q16566/T200A	Q16566	KCC4/T200A	KCC4_HUMAN	Reviewed;	MUTAGEN	T	200	A	 Loss of activation by CaMKK1 or CaMKK2."";/evidence=""ECO:0000269|PubMed:8855261""	loss	T200A	D
P10721/E839K	P10721	KIT/E839K	KIT_HUMAN	Reviewed;	VARIANT	E	839	K	 (in MASTC; sporadic case; somatic mutation;;dominant negative mutation; loss of autophosphorylation;;dbSNP:rs121913509)"";/evidence=""ECO:0000269|PubMed:9990072"";/id=""VAR_033136""	loss	E839K	D
P10721/R381A	P10721	KIT/R381A	KIT_HUMAN	Reviewed;	MUTAGEN	R	381	A	 Reduces autophosphorylation in response to;KITLG/SCF."";/evidence=""ECO:0000269|PubMed:17662946""	decrease	R381A	D
P10721/E386A	P10721	KIT/E386A	KIT_HUMAN	Reviewed;	MUTAGEN	E	386	A	 Reduces autophosphorylation in response to;KITLG/SCF."";/evidence=""ECO:0000269|PubMed:17662946""	decrease	E386A	D
Q15139/Y502E	Q15139	KPCD1/Y502E	KPCD1_HUMAN	Reviewed;	MUTAGEN	Y	502	E	 Loss of activation."";/evidence=""ECO:0000269|PubMed:12637538""	loss	Y502E	D
Q15139/K612W	Q15139	KPCD1/K612W	KPCD1_HUMAN	Reviewed;	MUTAGEN	K	612	W	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12637538""	loss	K612W	D
Q9BZL6/D695A	Q9BZL6	KPCD2/D695A	KPCD2_HUMAN	Reviewed;	MUTAGEN	D	695	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:23503467""	loss	D695A	D
Q9BZL6/Y717F	Q9BZL6	KPCD2/Y717F	KPCD2_HUMAN	Reviewed;	MUTAGEN	Y	717	F	 Abolishes phosphorylation. Decreases substrate;affinity and increases catalytic efficiency. Increases Ser-;706 or/and Ser-710 phosphorylation. Increases NF-kappa-B;activation in response to oxidative stress."";/evidence=""ECO:0000269|PubMed:28428613""	decrease	Y717F	D
Q05655/S299A	Q05655	KPCD/S299A	KPCD_HUMAN	Reviewed;	MUTAGEN	S	299	A	 Loss of phosphorylation."";/evidence=""ECO:0000269|PubMed:17603046""	loss	S299A	D
Q02156/K437W	Q02156	KPCE/K437W	KPCE_HUMAN	Reviewed;	MUTAGEN	K	437	W	 Abolishes activity and S-729 phosphorylation."";/evidence=""ECO:0000269|PubMed:11964154""	loss	K437W	D
Q02156/T566A	Q02156	KPCE/T566A	KPCE_HUMAN	Reviewed;	MUTAGEN	T	566	A	 Abolishes phosphorylation by PDK1, and S-729;phosphorylation."";/evidence=""ECO:0000269|PubMed:11964154""	loss	T566A	D
P41743/K274W	P41743	KPCI/K274W	KPCI_HUMAN	Reviewed;	MUTAGEN	K	274	W	 Abolishes activity."";/evidence=""ECO:0000269|PubMed:10906326""	loss	K274W	D
Q04759/K409A	Q04759	KPCT/K409A	KPCT_HUMAN	Reviewed;	MUTAGEN	K	409	A	E: Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10652356""	loss	K409A	D
Q04759/T538A	Q04759	KPCT/T538A	KPCT_HUMAN	Reviewed;	MUTAGEN	T	538	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11772397,;ECO:0000269|PubMed:16252004""	loss	T538A	D
Q04759/S676A	Q04759	KPCT/S676A	KPCT_HUMAN	Reviewed;	MUTAGEN	S	676	A	 Reduction in kinase activity."";/evidence=""ECO:0000269|PubMed:16252004""	decrease	S676A	D
Q04759/S695A	Q04759	KPCT/S695A	KPCT_HUMAN	Reviewed;	MUTAGEN	S	695	A	 Reduction in kinase activity."";/evidence=""ECO:0000269|PubMed:11772397,;ECO:0000269|PubMed:16252004""	decrease	S695A	D
P51812/R383W	P51812	KS6A3/R383W	KS6A3_HUMAN	Reviewed;	VARIANT	R	383	W	 (in XLID19; kinase activity is decreased but;not abolished; dbSNP:rs122454129)"";/evidence=""ECO:0000269|PubMed:10319851"";/id=""VAR_065897""	decrease	R383W	D
O75582/D195A	O75582	KS6A5/D195A	KS6A5_HUMAN	Reviewed;	MUTAGEN	D	195	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9687510""	loss	D195A	D
O75582/S360A	O75582	KS6A5/S360A	KS6A5_HUMAN	Reviewed;	MUTAGEN	S	360	A	 Decreases kinase activity by 60% in response;to PMA and UV-C."";/evidence=""ECO:0000269|PubMed:15568999""	decrease	S360A	D
O75582/S376A	O75582	KS6A5/S376A	KS6A5_HUMAN	Reviewed;	MUTAGEN	S	376	A	 Loss of kinase activity, and decreases the;phosphorylation of S-360 and T-581."";/evidence=""ECO:0000269|PubMed:15568999""	decrease	S376A	D
O75582/D565A	O75582	KS6A5/D565A	KS6A5_HUMAN	Reviewed;	MUTAGEN	D	565	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9687510""	loss	D565A	D
O75582/T581A	O75582	KS6A5/T581A	KS6A5_HUMAN	Reviewed;	MUTAGEN	T	581	A	 Loss of kinase activity, and blocks;phosphorylation of S-212; S-376 and S-381 in response to;PMA and UV-C."";/evidence=""ECO:0000269|PubMed:15568999""	loss	T581A	D
O75582/T700A	O75582	KS6A5/T700A	KS6A5_HUMAN	Reviewed;	MUTAGEN	T	700	A	D: Strongly reduces phosphorylation of T-581 in;response to PMA and UV-C."";/evidence=""ECO:0000269|PubMed:17117922""	decrease	T700A	D
Q9UK32/S389A	Q9UK32	KS6A6/S389A	KS6A6_HUMAN	Reviewed;	MUTAGEN	S	389	A	 Strongly decreases activity."";/evidence=""ECO:0000269|PubMed:15632195""	decrease	S389A	D
P23443/K167N	P23443	KS6B1/K167N	KS6B1_HUMAN	Reviewed;	MUTAGEN	K	167	N	 Greatly reduces activity. Greatly reduces;phosphorylation at T-412 and moderately reduces;phosphorylation at T-252."";/evidence=""ECO:0000269|PubMed:17446865""	decrease	K167N	D
P23443/S394A	P23443	KS6B1/S394A	KS6B1_HUMAN	Reviewed;	MUTAGEN	S	394	A	 Loss of activity. Loss of phosphorylation at;T-412."";/evidence=""ECO:0000269|PubMed:17446865""	loss	S394A	D
Q8IVT5/E72K	Q8IVT5	KSR1/E72K	KSR1_HUMAN	Reviewed;	MUTAGEN	E	72	K	 Loss of interaction with BRAF and MAP2K1 and;severe decrease in MAP2K1 phosphorylation levels."";/evidence=""ECO:0000269|PubMed:29433126""	decrease	E72K	D
Q6VAB6/D786A	Q6VAB6	KSR2/D786A	KSR2_HUMAN	Reviewed;	MUTAGEN	D	786	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:21441910""	loss	D786A	D
O95835/S464A	O95835	LATS1/S464A	LATS1_HUMAN	Reviewed;	MUTAGEN	S	464	A	 Abolishes phosphorylation by NUAK1 and NUAK2."";/evidence=""ECO:0000269|PubMed:19927127""	loss	S464A	D
O95835/K734A	O95835	LATS1/K734A	LATS1_HUMAN	Reviewed;	MUTAGEN	K	734	A	 Loss of kinase activity, autophosphorylation,;increased ploidy, prolonged duration of mitosis and lack of;p53 expression."";/evidence=""ECO:0000269|PubMed:15122335""	loss	K734A	D
Q9NRM7/K697A	Q9NRM7	LATS2/K697A	LATS2_HUMAN	Reviewed;	MUTAGEN	K	697	A	 Loss of kinase activity, autophosphorylation;and tumor suppressor activity."";/evidence=""ECO:0000269|PubMed:10871863,;ECO:0000269|PubMed:12853976""	loss	K697A	D
Q9NRM7/S872A	Q9NRM7	LATS2/S872A	LATS2_HUMAN	Reviewed;	MUTAGEN	S	872	A	 Loss of tumor suppressor activity."";/evidence=""ECO:0000269|PubMed:12853976""	loss	S872A	D
P53667/T508A	P53667	LIMK1/T508A	LIMK1_HUMAN	Reviewed;	MUTAGEN	T	508	A	 Abolishes activation by ROCK1."";/evidence=""ECO:0000269|PubMed:10196227,;ECO:0000269|PubMed:10652353""	loss	T508A	D
P53667/T508V	P53667	LIMK1/T508V	LIMK1_HUMAN	Reviewed;	MUTAGEN	T	508	V	 Reduces kinase activity."";/evidence=""ECO:0000269|PubMed:10196227,;ECO:0000269|PubMed:10652353""	decrease	T508V	D
P53671/T505V	P53671	LIMK2/T505V	LIMK2_HUMAN	Reviewed;	MUTAGEN	T	505	V	 Abolishes cofilin phosphorylation and;enhancement of stress fiber formation."";/evidence=""ECO:0000269|PubMed:11018042""	loss	T505V	D
Q38SD2/K1270W	Q38SD2	LRRK1/K1270W	LRRK1_HUMAN	Reviewed;	MUTAGEN	K	1270	W	 Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:16243488""	loss	K1270W	D
Q5S007/L760D	Q5S007	LRRK2/L760D	LRRK2_HUMAN	Reviewed;	MUTAGEN	L	760	D	 Decreased kinase activity and loss of RAB29-;mediated activation."";/evidence=""ECO:0000269|PubMed:29212815""	decrease	L760D	D
Q5S007/L761D	Q5S007	LRRK2/L761D	LRRK2_HUMAN	Reviewed;	MUTAGEN	L	761	D	 Decreased kinase activity and loss of RAB29-;mediated activation."";/evidence=""ECO:0000269|PubMed:29212815""	decrease	L761D	D
Q5S007/L762D	Q5S007	LRRK2/L762D	LRRK2_HUMAN	Reviewed;	MUTAGEN	L	762	D	 Decreased kinase activity and loss of RAB29-;mediated activation."";/evidence=""ECO:0000269|PubMed:29212815""	decrease	L762D	D
Q5S007/D1994A	Q5S007	LRRK2/D1994A	LRRK2_HUMAN	Reviewed;	MUTAGEN	D	1994	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:28720718""	loss	D1994A	D
P29376/K544M	P29376	LTK/K544M	LTK_HUMAN	Reviewed;	MUTAGEN	K	544	M	 Loss of interaction with PLCG1, PI3-kinase;subunit p85, Ras GTPase-activating protein and RAF1."";/evidence=""ECO:0000269|PubMed:8084603""	loss	K544M	D
P29376/Y862F	P29376	LTK/Y862F	LTK_HUMAN	Reviewed;	MUTAGEN	Y	862	F	 Impairs phosphorylation of CBLC (demonstrated;with chimeric EGFR-LTK)."";/evidence=""ECO:0000269|PubMed:9223670""	decrease	Y862F	D
P07948/K275L	P07948	LYN/K275L	LYN_HUMAN	Reviewed;	MUTAGEN	K	275	L	R: Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11435302,;ECO:0000269|PubMed:11517336, ECO:0000269|PubMed:15173188,;ECO:0000269|PubMed:18817770""	loss	K275L	D
P07948/Y397F	P07948	LYN/Y397F	LYN_HUMAN	Reviewed;	MUTAGEN	Y	397	F	 Strongly reduced kinase activity."";/evidence=""ECO:0000269|PubMed:16920712""	decrease	Y397F	D
Q16584/K144A	Q16584	M3K11/K144A	M3K11_HUMAN	Reviewed;	MUTAGEN	K	144	A	 Greatly reduced autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:11053428,;ECO:0000269|PubMed:8195146""	decrease	K144A	D
Q16584/K144R	Q16584	M3K11/K144R	M3K11_HUMAN	Reviewed;	MUTAGEN	K	144	R	 Loss of kinase activity. Prevents activation;of SAPK and MAPK14."";/evidence=""ECO:0000269|PubMed:11053428,;ECO:0000269|PubMed:8195146""	loss	K144R	D
Q16584/E164A	Q16584	M3K11/E164A	M3K11_HUMAN	Reviewed;	MUTAGEN	E	164	A	 Greatly reduced autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:8195146""	decrease	E164A	D
Q16584/T277A	Q16584	M3K11/T277A	M3K11_HUMAN	Reviewed;	MUTAGEN	T	277	A	 Severely reduced autophosphorylation activity.;Prevents phosphorylation of SAPK and MAPK14."";/evidence=""ECO:0000269|PubMed:11053428""	decrease	T277A	D
Q16584/S281A	Q16584	M3K11/S281A	M3K11_HUMAN	Reviewed;	MUTAGEN	S	281	A	 Reduced autophosphorylation activity. Reduced;activation of SAPK and MAPK14."";/evidence=""ECO:0000269|PubMed:11053428""	decrease	S281A	D
Q9NYL2/K45M	Q9NYL2	M3K20/K45M	M3K20_HUMAN	Reviewed;	MUTAGEN	K	45	M	 Loss of kinase activity. Does not affect;ability to activate EIF2AK4/GCN2 in response to mild;ribosome collision."";/evidence=""ECO:0000269|PubMed:11836244,;ECO:0000269|PubMed:32610081, ECO:0000269|PubMed:35857590""	loss	K45M	D
Q9NYL2/T161A	Q9NYL2	M3K20/T161A	M3K20_HUMAN	Reviewed;	MUTAGEN	T	161	A	 Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	loss	T161A	D
Q9NYL2/T162A	Q9NYL2	M3K20/T162A	M3K20_HUMAN	Reviewed;	MUTAGEN	T	162	A	 Slight loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	decrease	T162A	D
Q9NYL2/S165A	Q9NYL2	M3K20/S165A	M3K20_HUMAN	Reviewed;	MUTAGEN	S	165	A	 Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:15342622""	loss	S165A	D
Q9Y6R4/K1372R	Q9Y6R4	M3K4/K1372R	M3K4_HUMAN	Reviewed;	MUTAGEN	K	1372	R	 Loss of activity."";/evidence=""ECO:0000269|PubMed:12052864,;ECO:0000269|PubMed:9305639""	loss	K1372R	D
Q99683/K709M	Q99683	M3K5/K709M	M3K5_HUMAN	Reviewed;	MUTAGEN	K	709	M	 Loss of kinase activity. Inhibits activation;of JNK and apoptosis mediated by TNFRSF6 and DAXX. Does not;affect interaction with TRIM48."";/evidence=""ECO:0000269|PubMed:17210579,;ECO:0000269|PubMed:29186683, ECO:0000269|PubMed:9743501""	loss	K709M	D
Q99683/K709R	Q99683	M3K5/K709R	M3K5_HUMAN	Reviewed;	MUTAGEN	K	709	R	 Loss of kinase activity. Abolishes DAXX-;mediated apoptosis. Loss of RC3H2-mediated ubiquitination."";/evidence=""ECO:0000269|PubMed:17210579,;ECO:0000269|PubMed:24448648, ECO:0000269|PubMed:9743501""	loss	K709R	D
O43318/K63W	O43318	M3K7/K63W	M3K7_HUMAN	Reviewed;	MUTAGEN	K	63	W	 Loss of kinase activity. Loss of;autophosphorylation."";/evidence=""ECO:0000269|PubMed:12589052,;ECO:0000269|PubMed:22802624""	loss	K63W	D
P80192/K171A	P80192	M3K9/K171A	M3K9_HUMAN	Reviewed;	MUTAGEN	K	171	A	 Loss of kinase activity and threonine;phosphorylation."";/evidence=""ECO:0000269|PubMed:15610029""	loss	K171A	D
P80192/T304A	P80192	M3K9/T304A	M3K9_HUMAN	Reviewed;	MUTAGEN	T	304	A	 Reduces threonine phosphorylation. Impairs JNK;activation."";/evidence=""ECO:0000269|PubMed:15610029""	decrease	T304A	D
P80192/S308A	P80192	M3K9/S308A	M3K9_HUMAN	Reviewed;	MUTAGEN	S	308	A	 Impairs JNK activation."";/evidence=""ECO:0000269|PubMed:15610029""	decrease	S308A	D
P80192/T312A	P80192	M3K9/T312A	M3K9_HUMAN	Reviewed;	MUTAGEN	T	312	A	 Loss of threonine phosphorylation. Strongly;impairs JNK activation."";/evidence=""ECO:0000269|PubMed:15610029""	loss	T312A	D
Q8IVH8/K48E	Q8IVH8	M4K3/K48E	M4K3_HUMAN	Reviewed;	MUTAGEN	K	48	E	 Loss of kinase activity and ability to;activate JNK family."";/evidence=""ECO:0000269|PubMed:9275185""	loss	K48E	D
Q9Y4K4/K49R	Q9Y4K4	M4K5/K49R	M4K5_HUMAN	Reviewed;	MUTAGEN	K	49	R	 Loss of kinase activity and ability to;activate JNK family."";/evidence=""ECO:0000269|PubMed:9038372""	loss	K49R	D
P20794/G13S	P20794	MAK/G13S	MAK_HUMAN	Reviewed;	VARIANT	G	13	S	 (in RP62; results in a complete loss of;kinase activity compared to wild-type; dbSNP:rs387906647)"";/evidence=""ECO:0000269|PubMed:21835304"";/id=""VAR_066988""	loss	G13S	D
P20794/N130H	P20794	MAK/N130H	MAK_HUMAN	Reviewed;	VARIANT	N	130	H	 (in RP62; results in a complete loss of;kinase activity compared to wild-type; dbSNP:rs387906646)"";/evidence=""ECO:0000269|PubMed:21835304"";/id=""VAR_066990""	loss	N130H	D
P20794/K33R	P20794	MAK/K33R	MAK_HUMAN	Reviewed;	MUTAGEN	K	33	R	 Abolishes autophosphorylation."";/evidence=""ECO:0000269|PubMed:12084720""	loss	K33R	D
P20794/T157A	P20794	MAK/T157A	MAK_HUMAN	Reviewed;	MUTAGEN	T	157	A	 Abolishes autophosphorylation and impairs;kinase activity."";/evidence=""ECO:0000269|PubMed:21986944""	loss	T157A	D
P49137/K93R	P49137	MAPK2/K93R	MAPK2_HUMAN	Reviewed;	MUTAGEN	K	93	R	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:14517288""	loss	K93R	D
P49137/D207A	P49137	MAPK2/D207A	MAPK2_HUMAN	Reviewed;	MUTAGEN	D	207	A	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:8846784""	loss	D207A	D
P49137/T222A	P49137	MAPK2/T222A	MAPK2_HUMAN	Reviewed;	MUTAGEN	T	222	A	 Strong decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	decrease	T222A	D
P49137/S272A	P49137	MAPK2/S272A	MAPK2_HUMAN	Reviewed;	MUTAGEN	S	272	A	 Strong decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:8846784""	decrease	S272A	D
P49137/T334A	P49137	MAPK2/T334A	MAPK2_HUMAN	Reviewed;	MUTAGEN	T	334	A	 Slight decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:14517288,;ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:8846784""	decrease	T334A	D
P49137/K353R	P49137	MAPK2/K353R	MAPK2_HUMAN	Reviewed;	MUTAGEN	K	353	R	 Induces decreased sumoylation and increase in;protein kinase activity."";/evidence=""ECO:0000269|PubMed:21131586""	decrease	K353R	D
Q8IW41/K51M	Q8IW41	MAPK5/K51M	MAPK5_HUMAN	Reviewed;	MUTAGEN	K	51	M	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:12808055""	loss	K51M	D
Q7KZI7/S219A	Q7KZI7	MARK2/S219A	MARK2_HUMAN	Reviewed;	MUTAGEN	S	219	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:14517247,;ECO:0000269|PubMed:9108484""	loss	S219A	D
Q14680/D150A	Q14680	MELK/D150A	MELK_HUMAN	Reviewed;	MUTAGEN	D	150	A	 Abolishes enzymatic activity."";/evidence=""ECO:0000269|PubMed:14699119,;ECO:0000269|PubMed:16216881, ECO:0000269|PubMed:17280616""	loss	D150A	D
Q14680/T167A	Q14680	MELK/T167A	MELK_HUMAN	Reviewed;	MUTAGEN	T	167	A	 Abolishes activation of serine/threonine-;protein kinase activity and has only weak activity."";/evidence=""ECO:0000269|PubMed:14976552""	loss	T167A	D
Q14680/S171A	Q14680	MELK/S171A	MELK_HUMAN	Reviewed;	MUTAGEN	S	171	A	 Abolishes activation of serine/threonine-;protein kinase activity and has only weak activity."";/evidence=""ECO:0000269|PubMed:16216881""	loss	S171A	D
P45983/K55D	P45983	MK08/K55D	MK08_HUMAN	Reviewed;	MUTAGEN	K	55	D	 Abolished protein kinase activity."";/evidence=""ECO:0000269|PubMed:22966201""	loss	K55D	D
P53778/Y185F	P53778	MK12/Y185F	MK12_HUMAN	Reviewed;	MUTAGEN	Y	185	F	 Loss of activity."";/evidence=""ECO:0000269|PubMed:8633070""	loss	Y185F	D
O15264/T180A	O15264	MK13/T180A	MK13_HUMAN	Reviewed;	MUTAGEN	T	180	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9374491""	loss	T180A	D
O15264/Y182A	O15264	MK13/Y182A	MK13_HUMAN	Reviewed;	MUTAGEN	Y	182	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:9374491""	loss	Y182A	D
Q16539/A34V	Q16539	MK14/A34V	MK14_HUMAN	Reviewed;	MUTAGEN	A	34	V	 Lowered kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	decrease	A34V	D
Q16539/K53R	Q16539	MK14/K53R	MK14_HUMAN	Reviewed;	MUTAGEN	K	53	R	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	loss	K53R	D
Q16539/K54R	Q16539	MK14/K54R	MK14_HUMAN	Reviewed;	MUTAGEN	K	54	R	 Impairs MAP2K6/MKK6-dependent;autophosphorylation."";/evidence=""ECO:0000269|PubMed:11010976""	decrease	K54R	D
Q16539/Y69H	Q16539	MK14/Y69H	MK14_HUMAN	Reviewed;	MUTAGEN	Y	69	H	 Lowered kinase activity."";/evidence=""ECO:0000269|PubMed:15284239""	decrease	Y69H	D
Q16539/D168A	Q16539	MK14/D168A	MK14_HUMAN	Reviewed;	MUTAGEN	D	168	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	loss	D168A	D
Q16539/D177A	Q16539	MK14/D177A	MK14_HUMAN	Reviewed;	MUTAGEN	D	177	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15284239""	loss	D177A	D
Q16539/T180E	Q16539	MK14/T180E	MK14_HUMAN	Reviewed;	MUTAGEN	T	180	E	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	loss	T180E	D
Q16539/Y182F	Q16539	MK14/Y182F	MK14_HUMAN	Reviewed;	MUTAGEN	Y	182	F	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:7493921""	loss	Y182F	D
Q16539/A320T	Q16539	MK14/A320T	MK14_HUMAN	Reviewed;	MUTAGEN	A	320	T	 Lowered kinase activity."";/evidence=""ECO:0000269|PubMed:15284239""	decrease	A320T	D
Q16539/W337R	Q16539	MK14/W337R	MK14_HUMAN	Reviewed;	MUTAGEN	W	337	R	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15284239""	loss	W337R	D
Q8TD08/K42R	Q8TD08	MK15/K42R	MK15_HUMAN	Reviewed;	MUTAGEN	K	42	R	 Loss of autophosphorylation and activity. Does;not increase dopamine transporter activity. Impairs kinase;activity. Does not rescue cilium assembly in MAPK15-;depleted cells."";/evidence=""ECO:0000269|PubMed:11875070,;ECO:0000269|PubMed:28842414, ECO:0000269|PubMed:29021280""	loss	K42R	D
Q8TD08/R59Q	Q8TD08	MK15/R59Q	MK15_HUMAN	Reviewed;	MUTAGEN	R	59	Q	 Does not increase dopamine transporter;activity. Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:28842414""	decrease	R59Q	D
Q8TD08/Y177A	Q8TD08	MK15/Y177A	MK15_HUMAN	Reviewed;	MUTAGEN	Y	177	A	 Loss of autophosphorylation and activity.;Heavily phosphorylated at Thr-175."";/evidence=""ECO:0000269|PubMed:11875070,;ECO:0000269|PubMed:16336213""	loss	Y177A	D
Q9HBH9/D228G	Q9HBH9	MKNK2/D228G	MKNK2_HUMAN	Reviewed;	MUTAGEN	D	228	G	 Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:16917500""	decrease	D228G	D
Q02750/K97A	Q02750	MP2K1/K97A	MP2K1_HUMAN	Reviewed;	MUTAGEN	K	97	A	 Loss of catalytic activity. Strongly reduces;phosphorylation upon UV irradiation."";/evidence=""ECO:0000269|PubMed:20956560""	decrease	K97A	D
Q5VT25/K106A	Q5VT25	MRCKA/K106A	MRCKA_HUMAN	Reviewed;	MUTAGEN	K	106	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:11283256""	loss	K106A	D
Q5VT25/S234A	Q5VT25	MRCKA/S234A	MRCKA_HUMAN	Reviewed;	MUTAGEN	S	234	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	loss	S234A	D
Q5VT25/T240A	Q5VT25	MRCKA/T240A	MRCKA_HUMAN	Reviewed;	MUTAGEN	T	240	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	loss	T240A	D
Q5VT25/T403A	Q5VT25	MRCKA/T403A	MRCKA_HUMAN	Reviewed;	MUTAGEN	T	403	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:11283256""	loss	T403A	D
P42345/H2340A	P42345	MTOR/H2340A	MTOR_HUMAN	Reviewed;	MUTAGEN	H	2340	A	 Barely detectable kinase activity."";/evidence=""ECO:0000269|PubMed:23636326""	loss	H2340A	D
O15146/I575T	O15146	MUSK/I575T	MUSK_HUMAN	Reviewed;	VARIANT	I	575	T	 (in FADS1; reduces agrin-dependent AChR;aggregation and tyrosine kinase activity in developing;neuromuscular junction; dbSNP:rs751889864)"";/evidence=""ECO:0000269|PubMed:25537362"";/id=""VAR_072787""	decrease	I575T	D
O15146/M605I	O15146	MUSK/M605I	MUSK_HUMAN	Reviewed;	VARIANT	M	605	I	 (in CMS9; affects interaction with DOK7 and;impairs MUSK phosphorylation; altered AChR clustering;;dbSNP:rs766640370)"";/evidence=""ECO:0000269|PubMed:20371544"";/id=""VAR_066604""	decrease	M605I	D
O15146/A727V	O15146	MUSK/A727V	MUSK_HUMAN	Reviewed;	VARIANT	A	727	V	 (in CMS9; affects interaction with DOK7 and;impairs MUSK phosphorylation; altered AChR clustering;;dbSNP:rs397515450)"";/evidence=""ECO:0000269|PubMed:20371544"";/id=""VAR_066605""	decrease	A727V	D
O15146/V790M	O15146	MUSK/V790M	MUSK_HUMAN	Reviewed;	VARIANT	V	790	M	 (in CMS9; does not affect catalytic kinase;activity; reduces protein expression and stability;;dbSNP:rs199476083)"";/evidence=""ECO:0000269|PubMed:15496425"";/id=""VAR_023046""	decrease	V790M	D
O15146/G584C	O15146	MUSK/G584C	MUSK_HUMAN	Reviewed;	MUTAGEN	G	584	C	D: Mild decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:25029443""	decrease	G584C	D
O15146/K609R	O15146	MUSK/K609R	MUSK_HUMAN	Reviewed;	MUTAGEN	K	609	R	 Severe loss of kinase activity."";/evidence=""ECO:0000269|PubMed:25029443""	loss	K609R	D
Q15746/A1491S	Q15746	MYLK/A1491S	MYLK_HUMAN	Reviewed;	VARIANT	A	1491	S	 (in AAT7; decreases kinase activity;;dbSNP:rs1576422965)"";/evidence=""ECO:0000269|PubMed:29544503"";/id=""VAR_083425""	decrease	A1491S	D
Q15746/A1754T	Q15746	MYLK/A1754T	MYLK_HUMAN	Reviewed;	VARIANT	A	1754	T	 (in AAT7; 4-fold reduced affinity for;calmodulin; decreased kinase activity compared to wild-type;protein)"";/evidence=""ECO:0000269|PubMed:21055718"";/id=""VAR_065576""	decrease	A1754T	D
Q15746/K608A	Q15746	MYLK/K608A	MYLK_HUMAN	Reviewed;	MUTAGEN	K	608	A	 Loss of acetylation and no kinase activity;repression by NAA10/ARD1."";/evidence=""ECO:0000269|PubMed:19826488""	loss	K608A	D
Q6ZWH5/K548R	Q6ZWH5	NEK10/K548R	NEK10_HUMAN	Reviewed;	MUTAGEN	K	548	R	 Catalytically inactive. Impaired mucociliary;transport."";/evidence=""ECO:0000269|PubMed:20956560,;ECO:0000269|PubMed:31959991""	decrease	K548R	D
P51955/K37R	P51955	NEK2/K37R	NEK2_HUMAN	Reviewed;	MUTAGEN	K	37	R	 Loss of kinase activity and of ability to;activate NEK11. Loss of phosphorylation of CCDC102B."";/evidence=""ECO:0000269|PubMed:15161910,;ECO:0000269|PubMed:17197699, ECO:0000269|PubMed:30404835""	loss	K37R	D
P51955/D141A	P51955	NEK2/D141A	NEK2_HUMAN	Reviewed;	MUTAGEN	D	141	A	 Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:17197699""	loss	D141A	D
P51955/T175A	P51955	NEK2/T175A	NEK2_HUMAN	Reviewed;	MUTAGEN	T	175	A	 Kinase activity decreased by two fold."";/evidence=""ECO:0000269|PubMed:17197699""	decrease	T175A	D
P51955/T179A	P51955	NEK2/T179A	NEK2_HUMAN	Reviewed;	MUTAGEN	T	179	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17197699""	loss	T179A	D
P51955/T179E	P51955	NEK2/T179E	NEK2_HUMAN	Reviewed;	MUTAGEN	T	179	E	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17197699""	loss	T179E	D
P51955/S241A	P51955	NEK2/S241A	NEK2_HUMAN	Reviewed;	MUTAGEN	S	241	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17197699""	loss	S241A	D
P51955/S241D	P51955	NEK2/S241D	NEK2_HUMAN	Reviewed;	MUTAGEN	S	241	D	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:17197699""	loss	S241D	D
Q8TDX7/N33D	Q8TDX7	NEK7/N33D	NEK7_HUMAN	Reviewed;	MUTAGEN	N	33	D	 Significant decrease in catalytic activity."";/evidence=""ECO:0000269|PubMed:19941817""	decrease	N33D	D
Q8TD19/K81M	Q8TD19	NEK9/K81M	NEK9_HUMAN	Reviewed;	MUTAGEN	K	81	M	 Loss of activity and autophosphorylation."";/evidence=""ECO:0000269|PubMed:12101123""	loss	K81M	D
Q8TD19/T210A	Q8TD19	NEK9/T210A	NEK9_HUMAN	Reviewed;	MUTAGEN	T	210	A	 Significant reduction of autophosphorylation."";/evidence=""ECO:0000269|PubMed:11864968""	decrease	T210A	D
Q8IY84/T229A	Q8IY84	NIM1/T229A	NIM1_HUMAN	Reviewed;	MUTAGEN	T	229	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:15733851""	loss	T229A	D
P04629/G577R	P04629	NTRK1/G577R	NTRK1_HUMAN	Reviewed;	VARIANT	G	577	R	 (in CIPA; loss of function; processed as;wild-type but shows significantly diminished;autophosphorylation in both neuronal and non-neuronal;cells; dbSNP:rs121964866)"";/evidence=""ECO:0000269|PubMed:10567924,;ECO:0000269|PubMed:10982191, ECO:0000269|PubMed:11159935,;ECO:0000269|PubMed:8696348"";/id=""VAR_004103""	loss	G577R	D
P04629/D596N	P04629	NTRK1/D596N	NTRK1_HUMAN	Reviewed;	VARIANT	D	596	N	 (in CIPA; abolishes autophosphorylation)"";/evidence=""ECO:0000269|PubMed:28177573"";/id=""VAR_079404""	loss	D596N	D
P04629/R780P	P04629	NTRK1/R780P	NTRK1_HUMAN	Reviewed;	VARIANT	R	780	P	 (in CIPA; loss of function;;dbSNP:rs35669708)"";/evidence=""ECO:0000269|PubMed:10090906"";/id=""VAR_009635""	loss	R780P	D
P04629/K544N	P04629	NTRK1/K544N	NTRK1_HUMAN	Reviewed;	MUTAGEN	K	544	N	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:1281417,;ECO:0000269|PubMed:8155326""	loss	K544N	D
Q16620/Y706C	Q16620	NTRK2/Y706C	NTRK2_HUMAN	Reviewed;	VARIANT	Y	706	C	 (in OBHD; expressed normally on the cell;surface; results in markedly impaired ligand-induced;phosphorylation as well as impaired downstream MAPK1;phosphorylation; dbSNP:rs121434633)"";/evidence=""ECO:0000269|PubMed:15494731"";/id=""VAR_065890""	decrease	Y706C	D
Q16288/K572N	Q16288	NTRK3/K572N	NTRK3_HUMAN	Reviewed;	MUTAGEN	K	572	N	 Loss of autophosphorylation and loss of NTRK3;signaling."";/evidence=""ECO:0000269|PubMed:25196463""	loss	K572N	D
O60285/K84A	O60285	NUAK1/K84A	NUAK1_HUMAN	Reviewed;	MUTAGEN	K	84	A	 Abolishes kinase activity and ability to;induce senescence."";/evidence=""ECO:0000269|PubMed:19927127,;ECO:0000269|PubMed:21317932""	loss	K84A	D
O60285/T211A	O60285	NUAK1/T211A	NUAK1_HUMAN	Reviewed;	MUTAGEN	T	211	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex. Abolishes ability to induce;senescence."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:21317932""	loss	T211A	D
Q9H093/K81R	Q9H093	NUAK2/K81R	NUAK2_HUMAN	Reviewed;	MUTAGEN	K	81	R	 Loss of autophosphorylation, kinase activity;and of anti-apoptotic activity."";/evidence=""ECO:0000269|PubMed:15345718""	loss	K81R	D
O95747/K46A	O95747	OXSR1/K46A	OXSR1_HUMAN	Reviewed;	MUTAGEN	K	46	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:14707132,;ECO:0000269|PubMed:16389068""	loss	K46A	D
O95747/K46M	O95747	OXSR1/K46M	OXSR1_HUMAN	Reviewed;	MUTAGEN	K	46	M	 Loss of RELT, RELL1 and RELL2 phosphorylation.;Retention of some autophosphorylation activity may be due;to complex formation with other endogenous kinases in the;assay."";/evidence=""ECO:0000269|PubMed:14707132,;ECO:0000269|PubMed:16389068""	loss	K46M	D
Q13153/L107F	Q13153	PAK1/L107F	PAK1_HUMAN	Reviewed;	MUTAGEN	L	107	F	 Abolishes autoinhibition, leading to;constitutive kinase activity."";/evidence=""ECO:0000269|PubMed:10551809""	loss	L107F	D
Q13153/D393A	Q13153	PAK1/D393A	PAK1_HUMAN	Reviewed;	MUTAGEN	D	393	A	 Abolishes autophosphorylation at Thr-423."";/evidence=""ECO:0000269|PubMed:22153498""	loss	D393A	D
Q13153/T423A	Q13153	PAK1/T423A	PAK1_HUMAN	Reviewed;	MUTAGEN	T	423	A	 Decreases CDC42-stimulated activity and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:10551809""	decrease	T423A	D
Q13177/K278R	Q13177	PAK2/K278R	PAK2_HUMAN	Reviewed;	MUTAGEN	K	278	R	 Abolishes kinase activity and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:9786869""	loss	K278R	D
Q13177/T402A	Q13177	PAK2/T402A	PAK2_HUMAN	Reviewed;	MUTAGEN	T	402	A	 Abolishes kinase activity and greatly inhibits;autophosphorylation of PAK-2p27 and PAK-2p34."";/evidence=""ECO:0000269|PubMed:9786869""	loss	T402A	D
Q96RG2/K1028R	Q96RG2	PASK/K1028R	PASK_HUMAN	Reviewed;	MUTAGEN	K	1028	R	 Loss of autophosphorylating activity."";/evidence=""ECO:0000269|PubMed:11459942,;ECO:0000269|PubMed:20943661""	loss	K1028R	D
Q96RG2/R1058A	Q96RG2	PASK/R1058A	PASK_HUMAN	Reviewed;	MUTAGEN	R	1058	A	 Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	decrease	R1058A	D
Q96RG2/A1151K	Q96RG2	PASK/A1151K	PASK_HUMAN	Reviewed;	MUTAGEN	A	1151	K	 Induces lower protein kinase activity and;ability to autophosphorylate."";/evidence=""ECO:0000269|PubMed:20943661""	decrease	A1151K	D
Q96RG2/Y1152F	Q96RG2	PASK/Y1152F	PASK_HUMAN	Reviewed;	MUTAGEN	Y	1152	F	 Induces lower protein kinase activity."";/evidence=""ECO:0000269|PubMed:20943661""	decrease	Y1152F	D
Q96RG2/T1161A	Q96RG2	PASK/T1161A	PASK_HUMAN	Reviewed;	MUTAGEN	T	1161	A	 Loss of catalytic activity (PubMed:11459942).;According to another report, does not affect the protein;kinase activity (PubMed:20943661). Does not affect protein;translation."";/evidence=""ECO:0000269|PubMed:11459942,;ECO:0000269|PubMed:17595531, ECO:0000269|PubMed:20943661""	loss	T1161A	D
Q96RG2/T1165A	Q96RG2	PASK/T1165A	PASK_HUMAN	Reviewed;	MUTAGEN	T	1165	A	 Loss of catalytic activity. Does not affect;protein translation."";/evidence=""ECO:0000269|PubMed:11459942,;ECO:0000269|PubMed:17595531""	loss	T1165A	D
Q16654/Y157F	Q16654	PDK4/Y157F	PDK4_HUMAN	Reviewed;	MUTAGEN	Y	157	F	 Loss of activity."";/evidence=""ECO:0000269|PubMed:18658136""	loss	Y157F	D
Q16654/R161A	Q16654	PDK4/R161A	PDK4_HUMAN	Reviewed;	MUTAGEN	R	161	A	 Loss of activity."";/evidence=""ECO:0000269|PubMed:18658136""	loss	R161A	D
O15530/Y9F	O15530	PDPK1/Y9F	PDPK1_HUMAN	Reviewed;	MUTAGEN	Y	9	F	 Slight reduction in pervanadate-stimulated;tyrosine phosphorylation."";/evidence=""ECO:0000269|PubMed:11481331""	decrease	Y9F	D
O15530/T354A	O15530	PDPK1/T354A	PDPK1_HUMAN	Reviewed;	MUTAGEN	T	354	A	 Abolishes phosphorylation by MELK."";/evidence=""ECO:0000269|PubMed:22544756""	loss	T354A	D
P11309/P81S	P11309	PIM1/P81S	PIM1_HUMAN	Reviewed;	MUTAGEN	P	81	S	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	decrease	P81S	D
P11309/N82K	P11309	PIM1/N82K	PIM1_HUMAN	Reviewed;	MUTAGEN	N	82	K	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	decrease	N82K	D
P11309/L193F	P11309	PIM1/L193F	PIM1_HUMAN	Reviewed;	MUTAGEN	L	193	F	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:15808862""	decrease	L193F	D
Q9BXM7/T313M	Q9BXM7	PINK1/T313M	PINK1_HUMAN	Reviewed;	VARIANT	T	313	M	 (in PARK6; decreases PRKN and SNCAIP;ubiquitination and degradation; slightly decreases Drp1;phosphorylation; dbSNP:rs74315359)"";/evidence=""ECO:0000269|PubMed:17030667,;ECO:0000269|PubMed:18785233, ECO:0000269|PubMed:19229105,;ECO:0000269|PubMed:32484300"";/id=""VAR_046589""	decrease	T313M	D
Q9BXM7/G386A	Q9BXM7	PINK1/G386A	PINK1_HUMAN	Reviewed;	VARIANT	G	386	A	 (in PARK6; abolishes kinase activity)"";/evidence=""ECO:0000269|PubMed:16401616,;ECO:0000269|PubMed:24784582"";/id=""VAR_062776""	loss	G386A	D
Q16512/K644E	Q16512	PKN1/K644E	PKN1_HUMAN	Reviewed;	MUTAGEN	K	644	E	 Abolishes Serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:18066052,;ECO:0000269|PubMed:8135837""	loss	K644E	D
Q16512/K644R	Q16512	PKN1/K644R	PKN1_HUMAN	Reviewed;	MUTAGEN	K	644	R	 Substantial reduction of autophosphorylation."";/evidence=""ECO:0000269|PubMed:18066052,;ECO:0000269|PubMed:8135837""	decrease	K644R	D
Q16513/T816A	Q16513	PKN2/T816A	PKN2_HUMAN	Reviewed;	MUTAGEN	T	816	A	 Reduces catalytic activity."";/evidence=""ECO:0000269|PubMed:18835241""	decrease	T816A	D
Q16513/T958A	Q16513	PKN2/T958A	PKN2_HUMAN	Reviewed;	MUTAGEN	T	958	A	 Abolishes catalytic activity."";/evidence=""ECO:0000269|PubMed:18835241""	loss	T958A	D
Q16513/F977W	Q16513	PKN2/F977W	PKN2_HUMAN	Reviewed;	MUTAGEN	F	977	W	Y: Reduces catalytic activity by 50%."";/evidence=""ECO:0000269|PubMed:10226025,;ECO:0000269|PubMed:18835241""	decrease	F977W	D
Q16513/Y979A	Q16513	PKN2/Y979A	PKN2_HUMAN	Reviewed;	MUTAGEN	Y	979	A	 Reduces catalytic activity by 50%."";/evidence=""ECO:0000269|PubMed:10226025,;ECO:0000269|PubMed:18835241""	decrease	Y979A	D
Q16513/Y979F	Q16513	PKN2/Y979F	PKN2_HUMAN	Reviewed;	MUTAGEN	Y	979	F	L,W: Reduces catalytic activity by 25%."";/evidence=""ECO:0000269|PubMed:10226025,;ECO:0000269|PubMed:18835241""	decrease	Y979F	D
Q6P5Z2/K588E	Q6P5Z2	PKN3/K588E	PKN3_HUMAN	Reviewed;	MUTAGEN	K	588	E	 Abolishes autophosphorylation and catalytic;activity."";/evidence=""ECO:0000269|PubMed:10441506,;ECO:0000269|PubMed:15282551""	loss	K588E	D
Q6P5Z2/K588R	Q6P5Z2	PKN3/K588R	PKN3_HUMAN	Reviewed;	MUTAGEN	K	588	R	 Abolishes catalytic activity."";/evidence=""ECO:0000269|PubMed:10441506,;ECO:0000269|PubMed:15282551""	loss	K588R	D
Q6P5Z2/T718A	Q6P5Z2	PKN3/T718A	PKN3_HUMAN	Reviewed;	MUTAGEN	T	718	A	 Abolishes phosphorylation."";/evidence=""ECO:0000269|PubMed:15282551""	loss	T718A	D
P53350/D176N	P53350	PLK1/D176N	PLK1_HUMAN	Reviewed;	MUTAGEN	D	176	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:18615013""	loss	D176N	D
P53350/T210A	P53350	PLK1/T210A	PLK1_HUMAN	Reviewed;	MUTAGEN	T	210	A	 Abolishes activity. Abolishes checkpoint;recovery."";/evidence=""ECO:0000269|PubMed:12207013,;ECO:0000269|PubMed:12447691, ECO:0000269|PubMed:17461553,;ECO:0000269|PubMed:18615013, ECO:0000269|PubMed:19160488""	loss	T210A	D
Q9NYY3/N210A	Q9NYY3	PLK2/N210A	PLK2_HUMAN	Reviewed;	MUTAGEN	N	210	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:19001868""	loss	N210A	D
Q9H4B4/K91R	Q9H4B4	PLK3/K91R	PLK3_HUMAN	Reviewed;	MUTAGEN	K	91	R	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:11447225,;ECO:0000269|PubMed:14980500, ECO:0000269|PubMed:17804415,;ECO:0000269|PubMed:19103756, ECO:0000269|PubMed:19490146,;ECO:0000269|PubMed:20889502, ECO:0000269|PubMed:20940307""	loss	K91R	D
Q9H4B4/D203A	Q9H4B4	PLK3/D203A	PLK3_HUMAN	Reviewed;	MUTAGEN	D	203	A	 Kinase defective mutant, abolishes activity."";/evidence=""ECO:0000269|PubMed:11156373""	loss	D203A	D
O00444/K41M	O00444	PLK4/K41M	PLK4_HUMAN	Reviewed;	MUTAGEN	K	41	M	 Abolishes ability to phosphorylate CDC25C and;CHEK2."";/evidence=""ECO:0000269|PubMed:18239451,;ECO:0000269|PubMed:19164942""	loss	K41M	D
Q99640/N238A	Q99640	PMYT1/N238A	PMYT1_HUMAN	Reviewed;	MUTAGEN	N	238	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10373560""	loss	N238A	D
Q99640/D251A	Q99640	PMYT1/D251A	PMYT1_HUMAN	Reviewed;	MUTAGEN	D	251	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10504341""	loss	D251A	D
P78527/A3574V	P78527	PRKDC/A3574V	PRKDC_HUMAN	Reviewed;	VARIANT	A	3574	V	 (in IMD26; shows impaired function in;response to irradiation and a less severe defect in V(D)J;end-joining suggesting that the missense mutation retained;some functional capacity; consistent with a loss of;function mutation; dbSNP:rs587777686)"";/evidence=""ECO:0000269|PubMed:23722905"";/id=""VAR_072570""	loss	A3574V	D
P51817/K78R	P51817	PRKX/K78R	PRKX_HUMAN	Reviewed;	MUTAGEN	K	78	R	 Loss of function."";/evidence=""ECO:0000269|PubMed:12082174""	loss	K78R	D
Q13882/W44A	Q13882	PTK6/W44A	PTK6_HUMAN	Reviewed;	MUTAGEN	W	44	A	 Strong decrease in STAP2 phosphorylation.;Markedly decreased interaction between SH3 domain the;linker region."";/evidence=""ECO:0000269|PubMed:10980601,;ECO:0000269|PubMed:17822667""	decrease	W44A	D
Q13882/Y66A	Q13882	PTK6/Y66A	PTK6_HUMAN	Reviewed;	MUTAGEN	Y	66	A	 Decrease in STAP2 phosphorylation."";/evidence=""ECO:0000269|PubMed:10980601""	decrease	Y66A	D
Q13882/R105L	Q13882	PTK6/R105L	PTK6_HUMAN	Reviewed;	MUTAGEN	R	105	L	 Decrease in STAP2 phosphorylation."";/evidence=""ECO:0000269|PubMed:10980601""	decrease	R105L	D
Q13882/K219M	Q13882	PTK6/K219M	PTK6_HUMAN	Reviewed;	MUTAGEN	K	219	M	 Abolishes kinase activity and cell;transformation, and phosphorylation of STAP2."";/evidence=""ECO:0000269|PubMed:10980601,;ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083""	loss	K219M	D
Q13882/K219R	Q13882	PTK6/K219R	PTK6_HUMAN	Reviewed;	MUTAGEN	K	219	R	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:27480927""	loss	K219R	D
P04049/D486N	P04049	RAF1/D486N	RAF1_HUMAN	Reviewed;	VARIANT	D	486	N	 (in NS5; has reduced or absent kinase;activity; dbSNP:rs80338798)"";/evidence=""ECO:0000269|PubMed:17603483"";/id=""VAR_037817""	decrease	D486N	D
P04049/T491I	P04049	RAF1/T491I	RAF1_HUMAN	Reviewed;	VARIANT	T	491	I	 (in NS5; has reduced or absent kinase;activity; dbSNP:rs80338799)"";/evidence=""ECO:0000269|PubMed:17603483"";/id=""VAR_037818""	decrease	T491I	D
P04049/L603P	P04049	RAF1/L603P	RAF1_HUMAN	Reviewed;	VARIANT	L	603	P	 (in CMD1NN; shows impaired kinase activity;and reduced MAPK3 activation with this mutation;;dbSNP:rs587777586)"";/evidence=""ECO:0000269|PubMed:24777450"";/id=""VAR_071847""	decrease	L603P	D
P07949/Y1062F	P07949	RET/Y1062F	RET_HUMAN	Reviewed;	MUTAGEN	Y	1062	F	 Abolishes GFRAL-mediated MAPK1/MAPK2;phosphorylation."";/evidence=""ECO:0000269|PubMed:28953886""	loss	Y1062F	D
Q13546/S25D	Q13546	RIPK1/S25D	RIPK1_HUMAN	Reviewed;	MUTAGEN	S	25	D	 Phophomimetic mutant. Significant loss of;kinase activity."";/evidence=""ECO:0000269|PubMed:30988283""	loss	S25D	D
Q13546/K45A	Q13546	RIPK1/K45A	RIPK1_HUMAN	Reviewed;	MUTAGEN	K	45	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:30988283,;ECO:0000269|PubMed:8612133""	loss	K45A	D
Q13546/S161A	Q13546	RIPK1/S161A	RIPK1_HUMAN	Reviewed;	MUTAGEN	S	161	A	 Decreases RIPK1 kinase activity."";/evidence=""ECO:0000269|PubMed:18408713""	decrease	S161A	D
O43353/K47A	O43353	RIPK2/K47A	RIPK2_HUMAN	Reviewed;	MUTAGEN	K	47	A	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:9575181,;ECO:0000269|PubMed:9642260""	loss	K47A	D
O43353/D146N	O43353	RIPK2/D146N	RIPK2_HUMAN	Reviewed;	MUTAGEN	D	146	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:9705938""	loss	D146N	D
O43353/Y381A	O43353	RIPK2/Y381A	RIPK2_HUMAN	Reviewed;	MUTAGEN	Y	381	A	 Prevents phosphorylation. Reduces serine and;threonine phosphorylation of ARHGEF2."";/evidence=""ECO:0000269|PubMed:21887730""	decrease	Y381A	D
Q9Y572/K50D	Q9Y572	RIPK3/K50D	RIPK3_HUMAN	Reviewed;	MUTAGEN	K	50	D	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:10339433,;ECO:0000269|PubMed:10358032, ECO:0000269|PubMed:22265414""	loss	K50D	D
Q9Y572/D142N	Q9Y572	RIPK3/D142N	RIPK3_HUMAN	Reviewed;	MUTAGEN	D	142	N	 Abolishes kinase activity and ability to;mediate necroptosis."";/evidence=""ECO:0000269|PubMed:22265413""	loss	D142N	D
P57078/I121N	P57078	RIPK4/I121N	RIPK4_HUMAN	Reviewed;	VARIANT	I	121	N	 (in BPS; loss of function;;dbSNP:rs387906923)"";/evidence=""ECO:0000269|PubMed:22197489"";/id=""VAR_067332""	loss	I121N	D
P57078/T184I	P57078	RIPK4/T184I	RIPK4_HUMAN	Reviewed;	VARIANT	T	184	I	 (in BPS; loss of function)"";/evidence=""ECO:0000269|PubMed:22197489"";/id=""VAR_067333""	loss	T184I	D
Q05823/R462Q	Q05823	RN5A/R462Q	RN5A_HUMAN	Reviewed;	VARIANT	R	462	Q	 (risk factor for prostate cancer; reduced;enzymatic activity; dbSNP:rs486907)"";/evidence=""ECO:0000269|PubMed:11799394,;ECO:0000269|PubMed:11941539, ECO:0000269|PubMed:12415269,;ECO:0000269|PubMed:17344846"";/id=""VAR_012056""	decrease	R462Q	D
Q05823/K392R	Q05823	RN5A/K392R	RN5A_HUMAN	Reviewed;	MUTAGEN	K	392	R	 Complete loss of enzymatic activity and enzyme;dimerization. No change in binding to 2-5A and RNA."";/evidence=""ECO:0000269|PubMed:9862963""	loss	K392R	D
Q05823/D661A	Q05823	RN5A/D661A	RN5A_HUMAN	Reviewed;	MUTAGEN	D	661	A	 Complete loss of enzymatic activity."";/evidence=""ECO:0000269|PubMed:11333017""	loss	D661A	D
Q05823/R667A	Q05823	RN5A/R667A	RN5A_HUMAN	Reviewed;	MUTAGEN	R	667	A	 Complete loss of enzymatic activity. No change;in 2-5A binding and enzyme dimerization."";/evidence=""ECO:0000269|PubMed:11333017""	loss	R667A	D
Q05823/H672A	Q05823	RN5A/H672A	RN5A_HUMAN	Reviewed;	MUTAGEN	H	672	A	 Complete loss of enzymatic activity. No change;in 2-5A binding activity and enzyme dimerization."";/evidence=""ECO:0000269|PubMed:11333017""	loss	H672A	D
P08922/K1980M	P08922	ROS1/K1980M	ROS1_HUMAN	Reviewed;	MUTAGEN	K	1980	M	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12661006""	loss	K1980M	D
Q52WX2/K61R	Q52WX2	SBK1/K61R	SBK1_HUMAN	Reviewed;	MUTAGEN	K	61	R	 Loss of activity."";/evidence=""ECO:0000269|PubMed:16403448""	loss	K61R	D
P0C263/K73M	P0C263	SBK2/K73M	SBK2_HUMAN	Reviewed;	MUTAGEN	K	73	M	 Loss of activity."";/evidence=""ECO:0000269|PubMed:11322885""	loss	K73M	D
Q9H5K3/L137R	Q9H5K3	SG196/L137R	SG196_HUMAN	Reviewed;	VARIANT	L	137	R	 (in MDDGA12; loss of kinase activity;;dbSNP:rs397509385)"";/evidence=""ECO:0000269|PubMed:23519211,;ECO:0000269|PubMed:23929950"";/id=""VAR_069625""	loss	L137R	D
O00141/K127M	O00141	SGK1/K127M	SGK1_HUMAN	Reviewed;	MUTAGEN	K	127	M	 Abolishes enzymatic activity."";/evidence=""ECO:0000269|PubMed:11696533,;ECO:0000269|PubMed:12911626, ECO:0000269|PubMed:15040001""	loss	K127M	D
Q96BR1/K191M	Q96BR1	SGK3/K191M	SGK3_HUMAN	Reviewed;	MUTAGEN	K	191	M	 Abolishes activity."";/evidence=""ECO:0000269|PubMed:16790420""	loss	K191M	D
P57059/K56M	P57059	SIK1/K56M	SIK1_HUMAN	Reviewed;	MUTAGEN	K	56	M	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:18348280,;ECO:0000269|PubMed:19622832""	loss	K56M	D
P57059/S135A	P57059	SIK1/S135A	SIK1_HUMAN	Reviewed;	MUTAGEN	S	135	A	 Decreased kinase activity without affecting;much autophosphorylation status."";/evidence=""ECO:0000269|PubMed:18348280""	decrease	S135A	D
P57059/T182A	P57059	SIK1/T182A	SIK1_HUMAN	Reviewed;	MUTAGEN	T	182	A	 Prevents phosphorylation and activation by;STK11/LKB1 complex. Reduced inhibition of CRTC3-mediated;transcriptional activity."";/evidence=""ECO:0000269|PubMed:14976552,;ECO:0000269|PubMed:29211348""	decrease	T182A	D
P57059/S186A	P57059	SIK1/S186A	SIK1_HUMAN	Reviewed;	MUTAGEN	S	186	A	D,C,G: Impaired autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:18348280""	decrease	S186A	D
P57059/S209A	P57059	SIK1/S209A	SIK1_HUMAN	Reviewed;	MUTAGEN	S	209	A	 Decreased kinase activity without affecting;much autophosphorylation status."";/evidence=""ECO:0000269|PubMed:18348280""	decrease	S209A	D
P57059/S248A	P57059	SIK1/S248A	SIK1_HUMAN	Reviewed;	MUTAGEN	S	248	A	 Decreased kinase activity without affecting;much autophosphorylation status."";/evidence=""ECO:0000269|PubMed:18348280""	decrease	S248A	D
P57059/S575E	P57059	SIK1/S575E	SIK1_HUMAN	Reviewed;	MUTAGEN	S	575	E	 Strongly reduced but still present interaction;with 14-3-3 proteins in response to cAMP signaling and,;thus, still able to inhibit TORC activity."";/evidence=""ECO:0000269|PubMed:29211348""	decrease	S575E	D
Q9Y2K2/T469A	Q9Y2K2	SIK3/T469A	SIK3_HUMAN	Reviewed;	MUTAGEN	T	469	A	 Loss of interaction with 14-3-3 proteins in;response to cAMP signaling; inhibits cAMP signaling."";/evidence=""ECO:0000269|PubMed:29211348""	loss	T469A	D
Q9Y2K2/T469E	Q9Y2K2	SIK3/T469E	SIK3_HUMAN	Reviewed;	MUTAGEN	T	469	E	 Loss of interaction with 14-3-3 proteins in;response to cAMP signaling; inhibits cAMP signaling."";/evidence=""ECO:0000269|PubMed:29211348""	loss	T469E	D
Q9Y2K2/S551A	Q9Y2K2	SIK3/S551A	SIK3_HUMAN	Reviewed;	MUTAGEN	S	551	A	 Loss of interaction with 14-3-3 proteins in;response to cAMP signaling; inhibits cAMP signaling."";/evidence=""ECO:0000269|PubMed:29211348""	loss	S551A	D
Q9Y2K2/S551E	Q9Y2K2	SIK3/S551E	SIK3_HUMAN	Reviewed;	MUTAGEN	S	551	E	 Loss of interaction with 14-3-3 proteins in;response to cAMP signaling; inhibits cAMP signaling."";/evidence=""ECO:0000269|PubMed:29211348""	loss	S551E	D
Q9H2G2/K63R	Q9H2G2	SLK/K63R	SLK_HUMAN	Reviewed;	MUTAGEN	K	63	R	 Loss of activity."";/evidence=""ECO:0000269|PubMed:10699464""	loss	K63R	D
Q96Q15/D2335A	Q96Q15	SMG1/D2335A	SMG1_HUMAN	Reviewed;	MUTAGEN	D	2335	A	 Loss of function."";/evidence=""ECO:0000269|PubMed:11331269,;ECO:0000269|PubMed:11544179, ECO:0000269|PubMed:15175154""	loss	D2335A	D
P12931/K298M	P12931	SRC/K298M	SRC_HUMAN	Reviewed;	MUTAGEN	K	298	M	 Kinase inactive. Abolishes ubiquitination;promoted by CBLC."";/evidence=""ECO:0000269|PubMed:14661060""	loss	K298M	D
P12931/Y419F	P12931	SRC/Y419F	SRC_HUMAN	Reviewed;	MUTAGEN	Y	419	F	 Loss of kinase activity. Loss of interaction;with PDLIM4."";/evidence=""ECO:0000269|PubMed:19307596""	loss	Y419F	D
Q9H3Y6/W223A	Q9H3Y6	SRMS/W223A	SRMS_HUMAN	Reviewed;	MUTAGEN	W	223	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:23822091""	loss	W223A	D
Q96SB4/S51A	Q96SB4	SRPK1/S51A	SRPK1_HUMAN	Reviewed;	MUTAGEN	S	51	A	 Protein phosphorylation impaired at this;position."";/evidence=""ECO:0000269|PubMed:12565829""	decrease	S51A	D
Q96SB4/S555A	Q96SB4	SRPK1/S555A	SRPK1_HUMAN	Reviewed;	MUTAGEN	S	555	A	 Protein phosphorylation impaired at this;position."";/evidence=""ECO:0000269|PubMed:12565829""	decrease	S555A	D
Q9UEE5/K90A	Q9UEE5	ST17A/K90A	ST17A_HUMAN	Reviewed;	MUTAGEN	K	90	A	 Loss of activity and of apoptotic function."";/evidence=""ECO:0000269|PubMed:9786912""	loss	K90A	D
O94768/K62A	O94768	ST17B/K62A	ST17B_HUMAN	Reviewed;	MUTAGEN	K	62	A	 Loss of activity and of apoptotic function."";/evidence=""ECO:0000269|PubMed:9786912""	loss	K62A	D
Q9Y2H1/T75A	Q9Y2H1	ST38L/T75A	ST38L_HUMAN	Reviewed;	MUTAGEN	T	75	A	 Decreased kinase activity. Reduced binding of;S100B."";/evidence=""ECO:0000269|PubMed:15037617""	decrease	T75A	D
Q9Y2H1/K119A	Q9Y2H1	ST38L/K119A	ST38L_HUMAN	Reviewed;	MUTAGEN	K	119	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:15037617""	loss	K119A	D
Q9Y2H1/S282A	Q9Y2H1	ST38L/S282A	ST38L_HUMAN	Reviewed;	MUTAGEN	S	282	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:15037617""	loss	S282A	D
Q9Y2H1/T442A	Q9Y2H1	ST38L/T442A	ST38L_HUMAN	Reviewed;	MUTAGEN	T	442	A	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:15037617""	decrease	T442A	D
O94804/K65I	O94804	STK10/K65I	STK10_HUMAN	Reviewed;	MUTAGEN	K	65	I	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12639966""	loss	K65I	D
Q15831/L67P	Q15831	STK11/L67P	STK11_HUMAN	Reviewed;	VARIANT	L	67	P	 (in PJS; abolishes kinase activity, leading;to loss of autophosphorylation; dbSNP:rs137853077)"";/evidence=""ECO:0000269|PubMed:9428765,;ECO:0000269|PubMed:9837816"";/id=""VAR_006202""	loss	L67P	D
Q15831/D176N	Q15831	STK11/D176N	STK11_HUMAN	Reviewed;	VARIANT	D	176	N	 (in PJS; loss of kinase activity, leading to;greatly reduced autophosphorylation; fails to phosphorylate;PTEN in vitro; no significant effect on nucleocytoplasmic;localization; dbSNP:rs730881979)"";/evidence=""ECO:0000269|PubMed:15987703,;ECO:0000269|PubMed:9837816"";/id=""VAR_071058""	decrease	D176N	D
Q15831/D176Y	Q15831	STK11/D176Y	STK11_HUMAN	Reviewed;	VARIANT	D	176	Y	 (in sporadic cancer; somatic mutation; Loss;of kinase activity)"";/evidence=""ECO:0000269|PubMed:12805220,;ECO:0000269|PubMed:19892943"";/id=""VAR_065637""	loss	D176Y	D
Q15831/E199K	Q15831	STK11/E199K	STK11_HUMAN	Reviewed;	VARIANT	E	199	K	 (in colorectal cancer; somatic mutation;;impaired kinase activity; dbSNP:rs121913317)"";/evidence=""ECO:0000269|PubMed:9731485"";/id=""VAR_065641""	decrease	E199K	D
Q15831/W308C	Q15831	STK11/W308C	STK11_HUMAN	Reviewed;	VARIANT	W	308	C	 (in PJS; abolishes kinase activity, leading;to loss of autophosphorylation; dbSNP:rs1057520042)"";/evidence=""ECO:0000269|PubMed:9837816"";/id=""VAR_071059""	loss	W308C	D
Q15831/K78I	Q15831	STK11/K78I	STK11_HUMAN	Reviewed;	MUTAGEN	K	78	I	 Loss of kinase activity, leading to greatly;reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:11430832,;ECO:0000269|PubMed:9837816""	decrease	K78I	D
Q15831/K78M	Q15831	STK11/K78M	STK11_HUMAN	Reviewed;	MUTAGEN	K	78	M	 Loss of kinase activity, leading to reduced;autophosphorylation and acting as a dominant-negative;mutant."";/evidence=""ECO:0000269|PubMed:11430832,;ECO:0000269|PubMed:9837816""	decrease	K78M	D
Q15831/T189A	Q15831	STK11/T189A	STK11_HUMAN	Reviewed;	MUTAGEN	T	189	A	 Reduced phosphorylation."";/evidence=""ECO:0000269|PubMed:11430832""	decrease	T189A	D
Q15831/D194A	Q15831	STK11/D194A	STK11_HUMAN	Reviewed;	MUTAGEN	D	194	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:14517248,;ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:19892943""	loss	D194A	D
O75716/T192A	O75716	STK16/T192A	STK16_HUMAN	Reviewed;	MUTAGEN	T	192	A	 Loss of autophosphorylation."";/evidence=""ECO:0000269|PubMed:8662877""	loss	T192A	D
P49842/K300P	P49842	STK19/K300P	STK19_HUMAN	Reviewed;	MUTAGEN	K	300	P	 Partial loss of activity."";/evidence=""ECO:0000269|PubMed:9812991""	decrease	K300P	D
P49842/K315P	P49842	STK19/K315P	STK19_HUMAN	Reviewed;	MUTAGEN	K	315	P	 Partial loss of activity."";/evidence=""ECO:0000269|PubMed:9812991""	decrease	K315P	D
P49842/K317P	P49842	STK19/K317P	STK19_HUMAN	Reviewed;	MUTAGEN	K	317	P	 Complete loss of activity."";/evidence=""ECO:0000269|PubMed:9812991""	loss	K317P	D
Q9Y6E0/T18A	Q9Y6E0	STK24/T18A	STK24_HUMAN	Reviewed;	MUTAGEN	T	18	A	 Loss of phosphorylation by PKA."";/evidence=""ECO:0000269|PubMed:10644707""	loss	T18A	D
Q9Y6E0/K65A	Q9Y6E0	STK24/K65A	STK24_HUMAN	Reviewed;	MUTAGEN	K	65	A	 Loss of activity and autophosphorylation."";/evidence=""ECO:0000269|PubMed:12107159""	loss	K65A	D
Q9Y6E0/T190A	Q9Y6E0	STK24/T190A	STK24_HUMAN	Reviewed;	MUTAGEN	T	190	A	 Loss of activity and autophosphorylation."";/evidence=""ECO:0000269|PubMed:17046825""	loss	T190A	D
O00506/K49R	O00506	STK25/K49R	STK25_HUMAN	Reviewed;	MUTAGEN	K	49	R	 Loss of kinase activity and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:15037601""	loss	K49R	D
O00506/D158A	O00506	STK25/D158A	STK25_HUMAN	Reviewed;	MUTAGEN	D	158	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15037601""	loss	D158A	D
Q9P289/K53E	Q9P289	STK26/K53E	STK26_HUMAN	Reviewed;	MUTAGEN	K	53	E	 Abolished serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:29232556""	loss	K53E	D
Q15208/T74A	Q15208	STK38/T74A	STK38_HUMAN	Reviewed;	MUTAGEN	T	74	A	 Decreases autophosphorylation and kinase;activity. Reduced binding of S100B."";/evidence=""ECO:0000269|PubMed:12493777""	decrease	T74A	D
Q15208/K118A	Q15208	STK38/K118A	STK38_HUMAN	Reviewed;	MUTAGEN	K	118	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:12493777,;ECO:0000269|PubMed:7761441""	loss	K118A	D
Q15208/S281A	Q15208	STK38/S281A	STK38_HUMAN	Reviewed;	MUTAGEN	S	281	A	 Loss of autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:12493777""	loss	S281A	D
Q15208/T444A	Q15208	STK38/T444A	STK38_HUMAN	Reviewed;	MUTAGEN	T	444	A	 Decreases autophosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:12493777""	decrease	T444A	D
Q13188/K56R	Q13188	STK3/K56R	STK3_HUMAN	Reviewed;	MUTAGEN	K	56	R	 Loss of activity."";/evidence=""ECO:0000269|PubMed:16930133""	loss	K56R	D
Q13043/K59R	Q13043	STK4/K59R	STK4_HUMAN	Reviewed;	MUTAGEN	K	59	R	 Loss of activity."";/evidence=""ECO:0000269|PubMed:15109305,;ECO:0000269|PubMed:16930133""	loss	K59R	D
Q13043/T183A	Q13043	STK4/T183A	STK4_HUMAN	Reviewed;	MUTAGEN	T	183	A	 Loss of activity."";/evidence=""ECO:0000269|PubMed:15109305""	loss	T183A	D
Q13043/L444P	Q13043	STK4/L444P	STK4_HUMAN	Reviewed;	MUTAGEN	L	444	P	 Loss of homodimerization, activation, and;autophosphorylation."";/evidence=""ECO:0000269|PubMed:15109305""	loss	L444P	D
Q7RTN6/T329A	Q7RTN6	STRAA/T329A	STRAA_HUMAN	Reviewed;	MUTAGEN	T	329	A	 Loss of STK11/LKB1-mediated phosphorylation."";/evidence=""ECO:0000269|PubMed:12805220""	loss	T329A	D
Q7RTN6/T419A	Q7RTN6	STRAA/T419A	STRAA_HUMAN	Reviewed;	MUTAGEN	T	419	A	 Loss of STK11/LKB1-mediated phosphorylation."";/evidence=""ECO:0000269|PubMed:12805220""	loss	T419A	D
P21675/S137A	P21675	TAF1/S137A	TAF1_HUMAN	Reviewed;	MUTAGEN	S	137	A	 No decrease in kinase activity."";/evidence=""ECO:0000269|PubMed:9660973""	decrease	S137A	D
Q7L7X3/K57A	Q7L7X3	TAOK1/K57A	TAOK1_HUMAN	Reviewed;	MUTAGEN	K	57	A	 Abolishes kinase activity, ability to activate;the MAPK8/JNK cascade and cleavage by caspase-3 (CASP3)."";/evidence=""ECO:0000269|PubMed:16407310""	loss	K57A	D
Q7L7X3/D169A	Q7L7X3	TAOK1/D169A	TAOK1_HUMAN	Reviewed;	MUTAGEN	D	169	A	 Loss of serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:17396146""	loss	D169A	D
Q9H2K8/D165A	Q9H2K8	TAOK3/D165A	TAOK3_HUMAN	Reviewed;	MUTAGEN	D	165	A	 Loss of serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:17396146""	loss	D165A	D
Q9UHD2/R47H	Q9UHD2	TBK1/R47H	TBK1_HUMAN	Reviewed;	VARIANT	R	47	H	 (in FTDALS4; loss of kinase activity)"";/evidence=""ECO:0000269|PubMed:25803835"";/id=""VAR_073938""	loss	R47H	D
Q9UHD2/G159A	Q9UHD2	TBK1/G159A	TBK1_HUMAN	Reviewed;	VARIANT	G	159	A	 (in IIAE8; loss of kinase activity; loss of;autophosphorylation at S-172; loss of IFNB induction;;dbSNP:rs1555202947)"";/evidence=""ECO:0000269|PubMed:22851595,;ECO:0000269|PubMed:32972995"";/id=""VAR_080518""	loss	G159A	D
Q9UHD2/R308Q	Q9UHD2	TBK1/R308Q	TBK1_HUMAN	Reviewed;	VARIANT	R	308	Q	 (in FTDALS4; reduced kinase activity)"";/evidence=""ECO:0000269|PubMed:25803835"";/id=""VAR_073941""	decrease	R308Q	D
Q9UHD2/R357Q	Q9UHD2	TBK1/R357Q	TBK1_HUMAN	Reviewed;	VARIANT	R	357	Q	 (in FTDALS4; reduced kinase activity;;dbSNP:rs758357594)"";/evidence=""ECO:0000269|PubMed:25803835"";/id=""VAR_073942""	decrease	R357Q	D
Q9UHD2/M559R	Q9UHD2	TBK1/M559R	TBK1_HUMAN	Reviewed;	VARIANT	M	559	R	 (in FTDALS4; loss of kinase activity)"";/evidence=""ECO:0000269|PubMed:25803835"";/id=""VAR_073944""	loss	M559R	D
Q9UHD2/E696K	Q9UHD2	TBK1/E696K	TBK1_HUMAN	Reviewed;	VARIANT	E	696	K	 (in FTDALS4; loss of kinase activity; impairs;binding to OPTN; dbSNP:rs748112833)"";/evidence=""ECO:0000269|PubMed:25803835,;ECO:0000269|PubMed:25943890"";/id=""VAR_073948""	loss	E696K	D
Q9UHD2/D33A	Q9UHD2	TBK1/D33A	TBK1_HUMAN	Reviewed;	MUTAGEN	D	33	A	 Decreases phosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	D33A	D
Q9UHD2/K38A	Q9UHD2	TBK1/K38A	TBK1_HUMAN	Reviewed;	MUTAGEN	K	38	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10581243,;ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23453971,;ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:31709703""	loss	K38A	D
Q9UHD2/D135N	Q9UHD2	TBK1/D135N	TBK1_HUMAN	Reviewed;	MUTAGEN	D	135	N	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:21931631,;ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972,;ECO:0000269|PubMed:30842653""	loss	D135N	D
Q9UHD2/S172E	Q9UHD2	TBK1/S172E	TBK1_HUMAN	Reviewed;	MUTAGEN	S	172	E	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:11839743,;ECO:0000269|PubMed:23453972""	decrease	S172E	D
Q9UHD2/Y325E	Q9UHD2	TBK1/Y325E	TBK1_HUMAN	Reviewed;	MUTAGEN	Y	325	E	 Abolishes phosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:23453972""	loss	Y325E	D
Q9UHD2/R547D	Q9UHD2	TBK1/R547D	TBK1_HUMAN	Reviewed;	MUTAGEN	R	547	D	 Decreases phosphorylation and kinase activity.;Abolishes dimerization."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	R547D	D
Q9UHD2/Y577A	Q9UHD2	TBK1/Y577A	TBK1_HUMAN	Reviewed;	MUTAGEN	Y	577	A	 Decreases kinase activity. Reduced;phosphorylation of STING1."";/evidence=""ECO:0000269|PubMed:23453971,;ECO:0000269|PubMed:30842653""	decrease	Y577A	D
Q9UHD2/N578A	Q9UHD2	TBK1/N578A	TBK1_HUMAN	Reviewed;	MUTAGEN	N	578	A	 Reduced phosphorylation of STING1."";/evidence=""ECO:0000269|PubMed:30842653""	decrease	N578A	D
Q9UHD2/E580A	Q9UHD2	TBK1/E580A	TBK1_HUMAN	Reviewed;	MUTAGEN	E	580	A	 Decreases kinase activity."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	E580A	D
Q9UHD2/Q581A	Q9UHD2	TBK1/Q581A	TBK1_HUMAN	Reviewed;	MUTAGEN	Q	581	A	 Reduced phosphorylation of STING1."";/evidence=""ECO:0000269|PubMed:30842653""	decrease	Q581A	D
Q9UHD2/I582A	Q9UHD2	TBK1/I582A	TBK1_HUMAN	Reviewed;	MUTAGEN	I	582	A	 Decreases kinase activity."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	I582A	D
Q9UHD2/K589D	Q9UHD2	TBK1/K589D	TBK1_HUMAN	Reviewed;	MUTAGEN	K	589	D	 Decreases phosphorylation and kinase;activity."";/evidence=""ECO:0000269|PubMed:23453971""	decrease	K589D	D
P36897/T200V	P36897	TGFR1/T200V	TGFR1_HUMAN	Reviewed;	MUTAGEN	T	200	V	 Loss of phosphorylation. Loss of response to;TGF-beta."";/evidence=""ECO:0000269|PubMed:7774578""	loss	T200V	D
P36897/T204V	P36897	TGFR1/T204V	TGFR1_HUMAN	Reviewed;	MUTAGEN	T	204	V	 Reduced phosphorylation. Reduced response to;TGF-beta."";/evidence=""ECO:0000269|PubMed:7774578""	decrease	T204V	D
P37173/K277R	P37173	TGFR2/K277R	TGFR2_HUMAN	Reviewed;	MUTAGEN	K	277	R	 Abolishes kinase activity, TGF-beta signaling;and interaction with DAXX."";/evidence=""ECO:0000269|PubMed:11483955""	loss	K277R	D
Q02763/C224S	Q02763	TIE2/C224S	TIE2_HUMAN	Reviewed;	MUTAGEN	C	224	S	 Reduces protein abundance."";/evidence=""ECO:0000269|PubMed:27270174""	decrease	C224S	D
Q02763/K855R	Q02763	TIE2/K855R	TIE2_HUMAN	Reviewed;	MUTAGEN	K	855	R	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12609966,;ECO:0000269|PubMed:15851516""	loss	K855R	D
Q9UKI8/D607A	Q9UKI8	TLK1/D607A	TLK1_HUMAN	Reviewed;	MUTAGEN	D	607	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10523312,;ECO:0000269|PubMed:11470414""	loss	D607A	D
Q9UKI8/S743A	Q9UKI8	TLK1/S743A	TLK1_HUMAN	Reviewed;	MUTAGEN	S	743	A	 Loss of kinase inhibition in response to DNA;damage."";/evidence=""ECO:0000269|PubMed:12660173""	loss	S743A	D
Q9UKI8/S743D	Q9UKI8	TLK1/S743D	TLK1_HUMAN	Reviewed;	MUTAGEN	S	743	D	 Loss of kinase inhibition in response to DNA;damage."";/evidence=""ECO:0000269|PubMed:12660173""	loss	S743D	D
Q9UKI8/S743E	Q9UKI8	TLK1/S743E	TLK1_HUMAN	Reviewed;	MUTAGEN	S	743	E	 Loss of kinase inhibition in response to DNA;damage."";/evidence=""ECO:0000269|PubMed:12660173""	loss	S743E	D
Q86UE8/H493R	Q86UE8	TLK2/H493R	TLK2_HUMAN	Reviewed;	VARIANT	H	493	R	 (in MRD57; reduced kinase activity;;dbSNP:rs1567974030)"";/evidence=""ECO:0000269|PubMed:29861108,;ECO:0000269|PubMed:29955062"";/id=""VAR_081028""	decrease	H493R	D
Q86UE8/H518R	Q86UE8	TLK2/H518R	TLK2_HUMAN	Reviewed;	VARIANT	H	518	R	 (in MRD57; severely reduced kinase activity;;dbSNP:rs1567995650)"";/evidence=""ECO:0000269|PubMed:29861108,;ECO:0000269|PubMed:29955062"";/id=""VAR_081029""	decrease	H518R	D
Q86UE8/S617L	Q86UE8	TLK2/S617L	TLK2_HUMAN	Reviewed;	VARIANT	S	617	L	 (in MRD57; exhibits abnormal perinuclear;localization instead of diffuse nuclear localization;;impairs kinase activity; reduced phosphorylation of ASF1A)"";/evidence=""ECO:0000269|PubMed:21572417,;ECO:0000269|PubMed:33323470"";/id=""VAR_087042""	decrease	S617L	D
Q86UE8/D629N	Q86UE8	TLK2/D629N	TLK2_HUMAN	Reviewed;	VARIANT	D	629	N	 (in MRD57; reduced phosphorylation of ASF1A;;dbSNP:rs1568006217)"";/evidence=""ECO:0000269|PubMed:29861108,;ECO:0000269|PubMed:29955062"";/id=""VAR_081032""	decrease	D629N	D
Q86UE8/H518N	Q86UE8	TLK2/H518N	TLK2_HUMAN	Reviewed;	MUTAGEN	H	518	N	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	H518N	D
Q86UE8/D592V	Q86UE8	TLK2/D592V	TLK2_HUMAN	Reviewed;	MUTAGEN	D	592	V	 Loss of kinase activity. No impact on;interaction with ASF1A."";/evidence=""ECO:0000269|PubMed:33323470,;ECO:0000269|PubMed:35136069""	loss	D592V	D
Q86UE8/D613A	Q86UE8	TLK2/D613A	TLK2_HUMAN	Reviewed;	MUTAGEN	D	613	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:10523312,;ECO:0000269|PubMed:11470414, ECO:0000269|PubMed:29955062""	loss	D613A	D
Q86UE8/S617D	Q86UE8	TLK2/S617D	TLK2_HUMAN	Reviewed;	MUTAGEN	S	617	D	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	loss	S617D	D
Q86UE8/S659A	Q86UE8	TLK2/S659A	TLK2_HUMAN	Reviewed;	MUTAGEN	S	659	A	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	S659A	D
Q86UE8/S686A	Q86UE8	TLK2/S686A	TLK2_HUMAN	Reviewed;	MUTAGEN	S	686	A	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	S686A	D
Q86UE8/S686D	Q86UE8	TLK2/S686D	TLK2_HUMAN	Reviewed;	MUTAGEN	S	686	D	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	S686D	D
Q86UE8/T695A	Q86UE8	TLK2/T695A	TLK2_HUMAN	Reviewed;	MUTAGEN	T	695	A	 Reduced kinase activity."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	T695A	D
Q86UE8/R720A	Q86UE8	TLK2/R720A	TLK2_HUMAN	Reviewed;	MUTAGEN	R	720	A	 Reduced phosphorylation of ASF1A."";/evidence=""ECO:0000269|PubMed:29955062""	decrease	R720A	D
Q59H18/G526D	Q59H18	TNI3K/G526D	TNI3K_HUMAN	Reviewed;	VARIANT	G	526	D	 (in CCDD; the mutation results in decreased;protein solubility; causes abnormal aggregation; markedly;reduced protein expression is observed in the sarcoplasm;and nuclei of patient cardiomyocytes; dbSNP:rs606231469)"";/evidence=""ECO:0000269|PubMed:24925317"";/id=""VAR_072650""	decrease	G526D	D
Q59H18/K490R	Q59H18	TNI3K/K490R	TNI3K_HUMAN	Reviewed;	MUTAGEN	K	490	R	 Loss of autophosphorylation activity."";/evidence=""ECO:0000269|PubMed:12721663""	loss	K490R	D
Q9UKE5/K54A	Q9UKE5	TNIK/K54A	TNIK_HUMAN	Reviewed;	MUTAGEN	K	54	A	 Kinase dead. Loss of autophosphorylation and;loss of function in cytoskeleton regulation."";/evidence=""ECO:0000269|PubMed:15342639,;ECO:0000269|PubMed:19816403""	loss	K54A	D
O75962/E1299K	O75962	TRIO/E1299K	TRIO_HUMAN	Reviewed;	VARIANT	E	1299	K	 (in MRD44; severely decreased activation of;RAC1-mediated signaling; severely decreased neurite;outgrowth)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083920""	decrease	E1299K	D
O75962/R1428Q	O75962	TRIO/R1428Q	TRIO_HUMAN	Reviewed;	VARIANT	R	1428	Q	 (in MRD44; severely decreased activation of;RAC1-mediated signaling; severely decreased neurite;outgrowth; dbSNP:rs879255626)"";/evidence=""ECO:0000269|PubMed:27418539,;ECO:0000269|PubMed:32109419"";/id=""VAR_077096""	decrease	R1428Q	D
O75962/H1469R	O75962	TRIO/H1469R	TRIO_HUMAN	Reviewed;	VARIANT	H	1469	R	 (in MRD44; decreased activation of RAC1-;mediated signaling; severely decreased neurite outgrowth;;dbSNP:rs1554070777)"";/evidence=""ECO:0000269|PubMed:32109419"";/id=""VAR_083922""	decrease	H1469R	D
O75962/E1299A	O75962	TRIO/E1299A	TRIO_HUMAN	Reviewed;	MUTAGEN	E	1299	A	 50% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	E1299A	D
O75962/T1303A	O75962	TRIO/T1303A	TRIO_HUMAN	Reviewed;	MUTAGEN	T	1303	A	 40% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	T1303A	D
O75962/V1426A	O75962	TRIO/V1426A	TRIO_HUMAN	Reviewed;	MUTAGEN	V	1426	A	 90% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	V1426A	D
O75962/Q1427A	O75962	TRIO/Q1427A	TRIO_HUMAN	Reviewed;	MUTAGEN	Q	1427	A	 80% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	Q1427A	D
O75962/R1428A	O75962	TRIO/R1428A	TRIO_HUMAN	Reviewed;	MUTAGEN	R	1428	A	 80% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	R1428A	D
O75962/T1430A	O75962	TRIO/T1430A	TRIO_HUMAN	Reviewed;	MUTAGEN	T	1430	A	 80% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	T1430A	D
O75962/K1431A	O75962	TRIO/K1431A	TRIO_HUMAN	Reviewed;	MUTAGEN	K	1431	A	 Loss of nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	loss	K1431A	D
O75962/L1434A	O75962	TRIO/L1434A	TRIO_HUMAN	Reviewed;	MUTAGEN	L	1434	A	 40% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	L1434A	D
O75962/E1438A	O75962	TRIO/E1438A	TRIO_HUMAN	Reviewed;	MUTAGEN	E	1438	A	 30% decrease in nucleotide exchange activity."";/evidence=""ECO:0000269|PubMed:9790533""	decrease	E1438A	D
Q9BX84/K1804R	Q9BX84	TRPM6/K1804R	TRPM6_HUMAN	Reviewed;	MUTAGEN	K	1804	R	 Abolishes kinase activity but does not affect;expression levels or binding to RACK1."";/evidence=""ECO:0000269|PubMed:18258429""	loss	K1804R	D
Q9BX84/T1851A	Q9BX84	TRPM6/T1851A	TRPM6_HUMAN	Reviewed;	MUTAGEN	T	1851	A	 Significantly decreases autophosphorylation.;Does not alter binding to RACK1 but prevents inhibition by;RACK1."";/evidence=""ECO:0000269|PubMed:18258429""	decrease	T1851A	D
Q96QT4/K1648R	Q96QT4	TRPM7/K1648R	TRPM7_HUMAN	Reviewed;	MUTAGEN	K	1648	R	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12887921""	loss	K1648R	D
Q96QT4/G1799D	Q96QT4	TRPM7/G1799D	TRPM7_HUMAN	Reviewed;	MUTAGEN	G	1799	D	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:12887921""	loss	G1799D	D
Q9BXA7/T174A	Q9BXA7	TSSK1/T174A	TSSK1_HUMAN	Reviewed;	MUTAGEN	T	174	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15733851""	loss	T174A	D
Q6SA08/K54M	Q6SA08	TSSK4/K54M	TSSK4_HUMAN	Reviewed;	MUTAGEN	K	54	M	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:15964553""	loss	K54M	D
Q9BXA6/K41M	Q9BXA6	TSSK6/K41M	TSSK6_HUMAN	Reviewed;	MUTAGEN	K	41	M	 Loss of kinase activity. Loss of binding to;TSACC."";/evidence=""ECO:0000269|PubMed:15870294,;ECO:0000269|PubMed:20829357""	loss	K41M	D
Q6IQ55/D163A	Q6IQ55	TTBK2/D163A	TTBK2_HUMAN	Reviewed;	MUTAGEN	D	163	A	 Abolishes serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:21548880""	loss	D163A	D
Q6IQ55/R181E	Q6IQ55	TTBK2/R181E	TTBK2_HUMAN	Reviewed;	MUTAGEN	R	181	E	A: Impaired serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:21548880""	decrease	R181E	D
Q6IQ55/A184E	Q6IQ55	TTBK2/A184E	TTBK2_HUMAN	Reviewed;	MUTAGEN	A	184	E	G: Impaired serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:21548880""	decrease	A184E	D
P33981/D664A	P33981	TTK/D664A	TTK_HUMAN	Reviewed;	MUTAGEN	D	664	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:18243099,;ECO:0000269|PubMed:18480048""	loss	D664A	D
P33981/T686A	P33981	TTK/T686A	TTK_HUMAN	Reviewed;	MUTAGEN	T	686	A	 Loss of kinase activity."";/evidence=""ECO:0000269|PubMed:18480048""	loss	T686A	D
P42681/K299A	P42681	TXK/K299A	TXK_HUMAN	Reviewed;	MUTAGEN	K	299	A	 Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:9813138""	decrease	K299A	D
P29597/K930R	P29597	TYK2/K930R	TYK2_HUMAN	Reviewed;	MUTAGEN	K	930	R	 Complete loss of catalytic activity."";/evidence=""ECO:0000269|PubMed:8702790""	loss	K930R	D
P29597/D1023N	P29597	TYK2/D1023N	TYK2_HUMAN	Reviewed;	MUTAGEN	D	1023	N	 Complete loss of catalytic activity."";/evidence=""ECO:0000269|PubMed:24843152""	loss	D1023N	D
O75385/K46I	O75385	ULK1/K46I	ULK1_HUMAN	Reviewed;	MUTAGEN	K	46	I	 Abolished serine/threonine-protein kinase;activity."";/evidence=""ECO:0000269|PubMed:20921139,;ECO:0000269|PubMed:28821708""	loss	K46I	D
Q8IYT8/K39R	Q8IYT8	ULK2/K39R	ULK2_HUMAN	Reviewed;	MUTAGEN	K	39	R	 Decreased kinase activity and decreased;autophosphorylation."";/evidence=""ECO:0000269|PubMed:18936157""	decrease	K39R	D
Q6PHR2/K44R	Q6PHR2	ULK3/K44R	ULK3_HUMAN	Reviewed;	MUTAGEN	K	44	R	 Decreased kinase activity."";/evidence=""ECO:0000269|PubMed:19878745""	decrease	K44R	D
Q6PHR2/K139R	Q6PHR2	ULK3/K139R	ULK3_HUMAN	Reviewed;	MUTAGEN	K	139	R	 Loss of kinase activity. Does not promote GLI1;nuclear localization."";/evidence=""ECO:0000269|PubMed:19878745,;ECO:0000269|PubMed:20643644""	loss	K139R	D
P17948/Y914F	P17948	VGFR1/Y914F	VGFR1_HUMAN	Reviewed;	MUTAGEN	Y	914	F	 Reduces phosphorylation at other tyrosine;residues."";/evidence=""ECO:0000269|PubMed:9722576""	decrease	Y914F	D
P17948/Y1242F	P17948	VGFR1/Y1242F	VGFR1_HUMAN	Reviewed;	MUTAGEN	Y	1242	F	 Loss of phosphorylation site."";/evidence=""ECO:0000269|PubMed:9722576""	loss	Y1242F	D
P17948/Y1327F	P17948	VGFR1/Y1327F	VGFR1_HUMAN	Reviewed;	MUTAGEN	Y	1327	F	 Loss of phosphorylation site."";/evidence=""ECO:0000269|PubMed:9722576""	loss	Y1327F	D
P35968/V848E	P35968	VGFR2/V848E	VGFR2_HUMAN	Reviewed;	VARIANT	V	848	E	 (strongly reduced autophosphorylation and;kinase activity; dbSNP:rs1139776)"";/evidence=""ECO:0000269|PubMed:10037737,;ECO:0000269|PubMed:1656371"";/id=""VAR_046679""	decrease	V848E	D
P35968/R726A	P35968	VGFR2/R726A	VGFR2_HUMAN	Reviewed;	MUTAGEN	R	726	A	 Strongly reduced autophosphorylation and;activation of MAP kinases."";/evidence=""ECO:0000269|PubMed:20080685""	decrease	R726A	D
P35968/D731A	P35968	VGFR2/D731A	VGFR2_HUMAN	Reviewed;	MUTAGEN	D	731	A	 Strongly reduced autophosphorylation and;activation of MAP kinases."";/evidence=""ECO:0000269|PubMed:20080685""	decrease	D731A	D
P35968/K868M	P35968	VGFR2/K868M	VGFR2_HUMAN	Reviewed;	MUTAGEN	K	868	M	 Loss of enzyme activity."";/evidence=""ECO:0000269|PubMed:11387210""	loss	K868M	D
P35968/Y996F	P35968	VGFR2/Y996F	VGFR2_HUMAN	Reviewed;	MUTAGEN	Y	996	F	 Strongly reduced autophosphorylation. Reduces;phosphorylation of PLCG1."";/evidence=""ECO:0000269|PubMed:10102632""	decrease	Y996F	D
P35968/Y1175F	P35968	VGFR2/Y1175F	VGFR2_HUMAN	Reviewed;	MUTAGEN	Y	1175	F	 Abolishes phosphorylation of PLCG1 and MAP;kinases in response to VEGFA."";/evidence=""ECO:0000269|PubMed:11387210""	loss	Y1175F	D
P35968/Y1214F	P35968	VGFR2/Y1214F	VGFR2_HUMAN	Reviewed;	MUTAGEN	Y	1214	F	 Loss of phosphorylation site. Abolishes;reorganization of the actin cytoskeleton in response to;VEGFA."";/evidence=""ECO:0000269|PubMed:16966330""	loss	Y1214F	D
P35916/A855T	P35916	VGFR3/A855T	VGFR3_HUMAN	Reviewed;	VARIANT	A	855	T	 (in LMPHM1; recessive form; results in;reduced autophosphorylation; results in impaired ligand-;induced receptor internalization and downstream signaling;;dbSNP:rs121909657)"";/evidence=""ECO:0000269|PubMed:19289394"";/id=""VAR_074044""	decrease	A855T	D
P35916/G857R	P35916	VGFR3/G857R	VGFR3_HUMAN	Reviewed;	VARIANT	G	857	R	 (in LMPHM1; loss of kinase activity;;dbSNP:rs267606818)"";/evidence=""ECO:0000269|PubMed:10835628,;ECO:0000269|PubMed:15102829"";/id=""VAR_018409""	loss	G857R	D
P35916/H1035R	P35916	VGFR3/H1035R	VGFR3_HUMAN	Reviewed;	VARIANT	H	1035	R	 (in LMPHM1; loss of kinase activity;;dbSNP:rs121909653)"";/evidence=""ECO:0000269|PubMed:10856194"";/id=""VAR_018412""	loss	H1035R	D
P35916/R1041P	P35916	VGFR3/R1041P	VGFR3_HUMAN	Reviewed;	VARIANT	R	1041	P	 (in LMPHM1; loss of kinase activity;;dbSNP:rs121909650)"";/evidence=""ECO:0000269|PubMed:10835628,;ECO:0000269|PubMed:12881528"";/id=""VAR_018413""	loss	R1041P	D
P35916/L1044P	P35916	VGFR3/L1044P	VGFR3_HUMAN	Reviewed;	VARIANT	L	1044	P	 (in LMPHM1; loss of kinase activity;;dbSNP:rs121909651)"";/evidence=""ECO:0000269|PubMed:10835628"";/id=""VAR_018414""	loss	L1044P	D
P35916/P1114L	P35916	VGFR3/P1114L	VGFR3_HUMAN	Reviewed;	VARIANT	P	1114	L	 (in LMPHM1; loss of kinase activity;;dbSNP:rs121909652)"";/evidence=""ECO:0000269|PubMed:10835628,;ECO:0000269|PubMed:9817924"";/id=""VAR_018415""	loss	P1114L	D
P35916/K879G	P35916	VGFR3/K879G	VGFR3_HUMAN	Reviewed;	MUTAGEN	K	879	G	 Abolishes enzyme activity."";/evidence=""ECO:0000269|PubMed:12881528""	loss	K879G	D
P35916/Y1068F	P35916	VGFR3/Y1068F	VGFR3_HUMAN	Reviewed;	MUTAGEN	Y	1068	F	 Global loss of autophosphorylation. Abolishes;stimulation of cell proliferation and cell migration."";/evidence=""ECO:0000269|PubMed:16076871,;ECO:0000269|PubMed:20431062""	loss	Y1068F	D
P35916/Y1230F	P35916	VGFR3/Y1230F	VGFR3_HUMAN	Reviewed;	MUTAGEN	Y	1230	F	 Loss of phosphorylation site. Strongly reduces;stimulation of cell proliferation and cell migration."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:16076871""	decrease	Y1230F	D
P35916/Y1231F	P35916	VGFR3/Y1231F	VGFR3_HUMAN	Reviewed;	MUTAGEN	Y	1231	F	 Loss of phosphorylation site. Strongly reduces;stimulation of cell proliferation and cell migration."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:16076871""	decrease	Y1231F	D
P35916/Y1333F	P35916	VGFR3/Y1333F	VGFR3_HUMAN	Reviewed;	MUTAGEN	Y	1333	F	 Loss of phosphorylation site. Reduced;autophosphorylation."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:7675451""	decrease	Y1333F	D
P35916/Y1337F	P35916	VGFR3/Y1337F	VGFR3_HUMAN	Reviewed;	MUTAGEN	Y	1337	F	 Reduced autophosphorylation. Strongly reduces;stimulation of cell proliferation and cell migration."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:20431062, ECO:0000269|PubMed:7675451""	decrease	Y1337F	D
P35916/Y1363F	P35916	VGFR3/Y1363F	VGFR3_HUMAN	Reviewed;	MUTAGEN	Y	1363	F	 Loss of phosphorylation site. Slightly reduced;autophosphorylation."";/evidence=""ECO:0000269|PubMed:12881528,;ECO:0000269|PubMed:7675451""	decrease	Y1363F	D
Q99986/S342A	Q99986	VRK1/S342A	VRK1_HUMAN	Reviewed;	MUTAGEN	S	342	A	 Abolishes phosphorylation by PLK3 and;induction of Golgi fragmentation during mitosis. Strongly;reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:19103756,;ECO:0000269|PubMed:21543316""	decrease	S342A	D
Q99986/T353A	Q99986	VRK1/T353A	VRK1_HUMAN	Reviewed;	MUTAGEN	T	353	A	 Strongly reduced autophosphorylation."";/evidence=""ECO:0000269|PubMed:21543316""	decrease	T353A	D
Q86Y07/K179E	Q86Y07	VRK2/K179E	VRK2_HUMAN	Reviewed;	MUTAGEN	K	179	E	 Abolished protein serine/threonine kinase;activity."";/evidence=""ECO:0000269|PubMed:33076429""	loss	K179E	D
P30291/K328R	P30291	WEE1/K328R	WEE1_HUMAN	Reviewed;	MUTAGEN	K	328	R	 Abolishes activity."";/evidence=""ECO:0000269|PubMed:8428596""	loss	K328R	D
P30291/S642A	P30291	WEE1/S642A	WEE1_HUMAN	Reviewed;	MUTAGEN	S	642	A	 Abolishes phosphorylation by BRSK1 and BRSK2."";/evidence=""ECO:0000269|PubMed:20026642""	loss	S642A	D
P0C1S8/D234H	P0C1S8	WEE2/D234H	WEE2_HUMAN	Reviewed;	VARIANT	D	234	H	 (in OOMD5; decreased WEE2 phosphorylation at;serine residues; decreased CDK1/CDC2 phosphorylation at 'Y-;15'; dbSNP:rs1554415096)"";/evidence=""ECO:0000269|PubMed:29606300"";/id=""VAR_080992""	decrease	D234H	D
P43403/D461N	P43403	ZAP70/D461N	ZAP70_HUMAN	Reviewed;	MUTAGEN	D	461	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:17512407""	loss	D461N	D
P43403/D479N	P43403	ZAP70/D479N	ZAP70_HUMAN	Reviewed;	MUTAGEN	D	479	N	 Abolishes kinase activity."";/evidence=""ECO:0000269|PubMed:15292186""	loss	D479N	D
P43403/Y493F	P43403	ZAP70/Y493F	ZAP70_HUMAN	Reviewed;	MUTAGEN	Y	493	F	 Impairs kinase activity."";/evidence=""ECO:0000269|PubMed:7781602""	decrease	Y493F	D
